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NFTs Neurofibrillary tangles 
CA Cornus ammonis (hippocampal subfield) 
 
NIA National Institute of Aging 
 
CAA Cerebral amyloid angiopathy 
 
NSAIDs Non-steroidal anti-inflammatory drugs 
CSF Cerebrospinal fluid 
 
P.A.S. Periodic Acid-Schiff 
 
DAB 3, 3'-diaminobenzidine 
 
PET Positron emission tomography 
 
DAPI 4',6-diamidino-2-phenylindole 
 
pTau Phospho-tau 
DNA Deoxyribonucleic acid 
 
PHF1 Paired helical filament 1 
 
GFAP Glial Fibrillary Acidic Protein 
 
SDS Sodium dodecyl sulfate 
 
GSK3 Glycogen synthase kinase 3 
 
ThioS Thioflavin-S 
 
 VDAC1 Voltage dependent anion channel 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
11 
 
 
 
 
 
INDEX 
 
 
 
 
1 Introduction to Alzheimer disease…………………………………....13 
 
2 Rationale…………………………………………………………………..19  
 
3 Hypothesis and aims……………………………………………………25 
 
4 Methodological considerations……………………………………….29 
 
5 Results………………………………………………………………….…35 
 
6 Concluding remarks…………………………………………………....43 
 
7 References………………………………………………………..……...47 
 
8 Acknowledgements………………………………………………..…...55 
 
 
 	  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
13 
INTRODUCTION  
 TO ALZHEIMER 
DISEASE 
 
 
 
 
 
1.1. Neuropathology of Alzheimer disease. 
 
Alzheimer disease (AD) is the most common cause of dementia and the most common 
neurodegenerative disease. AD affects a 6% of people older than 65 and it has been estimated 
that its prevalence doubles every 5 years thereafter, so that nearly 50% of people over 85 suffer 
from AD (Hirtz et al., 2007; Alzheimer’s Association 2011). 
 
The pathological hallmarks of AD can be classified in “positive” and “negative” lesions. 
Positive lesions include amyloid plaques and cerebral amyloid angiopathy —its equivalent in 
arteries and capillaries–, neurofibrillary tangles (NFTs) and glial responses. Negative lesions 
consist of a progressive loss of neurons and synapses, which lead to the atrophy of cerebral 
cortex.  
 
The most characteristic pathological features of AD —amyloid plaques and neurofibrillary 
tangles– were already described by Alois Alzheimer more than a century ago, but the knowledge 
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about their composition and significance is far more recent. Amyloid plaques are protein 
extracellular deposits mainly composed of the amyloid-β peptide, a by-product of the catabolism 
of amyloid precursor protein (APP) that results after its sequential cleavage by the enzymes β- 
and γ-secretases. Although plaques have been classified in many different morphological 
subtypes according to their staining properties and associated pathologic features (diffuse, 
primitive, classical, burn-out), presumably representing different stages in plaque evolution, this 
classification can be simplified in two main subtypes: diffuse and dense-core plaques. Diffuse 
plaques are Aβ-immunoreactive deposits that do not alter their surrounding neuropil nor induce 
glial responses in their vicinity, and therefore, are considered “benign”. In fact, they are often 
seen in the cortex of elderly people without evidence of cognitive decline (Arriagada et al., 
1992b). By contrast, dense-core plaques have a central compact core that is positive for stainings 
that specifically display the β-sheet pleated conformation of amyloid fibrils, such as Congo red 
and Thioflavin-S. In addition, since they often contain and/or are surrounded by dystrophic 
neurites (neuritic plaques), reactive astrocytes, and activated microglial cells, these dense-core 
plaques are considered toxic and more specific of AD (Mirra et al., 1991).  
 
Neurofibrillary tangles (NFTs) are intraneuronal deposits of the microtubule-associated 
protein tau, which is aberrantly misfolded and abnormally hyperphosphorylated. In AD, tau 
aggregates forming paired helical filaments with a β-sheet pleated conformation, hence NFTs are 
also Thioflavin-S positive. As the disease advances, many tangle-bearing neurons die, leaving 
behind extracellular tangles, also called “ghost” or “tombstone” tangles. 
 
A number of clinico-pathologic studies in the 1990s demonstrated that the amount of NFTs, 
neuronal loss, and particularly synaptic loss, strongly correlates with the severity of cognitive 
decline. By contrast, these studies revealed that amyloid burden essentially does not correlate 
with the degree of cognitive impairment or the duration of clinical illness (DeKosky et al., 1990; 
Terry et al., 1991; Arriagada et al., 1992a; Bierer et al., 1995; Gómez-Isla et al., 1996 y 1997; 
Ingelsson et al., 2004). Indeed, as mentioned above, amyloid plaques are relatively common in 
cognitively intact elderly people (Arriagada et al, 1992b). Although the pathologic diagnosis of 
AD has long relied on the presence of plaques and tangles in a sufficient number and distribution 
in the cerebral cortex of a patient with documented clinical history of dementia (Braak y Braak, 
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1991; Mirra et al., 1991; NIA-Reagan Consensus, 1997), as discussed below, the current view is 
that AD is a continuum pathological spectrum between “normal” aging and dementia and, as 
such, the pathological diagnostic criteria have been recently revised to consider pre-symptomatic 
stages of the disease (Montine et al. 2011; Hyman et al., 2011).  
 
 
1.2. Pathophysiology of Alzheimer disease: the amyloid 
cascade hypothesis. 
 
Despite the lack of correlation between amyloid burden and severity of cognitive deficits, the 
most widely accepted hypothesis gives Aβ a central role in the pathophysiology of AD. 
According to this hypothesis, Aβ is the trigger of a cascade of adverse events that include 
synaptic dysfunction, glial-mediated inflammation and oxidative stress, hyperphosphorylation 
and aggregation of tau in NFTs, and ultimately, neuronal loss and dementia, hence the name  
“amyloid cascade hypothesis”. In its first formulation, the main contribution of this hypothesis 
was to place amyloid plaques and NFTs in a sequential order, attributing to Aβ an initiation 
effect and considering tau pathology as secondary to Aβ aggregation (Hardy and Higgins 1992, 
Selkoe 1992). Despite the fact that the vast majority of AD cases are sporadic, the basis of this 
hypothesis largely lays in genetics: the causative genes of the rare cases of familial autosomal 
dominant AD cases discovered so far encode the substrate (amyloid precursor protein, APP) and 
enzymes involved in Aβ generation (presenilins 1 and 2, PSEN1 and PSEN2, the catalytic 
subunits of the γ-secretase complex). Mutations in these three genes cause a form of early-onset 
AD that is clinically and pathologically very similar to the sporadic late-onset form. Also, 
virtually all patients with Down’s syndrome (trisomy 21) will develop early-onset AD in their 
40s or 50s due to an excessive production of Aβ derived from their three copies of the APP gene 
(Bertram y Tanzi 2008). However, the main genetic risk factor for sporadic AD, the  ε4 allele of 
the apolipoprotein E gene APOE, has been also associated to an increased level of Aβ, either by 
promoting its aggregation (Ma et al., 1994; Wisniewski et al., 1994; Castano et al., 1995) or by 
reducing its clearance from the brain parenchyma (Deane et al., 2008; Jiang et al., 2009; 
Castellano et al., 2011). In addition, other environmental factors that have been shown to 
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increase the risk of developing sporadic late-onset AD, such as traumatic brain injury or stroke, 
may also increase the production of Aβ by increasing the levels of the enzymes β- and γ-
secretases (Veliquette et al., 2005; Sun et al., 2006; Tesco et al., 2007; Loane et al., 2009). 
 
In addition, in its latest version this hypothesis elegantly sorted out the issue of the lack of 
correlation between plaque burden and cognitive impairment by emphasizing that AD is a 
“synaptic disease” and that soluble Aβ oligomers rather than Aβ fibrils within the plaques are the 
culprit Aβ species with toxic effects on synapses (Hardy and Selkoe, 2002). Indeed, it has been 
reported that the levels of soluble Aβ in the cortex do correlate with the severity of dementia 
(Lue et al., 1999; McLean et al., 1999; Näslund et al., 2000), and experiments in vitro and in 
mouse models have demonstrated that soluble Aβ oligomers cause synaptic dysfunction and loss 
(Lambert et al., 1998; Hsia et al., 1999; Lacor et al., 2004; Cleary et al., 2005; Lesné et al., 2006; 
Shankar et al., 2007; Shankar et al., 2008; Koffie et al., 2009; Li et al., 2009, Wu et al., 2010), 
and that they can induce neuronal tau hyperphosphorylation and aggregation (Zempel et al. 2010; 
Jin et al., 2011). However, a variety of oligomeric Aβ species with different physicochemical 
properties (tertiary conformation, molecular weight, SDS-solubility, etc.) have been described 
both in vitro and in vivo since this hypothesis was reformulated, and which soluble oligomeric 
Aβ species are present in vivo and whether any form of soluble Aβ is more deleterious than 
others are still controversial questions (reviewed in Benilova et al., 2012). 
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Figure 1. Amyloid cascade hypothesis (Hardy and Selkoe, 2002). 
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RATIONALE   
 
 
 
 
 
 
 
 
 
2.1. Recent criticisms to the amyloid cascade hypothesis. 
Although the amyloid cascade hypothesis has been widely accepted by most scientists in 
the last two decades as their research framework, a number of criticisms and questions have been 
casted on it in the past few years, largely due to the disappointment resulting from the failure of 
clinical trials targeting Aβ. Given its attributed role as the initiator of the pathogenic cascade 
ultimately leading to AD, major efforts to develop effective therapies for AD patients were 
directed against Aβ, including inhibitors and modulators of the enzymes β- y γ-secretases, anti-
Aβ aggregants (i.e. tramiprosate), and particularly, anti-Aβ immunization. However, so far none 
of the clinical trials using these approaches has significantly impacted the rate of cognitive 
decline of the patients enrolled (reviewed in Haas, 2012). Drugs with presumed Aβ-reducing and 
anti-inflammatory effects, such as non-steroidal anti-inflammatory drugs (NSAIDs) and statins, 
also failed in clinical trials in both MCI and mild-to-moderate AD patients, despite numerous 
prior epidemiological studies reporting a substantial reduction of the risk of developing AD in 
the general population (reviewed in McGuinness et al., 2010; Shepardson et al., 2011ab; and 
Jaturapatporn et al., 2012). 
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Although these failures could be partially explained by pharmacokinetic or 
pharmacodynamic issues (i.e. insufficient penetration of the drug in the brain, insufficient dose, 
side-effects), and specially, by the targeting of AD patients in a late stage of their disease 
(Selkoe, 2011), some authors have proposed a revision of the amyloid cascade hypothesis. A 
“dual pathway” model has been proposed in which Aβ and tau have their own parallel 
pathogenic cascades that would be linked by the same trigger and/or some molecular links acting 
more downstream. The APOEε4 allele and the glycogen synthase kinase 3 (GSK3) have been 
postulated as putative upstream molecular targets linking Aβ and tau cascades (Small and Duff, 
2011). As discussed in further detail within the hypothesis section, we propose a much less 
drastic modification of the amyloid cascade hypothesis consisting on the differentiation of two 
stages: a first stage, in which Aβ ignites not only a single but multiple pathogenic cascades, 
including oxidative stress, glial responses, and tau hyperphosphorylation and aggregation; and a 
second stage, in which these processes initially triggered by and dependent on Aβ, ultimately 
lead to a progressive synaptic and neuronal loss in a Aβ-independent fashion (Figure 2) (Hyman, 
2011). 
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Figure 2. Proposed models for the pathophysiology of Alzheimer disease. The classical 
“cascade” model is a serial model in which Aβ is a trigger of a series of downstream adverse 
events (Hardy and Selkoe, 2002). The “dual pathway” model proposes the existence of 
independent pathogenic cascades for Aβ and tau that are triggered by common molecular links 
(i.e. APOEε4, GSK3, retromer deficiency) (Small and Duff, 2008). The “two-stage” model 
supports the existence of a cascade with an amyloid-dependent stage triggered by Aβ (solid 
arrow), and an amyloid-independent stage, in which neurotoxic processes become progressively 
independent of Aβ (dotted and dashed arrows) (Hyman 2011).  
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2.2. Role of glia in Alzheimer disease. 
 
Besides amyloid plaques and NFTs, another very prominent (yet long neglected) positive 
lesion in the AD brain is the glial response mediated by reactive astrocytes and activated 
microglia. The classic view of glial cells as mere supporting cells offering trophic support to 
neurons is currently being revised. Microglial cells have been recently involved in the pruning of 
redundant and unnecessary synapses during the embryonic development and, in certain synapses, 
also during the postnatal period (Paolicelli et al., 2011; Schafer et al., 2012). Astrocytes 
modulate synaptic activity by releasing small molecules at the synaptic cleft, such as ATP, 
adenosine, D-serine, and possibly glutamate, a process termed gliotransmission. In fact, 
astrocytic end-feet are present in up to a 60% of excitatory synapses in the rat hippocampus, as 
part of the tripartite synapse (reviewed in Perea et al., 2009). Astrocytes are also part of the 
blood-brain barrier, where they regulate the neurovascular coupling. Both glial cell types not 
only produce neurotrophic factors but actively survey the environment and respond to certain 
signals that neurons present in their plasma membrane or secrete to the extracellular space when 
the brain suffers an insult or injury, either acute (i.e. infection, trauma, stroke) or chronic, such as 
AD and other neurodegenerative diseases. This response of glial cells is called activation and 
consist of a double change morphological and functional: on one hand, their somas become 
hypertrophic and their processes, normally very thinly ramified, retract and turn thicker; on the 
other hand, they acquire phagocytic capacity, and/or secrete potentially harmful biomolecules 
such as pro-inflammatory cytokines and reactive oxygen species.  
 
The role of glial cells in AD is controversial, perhaps because their effects are dual, initially 
beneficial but ultimately deleterious (Wyss-Coray, 2006). In the cerebral cortex of AD patients 
both reactive astrocytes and activated microglia tend to cluster within and around dense-core 
amyloid plaques, suggesting that Aβ triggers the recruitment and activation of glia and initiates 
an inflammatory cascade (Itagaki et al., 1989; Pike et al., 1995; Vehmas et al., 2003). The dual 
nature of glia in AD has been more investigated with respect to microglia: while some studies in 
mice models that recapitulate AD pathology have shown that microglia may contribute to 
neuronal loss (Furhmann et al., 2009), other studies support a role of activated microglia in Aβ 
phagocytosis and degradation (El Khoury et al., 2007; Bolmont et al., 2008), and other authors 
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defend the idea that microglia in AD is defective at clearing Aβ (Hickman et al., 2008; 
Grathwohl et al., 2009; Heneka et al., 2010). In the case of astrocytes, although they may be 
effective at forming a scar around plaques and preventing plaque growth, their recruitment by 
amyloid plaques may compromise their function at modulating synaptic activity and providing 
trophic support to neurons in areas distant from plaques. 
  
Surprisingly, the progression of astrocytic and microglial responses through the course of AD 
and with respect to the other AD neuropathological hallmarks has not been described in detail in 
the literature, despite the fact that such data may shed light about their role in the disease and 
have both diagnostic (i.e. development of diagnostic and progression biomarkers) and 
therapeutic (i.e. development of anti-inflammatory drugs) implications. Following our two-stage 
model of the AD natural history, we hypothesized that glial responses, although initially directed 
towards amyloid plaques, become independent of plaques and spread throughout the neuropil, 
paralleling the neurodegenerative process downstream Aβ rather than the extent of Aβ 
deposition. Thus, at some point during the progression of the disease, glial responses could 
behave as a surrogate marker of neurodegeneration or even contribute to the neurodegenerative 
cascade. 
 
 
2.3. Effects of anti-Aβ  immunization on the Alzheimer brain. 
The finding that monoclonal antibodies directed against the Aβ peptide sequence are able 
to dissolve pre-formed Aβ fibrils and prevent the polymerization of monomeric Aβ in vitro 
(Solomon et al., 1996 y 1997), prompted the study of the efficacy of immunotherapy in APP-
overexpresing mouse models, that recapitulate the amyloid deposits of human AD. Both active 
and passive immunization (with aggregates prepared with synthetic Aβ and with anti-Aβ 
monoclonal antibodies, respectively) rendered excellent results in these murine models. Both 
approaches were effective to prevent the amyloid deposition in young mice and to clear existing 
deposits in aged animals (Schenk et al., 1999; Janus et al., 2000; Morgan et al., 2000; Bard et al., 
2000; Bacskai et al., 2001; DeMattos et al., 2001; Dodart et al., 2002). Moreover, anti-Aβ 
immunization was able to prevent synaptic loss and to restore plaque-associated neuritic 
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dystrophies (Buttini et al., 2005; Brendza et al., 2005; Spires-Jones et al. 2009; Rozkalne et al. 
2009). These animal studies led to the design of clinical trials in patients with mild-to-moderate 
AD. However, after a phase 1 trial without significant adverse effects, the first active 
immunotherapy trial with a preparation of Aβ aggregates (AN1792) had to be halted in its phase 
2a after 6% of patients in the treatment group developed an autoimmune meningoencephalitis 
(Orgogozo et al., 2003). Currently, several clinical trials with passive immunotherapy have been 
completed or are ongoing (for updated information, see the website: 
http://clinicaltrials.gov/ct2/results?term=Alzheimer+disease). 
 
The effects of anti-Aβ active immunization on the neuropathology of AD observed can 
be summarized as: 1) significant reduction in amyloid load, with a relative abundance of 
collapsed “moth-eaten” plaques among the remaining ones; 2) increased severity of cerebral 
amyloid angiopathy (CAA), with increased frequency of CAA-related microbleeds; 3) decrease 
in the density of clusters of neuritic dystrophies, reactive astrocytes and activated microglia, due 
to an effective clearance of plaques; and 4) a number and distribution of NFTs typical of advance 
AD (Braak stage V or VI in most cases) (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 
2005; Bombois et al., 2007; Boche et al., 2008; Uro-Coste et al., 2010).  
 
Although there is a substantial evidence of the beneficial effects of both active and 
passive anti-Aβ immunization on the integrity of synapses and the morphology of neurites 
(dendrites and axons) in animal models that develop amyloid plaques, little is known about these 
effects in the brain of patients with AD. In addition, besides the original description of collapsed 
“moth-eaten” amyloid plaques, the characteristics and properties of plaques remaining after 
immunization have not been fully documented. Lastly, the effect of the reduction of amyloid 
plaques on the tau pathology, and specifically on the aberrant misfolding, hyperphosphorylation 
and aggregation of tau in NFTs, beyond the application of Braak staging, has not been 
investigated with detail. According to our two-stage model of the pathophysiology of AD, we 
hypothesized that removing plaques at the stage of mild-to-moderate AD, may improve neuropil 
changes that are directly induced by plaques and closely associated to them, but may not be 
effective at restoring more downstream pathological events such as the aggregation of tau within 
the neurons. 
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HYPOTHESIS 
AND AIMS  
  
 
 
 
 
 
 
3.1. Hypothesis. 
We postulate the existence of two phases in the pathophysiology of AD (Hyman, 2011): 
 
1. Amyloid-dependent stage: this initial phase is characterized by the widespread 
deposition of amyloid plaques in the cerebral cortex, where they will trigger a local 
cascade of adverse events including pro-inflammatory glial responses, oxidative stress, 
hyperphosphorylation and aggregation of tau in dystrophic neurites, and synaptic 
dysfunction and loss around them (Figure 1). This stage largely predates the appearance 
of the cognitive symptoms that characterize the disease, but represents a window of 
opportunity to prevent the onset of cognitive deficits through anti-Aβ therapies. 
 
2. Amyloid-independent stage: at this stage, the cascade of adverse events becomes 
independent of Aβ, its initial trigger, and is not restricted to the local environment around 
the plaques but extends to distant regions. This stage is characterized by an increasing 
accumulation of hyperphosphorylated tau in neurofibrillary tangles and a massive loss of  
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synapses and neurons extending through the association cortex, which leads to the 
disconnection of distant areas of the neural network. This stage parallels the development 
and progression of the constellation of cognitive symptoms that ultimately will conform 
the dementia syndrome associated to AD. As this cascade runs independently of Aβ, at 
this stage the therapies directed to remove amyloid plaques and/or soluble Aβ oligomers 
(i.e. anti-Aβ immunization) will be ineffective to arrest the clinical progression of the 
disease.  
 
 
3.2. Overall and specific aims. 
 
Overall aim#1 
 
To characterize the progression of the pathological hallmarks of AD (amyloid plaques and 
NFTs), the glial responses to these lesions, and the cortical atrophy.  
 
Specific aims: 
 
1.1. To address the temporal progression of these pathological lesions through the 
correlation of their quantitative measures with the duration of clinical disease;  
 
1.2. To evaluate whether glial responses correlate and remain associated to amyloid 
plaques through the disease course or whether, according to our hypothesis, they 
become independent of Aβ deposition.  
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Overall aim#2 
 
To characterize the effect of anti-Aβ active immunization in the brain of patients with AD who 
participated in a phase 2a clinical trial with this disease-modifying therapy (AN1792, Elan 
Pharmaceuticals Inc.). 
 
Specific aims: 
 
2.1. To assess its effect on the amyloid plaque burden; 
 
2.2. To evaluate its effect on plaque-associated neuritic changes;  
 
2.3. To describe the properties of amyloid plaques remaining after immunization (size, 
proportion of diffuse versus dense-core plaques, plaque-associated neuritic 
dystrophies and glial responses); 
 
2.4. To investigate the characteristics of neurofibrillary tangles (misfolding, 
hyperphosphorylation and aggregation of tau).  
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METHODOLOGICAL 
CONSIDERATIONS  
 
 
 
 
 
 
 
 
 
4.1. Postmortem brain tissue. 
 
Brains from patients with AD and from subjects without evidence of neurodegenerative 
disease were obtained from the Massachusetts General Hospital Brain Bank. Specifically, 
formalin-fixed, paraffin-embedded eight-micron-thick sections were obtained from the 
hippocampus at the level of the lateral geniculate nucleus and from the temporal association 
cortex (Brodmann Area 38).  
 
 
4.2. Immunohistochemistry. 
 
Sections were deparaffinized with xylenes and hydrated with increasing concentrations of 
ethanol before performing immunohistochemical techniques to reveal the AD pathological 
hallmarks. The antibodies used in these immunostainings, the antigen retrieval methods, and the 
visualization strategies are depicted in Table 1. The counterstaining procedures used in this study 
are described in Table 2. 
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4.3. Neuropathological quantitative analyses.  
 
Cortical thickness  
In AD there is a progressive cortical atrophy resulting from the loss of synapses, neurons 
and neurites. This cortical atrophy follows a hierarchical temporal and spatial pattern that starts 
in the medial temporal lobe and spreads towards the association temporal, frontal, parietal and 
occipital cortices. In this study, cortical thickness was used as a global parameter of the 
neurodegenerative process associated to AD progression. Cortical thickness was measured in the 
temporal cortex (BA38) on sections stained with hematoxylin, eosin, and Luxol Fast Blue, using 
an Olympus BX51 microscope, equipped with a motorized stage and a video camera and coupled 
with the computer software CAST. The average of 20 measures randomly distributed along the 
cortical ribbon of the specimen was obtained under the 1.6x objective, using the appropriate tool 
of CAST software. 
 
Amyloid burden 
The amyloid burden was measured as the percent of cortical surface occupied by amyloid 
plaques in sections immunostained with the mouse monoclonal anti-Aβ antibody 10D5 (Elan 
Pharmaceuticals), using the peroxidase technique with DAB as a substrate. Sections were place 
under the 10x objective on the motorized stage of a Leica microscope model DRMB equipped a 
video camera and coupled with the computer software BIOQUANT Nova Prime. The optical 
threshold application of this software was used to capture the particles (plaques) stained. The 
calibration was kept constant at a magnification factor of 1.6158 µm2/pixel.  
 
Stereology-based quantification of neuropathology  
Stereology is a technique that, when applied to histology, enables to obtain quantitative 
unbiased results of any given object (i.e. amyloid plaques or NFTs), by performing a systematic 
and random sampling of the specimen under the microscope and, then, extrapolating this result to 
the entire specimen (Hyman et al., 1998). Modern stereology is performed with microscopes 
equipped with a motorized stage and a videocamera and coupled with computer software.   
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Stereology-based analyses on sections stained with the peroxidase-DAB technique were 
performed with a Leica-BIOQUANT system, whereas those conducted on fluorescently stained 
sections were performed with a Olympus-CAST system. In both cases, the densities of total 
(10D5+) amyloid plaques, dense-core (ThioS+) amyloid plaques, oligomeric Aβ-enriched 
(NAB61+) plaques, NFTs (PHF1+), activated (CD68+, IBA1+) microglial cells, and reactive 
(GFAP+) astrocytes, were obtained. These densities were then corrected by the cortical thickness 
of each specimen to prevent bias due to disease-related atrophy.  
 
Quantitative characterization of the properties of amyloid plaques 
 
Plaque size distribution 
The size distribution of total (10D5+) amyloid plaques was obtained with the Leica-
BIOQUANT system that provides not only the quantification of amyloid burden, but also the 
size of each of the particles captured above the optical threshold. The size distribution of dense-
core (ThioS+) plaques was obtained using the appropriate tool of the public domain sotware 
ImageJ (http://rsbweb.nih.gov/ij/). The selection of fields with dense-core plaques included in 
this analysis was performed in a random fashion using the system Olympus-CAST.  
 
Percent of dense-core plaques 
For this analysis, plaques were immunostained with the anti-Aβ monoclonal antibody 
3D6 and counterstained with Thioflavin-S. The plaques were randomly selected using the optical 
dissector technique in the stereology software CAST. 
 
Neuritic changes 
The plaques and neuritis included in these analyses were also randomly selected with the 
system Olympus-CAST. The quantification of the number of neuritic dystrophies per plaque and 
of the percent of dense-core plaques with mitochondrial accumulation in those dystrophic 
neurites was performed on sections double-stained with Thioflavin-S and the anti-SMI312 or the 
anti-VDAC1 antibodies, respectively. In addition, the curvature ratio of neurites surrounding 
dense-core plaques was measured in sections doubly stained with Thioflavin-S and the anti-NF-
H antibody, which labels both dendrites and axons. The curvature ratio was calculated as a 
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fraction with the neurite length as numerator and the end-to-end distance as the denominator. 
Therefore, if a neurite is completely straight, its curvature ratio will equal 1, and the more 
tortuous the neurite the higher will be its curvature ratio. Prior studies have demonstrated that the 
neurite curvature ratio is higher in AD patients compared to non-demented subjects and in 
plaque-bearing transgenic mice than in their wild-type littermates. Moreover, these studies have 
shown that the curvature ratio is higher in the vicinity of dense-core plaques (≤ 50 µm) than far 
away from them (Knowles et al., 1999; D’Amore et al., 2003). Thus, the curvature ratio is a 
measure of the toxic effect of amyloid plaques on the trajectory of surrounding neurites that is 
much more subtle than the notorious neuritic changes present within the plaques.  
 
Glial responses 
Plaque-associated glial responses were quantified in sections doubly stained with 
Thioflavin-S and an antibody against GFAP (reactive astrocytes) or Iba1 or CD68 (activated 
microglia). Again, plaques and glial cells were randomly selected using the Olympus-CAST 
system. Only glial cells with a DAPI-positive nucleus were counted and only the soma (not the 
processes) was used to refer the location of the glial cell with respect to the closest plaque or 
NFT. A boundary of 50 µm from the edge of the closest plaque was used to consider a glial cell 
close to a plaque. The same boundary was considered to quantify glial cells located in the 
vicinity of NFTs but far from dense-core plaques.  
 
 
 
 
 
 
 
 
 METHODOLOGICAL CONSIDERATIONS 
 	  
35 
RESULTS  
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Neuropathological Alterations
in Alzheimer Disease
Alberto Serrano-Pozo1, Matthew P. Frosch1,2, Eliezer Masliah3, and Bradley T. Hyman1
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The neuropathological hallmarks of Alzheimer disease (AD) include “positive” lesions such
as amyloid plaques and cerebral amyloid angiopathy, neurofibrillary tangles, and glial
responses, and “negative” lesions such as neuronal and synaptic loss. Despite their inher-
ently cross-sectional nature, postmortem studies have enabled the staging of the progression
of both amyloid and tangle pathologies, and, consequently, the development of diagnostic
criteria that are now used worldwide. In addition, clinicopathological correlation studies
have been crucial to generate hypotheses about the pathophysiology of the disease, by estab-
lishing that there is a continuum between “normal” aging and AD dementia, and that the
amyloid plaque build-up occurs primarily before the onset of cognitive deficits, while neuro-
fibrillary tangles, neuron loss, and particularly synaptic loss, parallel the progression of cog-
nitive decline. Importantly, these cross-sectional neuropathological data have been largely
validated by longitudinal in vivo studies using modern imaging biomarkers such as
amyloid PET and volumetric MRI.
The neuropathological changes of Alzheimerdisease (AD) brain include both posi-
tive and negative features. Classical positive le-
sions consist of abundant amyloid plaques
and neurofibrillary tangles, neuropil threads,
and dystrophic neurites containing hyper-
phosphorylated tau (see Box 1 for glossary)
(Terry et al. 1994, Mandelkow and Mandelkow
1998, Trojanowski and Lee 2000; Iqbal and
Grundke-Iqbal 2002; Crews and Masliah 2010),
that are accompanied by astrogliosis (Beach
et al. 1989; Itagaki et al. 1989), and microglial
cell activation (Rogers et al. 1988; Itagaki et al.
1989;Masliah et al. 1991). Congophilic amyloid
angiopathy is a frequent concurrent feature.
Unique lesions, found primarily in the hip-
pocampal formation, include Hirano bodies
and granulovacuolar degeneration. In addition
to these positive lesions, characteristic losses
of neurons, neuropil, and synaptic elements
are core negative features of AD (Scheff et al.
1990, 2006, 2007; DeKosky and Scheff 1990;
Editors: Dennis J. Selkoe, David M. Holtzman, and Eckhard Mandelkow
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Terry et al. 1991;Masliah et al. 1993b; Scheff and
Price 1993, 1994; Gomez-Isla et al. 1996, 1997;
Knowles et al. 1999). Each of these lesions
has a characteristic distribution, with plaques
found throughout the cortical mantle, and
tangles primarily in limbic and association
cortices (Arnold et al. 1991; Braak and Braak
1991; Thal et al. 2002). The hierarchical pattern
of neurofibrillary degeneration among brain
regions is so consistent that a staging scheme
based on early lesions in the entorhinal/
perirhinal cortex, then hippocampal Ammon
subfields, then association cortex, and finally
primary neocortex is well accepted as part of
the 1997 NIA-Reagan diagnostic criteria
(NIA-RI Consensus 1997). Neuronal loss and
synapse loss largely parallel tangle formation,
although whether tangles are causative of neu-
ronal loss or synaptic loss remains uncertain
(Go´mez-Isla et al. 1997; Iqbal and Grundke-
Iqbal 2002; Bussie`re et al. 2003; Hof et al.
2003; Yoshiyama et al. 2007; Spires-Jones et al.
2008; de Calignon et al. 2009, 2010; Kimura
et al. 2010).
BOX 1. Glossary
Amyloid plaques: extracellular deposits of amyloid b abundant in the cortex of AD patients. Amyloid
plaques are commonly classified in diffuse and dense-core based on their morphology and positive
or negative staining with Thioflavin-S or Congo Red.
Dense-core plaques: fibrillar amyloid deposits with compact core that stains with Thioflavin-S and
Congo Red. Dense-core plaques are typically surrounded by dystrophic neurites (neuritic
plaques), reactive astrocytes and activated microglial cells, and associated with synaptic loss. A semi-
quantitative score of neuritic plaques is used for the pathological diagnosis of AD because their pres-
ence is generally associated with the presence of cognitive impairment.
Diffuse plaques: amorphous amyloid deposits with ill-defined contours that are Congo Red and
Thioflavin S negative. Diffuse plaques are usually nonneuritic and not associated with glial responses
or synaptic loss. This plaque type is not considered for the pathological diagnosis of AD because it is a
relatively common finding in the brain of cognitively intact elderly people.
Cerebral amyloid angiopathy (CAA): deposits of amyloid b in the tunica media of leptomeningeal
arteries and cortical capillaries, small arterioles and medium-size arteries, particularly in posterior
areas of the brain. Some degree of CAA, usually mild, is present in 80% of AD patients. If
severe, CAA can weaken the vessel wall and cause life-threatening lobar hemorrhages.
Amyloid b: a 40 or 42 amino acid peptide derived from amyloid precursor protein (APP) after its
sequential cleavage by b- and g-secretases. Its physiological role is likely related to the modulation
of synaptic activity although still controversial. In AD Ab accumulates forming intermediate soluble
oligomers that are synaptotoxic as well as insoluble b-sheet pleated amyloid fibrils that are the main
constituent of dense-core plaques (mainly Ab42) and cerebral amyloid angiopathy (primarily Ab40).
Neuroﬁbrillary tangles (NFTs): intraneuronal aggregates of hyperphosphorylated and misfolded tau
that become extraneuronal (“ghost” tangles) when tangle-bearing neurons die. NFTs have a stereo-
typical spatiotemporal progression that correlates with the severity of the cognitive decline. In fact, a
topographic staging of NFTs (Braak and Braak 1991) is used for the pathological diagnosis of AD.
Neuropil threads: axonal and dendritic segments containing aggregated and hyperphosphorylated tau
that invariably accompany neurofibrillary tangles in AD.
Tau: a microtubule-associated protein normally located to the axon, where it physiologically facili-
tates the axonal transport by binding and stabilizing the mictrotubules. In AD, tau is translocated
to the somatodendritc compartment and undergoes hyperphosphorylation, misfolding, and aggrega-
tion, giving rise to neurofibrillary tangles and neuropil threads.
A. Serrano-Pozo et al.
2 Cite this article as Cold Spring Harb Perspect Med 2011;1:a006189
w
w
w
.p
er
sp
ec
ti
ve
si
n
m
ed
ic
in
e.
o
rg
Although all these neuropathological char-
acteristics are useful diagnostic markers, the
cognitive impairment in patients with AD is
closely associated with the progressive degener-
ation of the limbic system (Arnold et al. 1991;
Klucken et al. 2003), neocortical regions (Terry
et al. 1981), and the basal forebrain (Teipel et al.
2005). This neurodegenerative process is
characterized by early damage to the synapses
(Masliah and Terry 1993, 1994; Masliah 2000;
Crews and Masliah 2010) with retrograde
degeneration of the axons and eventual atro-
phy of the dendritic tree (Coleman and Perry
2002; Higuchi et al. 2002; Grutzendler et al.
2007; Perlson et al. 2010) and perikaryon
(Hyman et al. 1986; Lippa et al. 1992). Indeed,
the loss of synapses in the neocortex and lim-
bic system is the best correlate of the cognitive
impairment in patients with AD (DeKosky
and Scheff 1990; Terry et al. 1991; DeKosky
et al. 1996).
In addition to the lesions detected by clas-
sical histopathological stains, including silver
stains for tangles and plaques or immunostain-
ing and quantitative analysis (or quantitative
EM) for synaptic alterations, several lines of
investigation now support the view that in-
creased levels of soluble amyloid-b1–42 (Ab)
oligomers, might lead to synaptic damage
and neurodegeneration (Lambert et al. 1998;
Klein et al. 2001; Klein 2002; Walsh et al.
2002;Walsh and Selkoe 2004; Glabe 2005; Lesne
et al. 2006; Townsend et al. 2006; Lacor et al.
2007). In experimental models, it has been
shown that transsynaptic delivery of Ab, for
example from the entorhinal cortex to the
molecular layer of the dentate gyrus, promotes
neurodegeneration characterized by synapse
loss (Harris et al. 2010a) and alterations to
calbindin-positive neurons (Palop et al. 2003).
This is accompanied by circuitry dysfunction
and aberrant innervation of the hippocampus
by NPY-positive fibers among others (Harris
et al. 2010b; Palop et al. 2011). The Ab oligo-
mers secreted by cultured neurons inhibit long-
term potentiation (LTP), damage spines and
interfere with activity-regulated cytoskeleton
associated protein (Arc) distribution (Klein
et al. 2001; Walsh and Selkoe 2004; Townsend
et al. 2006; Selkoe 2008). Together, these studies
indicate that Ab oligomers ranging in size
from 2 to 12 subunits might be responsible for
the synaptic damage and memory deficits in
AD (Lacor et al. 2007). Similar neurotoxic
Ab oligomers found in vitro and in APP trans-
genic models have been also identified in the
CSF (Klyubin et al. 2008) and in the brains
of patients with AD (Shankar et al. 2008;
McDonald et al. 2010; Pham et al. 2010).
These studies have shown that Ab oligomers
progressively accumulate in the brains of AD
patients, although their relationship to the
severity of the cognitive impairment remains
uncertain.
In summary, in recent years, the concept of
neurodegeneration in AD has been expanded
from the idea of general neuronal loss and astro-
gliosis to include earlier alterations such as syn-
aptic and dendritic injury and disturbances in
the process of adult neurogenesis (Jin et al.
2004; Li et al. 2008; Crews et al. 2010), circuitry
dysfunction, and aberrant innervation. All of
these factors are important targets to consider
when developing neuroprotective treatments
for AD.
MACROSCOPIC FEATURES
Although the gross visual examination of the
AD brain is not diagnostic, a typical symmetric
pattern of cortical atrophy predominantly
affecting the medial temporal lobes and rela-
tively sparing the primary motor, sensory, and
visual cortices, is considered strongly sugges-
tive of AD being the condition underlying the
patient’s dementia. As a result of this pattern
of cortical thinning, the lateral ventricules, par-
ticularly their temporal horns, can appear
prominently dilated (ex vacuo hydrocephalus).
This pattern is stereotypic and can be recog-
nized early in the clinical course of the disease
by MRI scan (Dickerson et al. 2009, 2011).
Cerebrovascular disease, usually in the form of
small vessel occlusive disease caused by chronic
hypertension and other vascular risk factors, is
a condition that frequently accompanies ag-
ing in general and also AD in particular. Thus,
it is relatively common to find some cortical
Neuropathological Alterations in Alzheimer Disease
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microinfarcts, lacunar infarcts in the basal
ganglia, and demyelination of the periven-
tricular white matter. The presence of cortical
petechial microbleeds or even evident lobar
hemorrhages, particularly in the posterior
parietal and occipital lobes, should lead to the
suspicion of a concurrent severe cerebral amy-
loid angiopathy. Unless there is a concomitant
Parkinson’s disease or dementia with Lewy
bodies, the substantia nigra shows a normal
coloration; in contrast, the locus coeruleus is
affected in the early stages of AD (Braak and
Del Tredici 2011).
MICROSCOPIC FEATURES
Neurofibrillary Tangles
Composition
The neurofibrillary tangles (NFTs) were first
described by Alois Alzheimer in his original
autopsy case report as intraneuronal filamen-
tous inclusions within the perikaryal region of
pyramidal neurons. Ultrastructural studies on
AD brain specimens revealed that NFTs are pri-
marily made of paired helical filaments (PHFs),
that is, fibrils of 10 nm in diameter that form
pairs with a helical tridimensional conforma-
tion at a regular periodicity of 65 nm (Kidd
1963, 1964; Wisniewski et al. 1976). A small
proportion of fibrils within the NFTs do not
form pairs, but give the appearance of straight
filaments without the periodicity of PHFs
(Crowther 1991). Occasional hybrid filaments,
with a sharp transition between a paired he-
lical segment and a straight segment, have also
been described within NFTs (Crowther 1991).
Recently, modern high-resolution molecular
microscopy techniques have revealed the pres-
ence of twisted ribbon-like assemblies of tau
fibrils in vitro, thus challenging the PHF
concept (Wegmann et al. 2010). Regardless of
the morphology of their structural units, the
major constituent of NFTs was found to be the
microtubule-associated protein tau, which is
aberrantly misfolded and abnormally hyper-
phosphorylated. Invariably accompanying NFTs
are the neuropil threads, which are thought to
result from the breakdown of dendrites and
axons of the tangle-bearing neurons.
Morphological Characteristics
The NFTs are argyrophilic and can be shown
by silver impregnation methods such as the
Gallyas technique (Braak and Braak 1991).
An alternative method to examine NFTs is their
staining with fluorescent dyes such as Thiofla-
vin-S, which recognize the b-sheet pleated
structure of the paired helical filaments (Arnold
et al. 1991), or by immunostaining with anti-
tau antibodies (Fig. 1). Three morphological
stages have been distinguished: (1) Pre-NFTs
or diffuse NFTs are defined by a diffuse, some-
times punctate, tau staining within the cyto-
plasm of otherwise normal-looking neurons,
with well-preserved dendrites and a centered
nucleus; (2) Mature or fibrillar intraneuronal
NFTs (iNFTs) consist of cytoplasmic filamen-
tous aggregates of tau that displace the nucleus
toward the periphery of the soma and often
extend to distorted-appearing dendrites and
to the proximal segment of the axon; (3) extra-
neuronal “ghost” NFTs (eNFTs) result from
the death of the tangle-bearing neurons and
are identifiable by the absence of nucleus
and stainable cytoplasm (Su et al. 1993;
Braak et al. 1994; Augustinack et al. 2002).
Both silver and Thioflavin-S stains, as well as
some phosphotau antibodies such as AT8 and
PHF1, preferentially identify the iNFTs and
the eNFTs (Braak et al. 1994; Augustinack
et al. 2002). By contrast, other phosphoepitopes
(e.g., pThr153, pSer262, pThr231) and a certain
conformational epitope recognized by the anti-
bodiesMC1 and Alz50 also recognize pre-NFTs,
suggesting that the misfolding of the tau mole-
cule and its phosphorylation in certain sites
represent an early step prior to tau aggregation
(Carmel et al. 1996; Weaver et al. 2000; Augusti-
nack et al. 2002). Interestingly, the immuno-
reactivity for a caspase-cleaved form of tau
with a faster rate of fibrillization than the full
length molecule in vitro colocalize with Alz50
immunoreactivity in pre-NFTs, suggesting
that the caspase-mediated cleavage of the car-
boxy-terminal region of the tau molecule is
A. Serrano-Pozo et al.
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also a necessary step prior to further aggrega-
tion (Guillozet-Bongaarts et al. 2005).
Topographical Distribution
The spatiotemporal pattern of progression of
NFTs (and neuropil threads in parallel) is ra-
ther stereotypical and predictable (Arnold et al.
1991; Braak and Braak 1991; Braak et al.
2006). Briefly, the neurofibrillary degeneration
starts in the allocortex of the medial temporal
lobe (entorhinal cortex and hippocampus)
and spreads to the associative isocortex, rela-
tively sparing the primary sensory, motor, and
visual areas. In their clinicopathological study,
Braak and Braak distinguished six stages that
can be summarized in three: entorhinal, limbic,
and isocortical (Fig. 2). The first NFTs consis-
tently appear in the transentorhinal (perirhi-
nal) region (stage I) along with the entorhinal
cortex proper, followed by the CA1 region of
the hippocampus (stage II). Next, NFTs develop
and accumulate in limbic structures such as
the subiculum of the hippocampal formation
(stage III) and the amygdala, thalamus, and
claustrum (stage IV). Finally, NFTs spread to
all isocortical areas (isocortical stage), with the
associative areas being affected prior and more
severely (stage V) than the primary sensory,
motor, and visual areas (stage VI). A severe
involvement of striatum and substantia nigra
can occur during the late isocortical stage.
Of note, this neurofibrillary degeneration fol-
lows a laminar pattern affecting preferentially
the stellate neurons of layer II, the superficial
portion of layer III, and the large multipolar
neurons of layer IV within the entorhinal cor-
tex; the stratum pyramidale of CA1 and subicu-
lumwithin the hippocampal formation, and the
pyramidal neurons of layers III and Vwithin the
isocortical areas (Hyman et al. 1984; Arnold
et al. 1991; Braak and Braak 1991).
Clinicopathological Correlations
Multiple clinicopathological studies from differ-
ent groups have established that the amount and
distribution of NFTs correlate with the severity
and the duration of dementia (Arriagada et al.
1992a; Bierer et al. 1995; Go´mez-Isla et al.
A B C
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Figure 1. Photomicrographs of the core pathological lesions observed in Alzheimer and Lewy body diseases.
(A) Plaque evident on routine H&E stained section of frontal cortex; (B) tangle in a hippocampal pyramidal
neuron on routine H&E stained section; (C) silver stain highlights both a plaque and a tangle; (D) immunohis-
tochemistry against Ab highlights plaques; (E) immunohistochemistry against tau highlights tangles; (F) a cort-
ical Lewy body can be seen in a layer V neuron on a routine H&E stained section of frontal cortex.
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1997; Giannakopoulos et al. 2003; Ingelsson
et al. 2004). Moreover, the selective rather
than widespread topographical distribution of
NFTs described above matches with the hier-
archical neuropsychological profile typical of
the AD-type dementia syndrome. The promi-
nent initial impairment of episodic memory
characteristic of AD is explained by the isolation
of the medial temporal lobe structures from the
association isocortex and the subcortical nuclei
because of the ongoing massive neurofibrillary
degeneration. Next, the involvement of multi-
modal high-order association isocortical areas
accounts for the progressive impairment of
additional cognitive domains, including execu-
tive dysfunction (prefrontal cortex), apraxias
(parietal cortex), visuospatial navigation defi-
cits (occipitoparietal cortex), visuoperceptive
deficits (occipitotemporal cortex), and seman-
tic memory (anterior temporal cortex), giving
rise to the full-blown dementia syndrome. By
contrast, the late involvement of primary
motor, sensory, and visual isocortical areas
explains the sparing of motor, sensory, and
primary visual functions (Hyman et al. 1984;
Arnold et al. 1991; Braak and Braak 1991).
However, as discussed below, whether NFT
formation is a necessary precursor of the neu-
ronal death in AD or represents a protective re-
sponse of damaged neurons (and thus more of
a surrogate marker of the ongoing pathological
process) is still controversial.
Amyloid Plaques
Composition
The senile plaques described by Alois Alzheimer
in his original case report result from the abnor-
mal extracellular accumulation and deposition
of the amyloid-b peptide (Ab) with 40 or 42
amino acids (Ab40 and Ab42), two normal
byproducts of the metabolism of the amyloid
precursor protein (APP) after its sequential
cleavage by the enzymes b- and g-secretases in
neurons. Because of its higher rate of fibrilliza-
tion and insolubility, Ab42 is more abundant
than Ab40 within the plaques.
Transentorhinal
(I-II)
4 3-1-2
18
PrecCg
Amyg
EC
CAI 18
17
Limbic
(III-IV)
Isocortical
(V-VI)
Figure 2. Spatiotemporal pattern of neurofibrillary degeneration. Shading indicates the distribution of NFTs
with darker colors representing increasing densities. Amyg ¼ Amygdala; EC ¼ Entorhinal cortex; CA1 ¼ Cor-
nus ammonis 1 hippocampal subfield; Cg ¼ Cingulate cortex; Prec ¼ Precuneus; 4 ¼ Primary motor cortex;
3-1-2 ¼ Primary sensory cortex; 17 ¼ Primary visual cortex; 18 ¼ Associative visual cortex (data based on
Arnold et al. 1991; Braak and Braak 1991; Arrigada et al 1992a,b; Braak et al. 1994).
A. Serrano-Pozo et al.
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Morphological Characteristics
Attempts to understand the evolution of the
amyloid plaque after its formation based on
morphological criteria gave rise to a number
of terms, including “primitive,” “classical,”
and “burn-out” plaques. However, a more prac-
tical and widely used morphological classifi-
cation distinguishes only two types of amyloid
plaques–diffuse versus dense-core plaques-
based on their staining with dyes specific for
the b-pleated sheet conformation such as
Congo Red and Thioflavin-S. This simpler cat-
egorization is relevant to the disease because,
unlike diffuse Thioflavin-S negative plaques,
Thioflavin-S positive dense-core plaques are
associated with deleterious effects on the sur-
rounding neuropil including increased neurite
curvature and dystrophic neurites, synaptic
loss, neuron loss, and recruitment and activa-
tion of both astrocytes and microglial cells
(Itagaki et al. 1989; Masliah et al. 1990, 1994;
Pike et al. 1995; Knowles et al. 1999; Urbanc
et al. 2002; Vehmas et al. 2003). Indeed, diffuse
amyloid plaques are commonly present in the
brains of cognitively intact elderly people,
whereas dense-core plaques, particularly those
with neuritic dystrophies, are most often found
in patients with AD dementia. However, the
pathological boundaries between normal aging
and AD dementia are not clear-cut and, as we
will further discuss below, many cognitively
normal elderly people have substantial amyloid
burden in their brains.
Electron microscopy studies revealed that
the ultrastructure of dense-core plaques is
comprised of a central mass of extracelullar fila-
ments that radially extend toward the periphery,
where they are intermingled with neuronal,
astrocytic, and microglial processes. These neu-
ronal processes, known as dystrophic neurites,
often contain packets of paired helical filaments,
as well as abundant abnormal mitochondria
and dense bodies of probable mitochondrial
and lysosomal origin (Kidd 1964; Hirai et al.
2001; Fiala et al. 2007). Plaque-associated
neuritic dystrophies represent the most noto-
rious evidence of Ab-induced neurotoxicity
and feature many of the pathophysiological
processes downstream Ab. Their origin can
be axonal or dendritic and their morphology
can be either elongated and distorted or
bulbous (Su et al. 1993). They can be argyro-
phylic (Fig. 1C) and Thioflavin-S positive
because of the aggregation of b-sheet pleated
tau fibrils, which can also be shown with
many phosphotau and conformation-specific
tau antibodies (Su et al. 1993, 1994, 1996).
Interestingly, dystrophic neurites can also be
immunoreactive for APP (Cras et al. 1991;
Su et al. 1998). Cytoskeletal abnormalities in
dystrophic neurites explain their immunoreac-
tivity for neurofilament proteins (Su et al.
1996, 1998; Dickson et al. 1999; Knowles et al.
1999). These cytoskeletal abnormalities can
lead to a disruption of the normal axonal trans-
port and, indeed, a subset of dystrophic neurites
are positive for mitochondrial porin and
chromogranin-A because of the abnormal ac-
cumulation of mitochondria and large synap-
tic vesicles, respectively (Dickson et al. 1999;
Woodhouse et al. 2006a; Pe´rez-Gracia et al.
2008). Moreover, some axonal dystrophic
neurites contain either cholinergic, glutamater-
gic, or gabaergic markers, suggesting a plaque-
induced aberrant sprouting (Benzing et al.
1993; Ferrer et al. 1993; Masliah et al. 2003;
Bell et al. 2007). Finally, dystrophic neurites
can be displayed with immunohistochemical
studies for ubiquitin and lysosomal proteins,
indicating that there is a compensatory attempt
to degrade and clear the abnormal accumula-
tion of proteins and organelles (Dickson et al.
1990; Barrachina et al. 2006). A less-evident
expression of the plaque-induced neuritic
changes is the increase in the curvature of
neurites located in the proximity of dense-core
plaques (Knowles et al. 1999).
Topographic Distribution
Unlike NFTs, amyloid plaques accumulate
mainly in the isocortex. Although the spatio-
temporal pattern of progression of amyloid
deposition is far less predictable than that of
NFTs, in general the allocortex (including
entorhinal cortex and hippocampal forma-
tion), the basal ganglia, relevant nuclei of the
Neuropathological Alterations in Alzheimer Disease
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brainstem, and the cerebellum, are involved to a
lesser extent and later than the associative iso-
cortex. The dissociation between amyloid and
NFT burdens in the medial temporal lobe is
particularly noticeable. Among the isocortical
areas, likewise NFTs, primary sensory, motor,
and visual areas tend to be less affected as com-
pared to association multimodal areas. (Arnold
et al. 1991; Braak and Braak 1991). Despite this
poorer predictability of the progression of
amyloid deposition, two staging systems have
been proposed. Braak and Braak distinguished
three stages: (1) Stage A, with amyloid deposits
mainly found in the basal portions of the
frontal, temporal, and occipital lobes; (2) Stage
B, with all isocortical association areas affected
while the hippocampal formation is only mildly
involved, and the primary sensory, motor,
and visual cortices are devoid of amyloid;
and (3) Stage C, characterized by the deposition
of amyloid in these primary isocortical areas
and, in some cases, the appearance of amyloid
deposits in the molecular layer of the cerebel-
lum and subcortical nuclei such as striatum,
thalamus, hypothalamus, subthalamic nucleus,
and red nucleus (Braak and Braak 1991). Thal
et al. proposed a descendent progression of
amyloid deposition in five stages: (1) Stage 1
or isocortical; (2) Stage 2, with additional
allocortical deposits (entorhinal cortex, hippo-
campal formation, amygdala, insular, and
cingulated cortices); (3) Stage 3, with additional
involvement of subcortical nuclei including
striatum, basal forebrain cholinergic nuclei,
thalamus and hypothalamus, and white matter;
(4) Stage 4, characterized by the involvement
of brainstem structures, including red nucleus,
substantia nigra, reticular formation of the
medulla oblongata, superior and inferior
colliculi; and (5) Stage 5, with additional
amyloid deposits in the pons (reticular forma-
tion, raphe nuclei, locus ceruleus) and the
molecular layer of the cerebellum (Thal et al.
2002). These five Thal stages can be summar-
ized in three: stage 1 or isocortical; stage 2, allo-
cortical or limbic, and stage 3 or subcortical
(Fig. 3).
Amyloid deposits usually involve the six
layers of the isocortex, although layers I and
VI are usually relatively more spared than layers
II-V (Arnold et al. 1991; Braak and Braak 1991).
However, in advanced cases it is frequent to
observe band-like diffuse amyloid deposits in
the subpial surface of the cortex and even a
few amyloid deposits in the white matter close
to its transition with the cortical layer VI.
Pons
ECEC
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A B C
Cg
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s
Figure 3. Spatiotemporal pattern of amyloid plaque deposition according to Thal et al. (2002). Coronal (A), axial
(B), and sagittal (C) views of the brain. The five Thal stages of amyloid deposition are here summarized in three
stages. Amyloid deposits accumulate first in isocortical areas (stage 1 or isocortical, in red), followed by limbic
and allocortical structures (stage 2 or limbic, in orange), and in a later stage, by subcortical structures including
basal ganglia, selected nuclei in diencephalon and brainstem, and the cerebellar cortex (stage 3 or subcortical, in
yellow). Amyg ¼ Amygdala; EC ¼ Entorhinal cortex; Hipp ¼ Hippocampus; Cg ¼ Cingulate cortex; Cd ¼
Caudate nucleus; Put ¼ Putamen; Gpe ¼ Globus pallidus externus; Gpi ¼ Globus pallidus internus; Cl ¼
Claustrum; Ins ¼ Insular cortex; Die ¼ Diencephalon; Mid ¼ Midbrain; Med ¼ Medulla oblongata; Cblm
¼ Cerebellum.
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Clinicopathological Correlations
Clinicopathological studies have established that
the amyloid burden (either total amyloidplaques,
dense-core plaques oronly neuritic plaques) does
not correlate with the severity or the duration of
dementia (Arriagada et al. 1992a, Hyman et al.
1993; Bierer et al. 1995; Go´mez-Isla et al. 1997;
Giannakopoulos et al. 2003; Ingelsson et al.
2004). Indeed, in a region of early amyloid depo-
sition such as the temporal associative isocortex,
the amyloid burden reaches a plateau early after
the onset of the cognitive symptoms or even in
the preclinical phase of the disease (Ingelsson
et al. 2004; Serrano-Pozo et al. 2011) and not
even the size of the plaques grows significantly
with the progression of the disease (Hyman
et al. 1993). However, it is possible that the
amount of amyloid measured over the entire
cortical mantle does increase during the clinical
course of the disease as the distribution of amy-
loid deposits “spread” following the above stages.
Preliminary data from longitudinal amyloid PET
imaging studies in living patients have recently
supported this possibility (Jack et al. 2009).
Cerebral Amyloid Angiopathy
Composition
The amyloid-b peptide not only deposits in
the brain parenchyma in the form of amyloid
plaques but also in the vessel walls in the form
of cerebral amyloid angiopathy (CAA). Indeed,
themore insoluble and aggregation-prone Ab42
peptide tends to accumulate in the core of
senile plaques, while the more soluble Ab40
peptide is the major constituent of CAA, accu-
mulating mainly in the interstitium between
the smooth muscle cells of the tunica media.
Although CAA can also appear in isolation
(pure CAA), it is more common in the context
of AD, with 80% of AD patients showing
some degree, usually mild, of CAA at autopsy,
Morphological Characteristics
The same methods described for the examina-
tion of amyloid plaques are valid for CAA,
that is Thioflavin-S or Congo red staining or
immunohistochemical studies with anti-Ab
antibodies. A morphological staging system
has been implemented to describe the severity
of CAAwithin a single vessel: grade 0 or absence
of staining; grade 1 or congophilic rim around
an otherwise nomal-appearance vessel; grade 2
or complete replacement of the tunica media
by congophilic material; grade 3 or cracking of
50% of the circumference of the vessel, giving
a “vessel-within-vessel” or “double-barrel” ap-
pearance; and grade 4 or fibrinoid necrosis of
the vessel wall, often accompanied by additional
amyloid deposits in the surrounding neuropil
(“dyshoric” changes) (Greenberg and Vonsattel
1997). In this severe stage, Prussian blue (Perl’s)
staining is useful to show hemosiderin-laden
macrophages in the parenchyma surrounding
CAA-affected vessels, indicative of chronic
microbleeds.
Topographic Distribution
CAA usually affects cortical capillaries, small
arterioles and middle-size arteries as well as
leptomeningeal arteries, whereas venules, veins,
and white-matter arteries are rarely involved.
For unknown reasons, posterior parietal and
occipital areas are usually more prominently
affected than frontal and temporal lobes, and
within the same area, leptomeningeal arteries
usually show more severe CAA than cortical
arteries. A semiquantitative scoring system has
been proposed to characterize the severity of
CAA within a region of the cortex: 0 ¼ no
Thioflavin-S-stained leptomeningeal or cortical
vessels; 1 ¼ scattered positivity in either lepto-
meningeal or cortical vessels; 2 ¼ strong cir-
cumferential positivity in at least some vessels
either leptomeningeal or cortical; 3 ¼ wide-
spread circumferential staining in many
leptomeningeal and cortical vessels, and 4 ¼
presence of “dyshoric” perivascular amyloid
deposits in addition to score 3. A global severity
score can be obtained by averaging the scores
from several regions (Olichney et al. 2000).
Clinicopathological Correlations
According to the Boston criteria, CAA should
be suspected after one or multiple major symp-
tomatic lobar hemorrhages in an elderly patient
Neuropathological Alterations in Alzheimer Disease
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(Knudsen et al. 2001). But in the context of
AD, unless it becomes symptomatic because of
this hemorrhagic complication, CAA is usually
diagnosed at autopsy. However, three inde-
pendent postmortem longitudinal studies have
revealed that the otherwise apparently asympto-
matic CAA can also be a synergistic contributor
to cognitive decline in AD (MRC CFAS 2001;
Pfeifer et al. 2002; Greenberg et al, 2004;
Arvanitakis et al. 2011).
Granuovacuolar Degeneration and
Hirano Bodies
Granulovacuolar degeneration (GVD) and Hi-
rano bodies are two poorly understood lesions
present in the cytoplasm of hippocampal pyra-
midal neurons of AD patients. Although they
are increasingly observed with aging in cogni-
tively intact elderly people, these two lesions
are more severe and frequent in age-matched
AD patients. (Ball 1978; Xu et al. 1992).
GVD consists of the accumulation of large
double-membrane bodies. Their origin and
significance are uncertain. Early immunohisto-
chemical studies reported immunoreactivity
of GVD bodies for cytoskeletal proteins includ-
ing tubulin, neurofilament proteins and tau
(Kahn et al. 1985; Price et al. 1986; Dickson
et al. 1987; Bondareff et al. 1991; Mena et al.
1992; Ikegami et al. 1996). Because GVD bodies
are also positive for some tau kinases, a role in
tangle formation has been proposed (Ghoshal
et al. 1999; Leroy et al. 2002; Kannanayakal
et al. 2006). Other authors have postulated a
role in the apoptotic cell death because of
their immunoreactivity for activated caspase-3
(Selznick et al. 1999; Stadelmann et al. 1999;
Su et al. 2002). More recent studies have
suggested that these bodies might derive from
the endoplasmic reticulum and represent the
stress granules that feature the unfolded protein
response, because they are positive for several
stress kinases (Zhu et al. 2001; Lagalwar et al.
2007; Thakur et al. 2007; Hoozemans et al.
2009). Finally, based on their positivity for
ubiquitin and autophagic markers, it has been
proposed that these granules are late-stage
autophagic vacuoles (Okamoto et al. 1991;
Barrachina et al. 2006; Yamazaki et al. 2010;
Funk et al. 2011).
Hirano bodies are eosinophilic rod-like
cytoplasmic inclusions relatively common in the
stratum lacunosum of the hippocampal CA1
region in the elderly. However, in AD patients
the number of Hirano bodies is abnormally
high and they are translocated to the neurons of
the stratum pyramidale (Gibson and Tomlison
1977). Although the significance of Hirano
bodies in AD is not completely understood,
they are recognized by antibodies against tau,
neurofilament proteins, actin, and other cytoske-
letal proteins (Goldman 1983; Galloway et al.
1987a,b; Schmidt et al. 1989; Maciver and Har-
rington 1995; Rossiter et al. 2000). Other immu-
noreactivities associated with Hirano bodies are
inducible nitric oxide synthase (Lee et al. 1999),
advanced glycation endproducts (Mu¨nch et al.
1998), and the carboxy-terminal fragments of
APP (Mun˜oz et al. 1993).
Glial Responses
Reactive astrocytes and activatedmicroglial cells
are commonly associated to dense-core amyloid
plaques, indicating that amyloid-b is a major
trigger of this glial response (Itagaki et al.
1989; Pike et al. 1995; Vehmas et al. 2003). How-
ever, we have recently observed a linear increase
in reactive astrocytes and activated microglial
cells through the entire disease course despite
an early plateau in amyloid deposition in
the temporal associative isocortex. Indeed, we
found a highly significant positive correlation
between both astrocytosis and microgliosis
and NFT burden but not between both reactive
glial cell types and amyloid burden, suggesting
that glial responses are also related to neuro-
fibrillary degeneration (Ingelsson et al. 2004;
Serrano-Pozo et al. 2011).
Neuronal Loss
Neuronal loss is the main pathological substrate
of cortical atrophy and, although usually evi-
dent in sections stained with hematoxylin
and eosin, it can be more readily shown with a
Nissl staining or a NeuN immunohistochem-
istry. Nissl staining (for example with cresyl
A. Serrano-Pozo et al.
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violet) reveals the negatively charged riboso-
mic RNA present in the ribosomes of the rough
endoplasmic reticulum (Nissl substance or
granules), giving a dark blue appearance to
the perinuclear region of neurons. By contrast,
NeuN is a neuronal-specific nuclear antigen,
although NeuN immunohistochemistry also
stains the perinuclear region and some proxi-
mal processes of neurons.
The regional and laminar pattern of neuro-
nal loss matches that of NFTs, but, importantly,
within the same region neuronal loss exceeds
the numbers of NFTs, so that it is a better corre-
late of cognitive deficits than the number of
NFTs (Go´mez-Isla et al. 1996, 1997). Indeed,
quantitative stereology-based studies of neu-
rons, iNFTs and eNFTs have concluded that
iNFTs can last for up to two decades and that
neurons bearing iNFTs might still be viable as
evidenced by their positive Nissl staining (Bus-
sie´re et al. 2003; Hof et al. 2003). This dissocia-
tion between the extent of neuronal loss and
that of NFTs suggests that there are least two
mechanisms of neuronal death in AD: one
affecting tangle-bearing neurons, that will lead
to the appearance of ghost extracellular tan-
gles, and another affecting tangle-free neurons.
Although the mechanisms of neuronal death in
AD are beyond the scope of this article, it will be
noted that postmortem studies on apoptosis
have yielded controversial results, with some
studies showing a widespread distribution of
apoptotic markers (Troncoso et al. 1996; Su
et al. 2001), while others have only reported a
scattered distribution (Selznick et al. 1999;
Woodhouse et al. 2006b).
Synapse Loss
Besides neuronal loss, synapse loss is another
contributor to the cortical atrophy of the AD
brain. Synapse loss in AD was shown with
immunohistochemical studies using antibodies
against pre- or postsynaptic proteins—typically
the presynaptic protein synaptophysin—and
with electron microscopy studies.
The spatiotemporal and laminar pattern of
synapse lossmatches that of neuron loss. Synap-
tic loss is not only caused by neuronal loss but
can exceed the existing neuronal loss within a
particular cortical area. This indicates that syn-
apse loss predates neuronal loss and that the
remaining neurons become less well connected
to their synaptic partners than expected just by
the number of viable neurons surviving in a
particular circuit. Likely this is why synaptic
density is the best correlate of cognitive decline
in AD (DeKosky and Scheff 1990; Scheff et al.
1990, 1993, 2007; Terry et al. 1991; Masliah
et al. 1994; Ingelsson et al. 2004). Interestingly,
an inverse correlation has been observed
between synaptic density and the size of re-
maining synapses as measured by the length of
the postsynaptic density. This enlargement of
remaining synapses has been interpreted as a
compensatory response, rather than as selective
loss of small synapses (DeKosky and Scheff
1990; Scheff et al. 1990; Scheff and Price 1993).
CRITERIA FOR THE PATHOLOGICAL
DIAGNOSIS OF ALZHEIMER DISEASE
Of all pathological features described above,
amyloid plaques and NFTs are the most charac-
teristic of AD and, understandably, the criteria
for the pathological diagnosis of AD rely on
their amount and/or distribution.
The first pathological criteria for the diag-
nosis of AD were based on the highest density
of total amyloid plaques (both diffuse and
neuritic) in any cortical field, adjusted for
age so that the older the patient at death, the
greater the density required for diagnosis
(Khachaturian 1985). The presence of NFTs
was not required and diffuse plaques—relatively
frequent in nondemented elderly people—had
the same consideration as neuritic plaques.
Although meritorious, these criteria were soon
abandoned because, despite a very high sensi-
tivity to diagnose AD dementia, they lacked
sufficient specificity (Geddes et al. 1997). In
1991, the Consortium to Establish a Registry for
Alzheimer Disease (CERAD) proposed more
specific diagnostic criteria by emphasizing the
importance of neuritic plaques over diffuse
plaques (Mirra et al. 1991, 1997). CERAD criteria
use a semiquantitative score of the densityof neu-
ritic plaques in themost severelyaffected regionof
Neuropathological Alterations in Alzheimer Disease
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the isocortex (frontal, temporal, or parietal) and
the patient’s age at death to obtain an age-related
plaque score. This score is then integrated with
clinical information regarding the presence or
absence of dementia to establish one of three lev-
els of certainty that dementia is explained by the
AD pathological changes: possible, probable,
and definite. A diagnosis of AD is made if the
criteria for probable or definite AD are met.
Although higher than that of Khachaturian crite-
ria, the specificity of CERADcriteria proved to be
still insufficient because they did not incorporate
the scoring of the severity of NFTs (Geddes et al.
1997). By contrast, the use of Braak and Braak
staging ofNFTs alone—with the isocortical stages
V and VI as criteria of definite AD—showed a
high specificity at the expense of a low sensitivity
(Geddes et al. 1997).
Current pathological criteria for AD were
defined in 1997 by a workshop of the National
Institute of Aging and the Reagan Institute.
The NIA-RI consensus recommendations com-
bine the CERAD semiquantitative score of neu-
ritic plaques and the Braak and Braak staging
of NFTs to distinguish three probabilistic diag-
nostic categories: (1) high likelihood, if there
are frequent neuritic plaques (CERAD definite)
and abundant isocortical NFTs (Braak stage V/
VI); (2) intermediate likelihood, if there are
moderate neuritic plaques (CERAD probable)
and NFTs are restricted to limbic regions (Braak
III/IV), and (3) low likelihood, if there are
infrequent neuritic plaques (CERAD possible)
and NFTs are restricted to the entorhinal cortex
and/or hippocampus (Braak I/II). A diagnosis
of AD is made when the criteria for inter-
mediate or high likelihood of AD are met and
the patient had a clinical history of dementia
(NIA-RI Consensus 1997). Because experience
has revealed infrequent cases with many AD
pathological lesions but no or few cognitive
symptoms (and vice versa) and these circum-
stances were not addressed by the NIA-RI con-
sensus workgroup, these diagnostic criteria are
currently under review.
Both CERAD and NIA-RI criteria also
incorporated the assessment of other patholo-
gies, particularly vascular and Lewy body dis-
eases, already recognizing the high prevalence
of mixed pathologies underlying dementia in
elderly people, a circumstance well documented
by more recent longitudinal community-based
clinicopathological studies (MRC CFAS 2001;
Schneider et al. 2007). Thus, in many practical
instances, the CERAD criteria for “possible
AD” and the NIA-RI criteria for “intermediate
probability of AD” are not only based on amod-
erate amount and distribution of AD pathology
but also on the coexistence of vascular or Lewy
body pathology with sufficient severity to con-
tribute to the patient’s dementia.
NEUROPATHOLOGY OF MILD COGNITIVE
IMPAIRMENT AND EARLY ALZHEIMER
DISEASE
Clinicopathological correlation studies have
taught us that at the moment of the clinical
diagnosis, patients with AD-type dementia
often already have a Braak stage V or VI of
neurofibrillary degeneration and a substantial
and widespread synaptic and neuronal loss. To
anticipate the clinical diagnosis of AD before
the stage of full-blown dementia, a new clinical
construct was needed. Petersen et al. proposed
the concept of “mild cognitive impairment”
(MCI) as a new diagnostic entity for the transi-
tion between normal aging and AD dementia.
Patients with MCI have already some cognitive
complaints that are detectable with the appro-
priate cognitive tests and represent a decline
from a previous higher baseline level but that,
unlike the definition of dementia, do not inter-
fere with their activities of daily life. Impor-
tantly, MCI patients have an increased risk of
developing dementia, which has been reported
between 10% and 15% per year (Petersen
et al. 1999, 2001; Petersen 2004).
Autopsy studies on MCI patients are scarce
but they have reproducibly found a stage of
AD pathology intermediate between cognitively
intact subjects and demented patients, pa-
rticularly regarding neurofibrillary degenera-
tion, that is consistent with the idea of a
transition phase between normal aging and def-
inite AD (Jicha et al. 2006; Markesbery et al.
2006; Petersen et al. 2006; Schneider et al.
2009). Specifically, MCI patients usually have
A. Serrano-Pozo et al.
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a moderate number of neuritic plaques and a
limbic stage of NFTs (Braak stage III or IV), fit-
ting into the NIA-RI category of intermediate
likelihood of AD (sufficient to cause dementia)
and providing a pathological validation for this
clinical construct. Along the same lines, patients
with a Clinical Dementia Rating score of 0.5
(equivalent to MCI or very mild AD) have
already a30% of neuron loss in the entorhinal
cortex compared to cognitively intact controls
(CDR ¼ 0), but still no evident neuronal loss
in the superior temporal sulcus (Go´mez-Isla
et al. 1996, 1997). Moreover, electron micro-
scopy studies have shown that MCI patients
also have an intermediate number of synapses
between nondemented controls and mild AD
patients in the hippocampus, further indicating
that many individuals with the clinical symp-
toms of MCI have early AD (Scheff et al. 2006,
2007). Of note, a paradoxical, presumably
compensatory, up-regulation in the density of
presynaptic glutamatergic boutons has been
reported in the frontal cortex of MCI patients
compared to nondemented controls and mild
AD patients (Bell et al. 2007).
Although AD was the most common patho-
logical diagnosis underlying MCI in the above
case series, it should be noted that there was
a high degree of pathological heterogeneity
underlying the clinical diagnosis of MCI, with
vascular disease, Lewy body disease, argyro-
philic grain disease, and hippocampal sclerosis
as major concurrent or alternative pathologies
(Jicha et al. 2006; Petersen et al. 2006; Schneider
et al. 2009). Inaddition, in the largest studyahigh
proportion (up to 25%) of MCI patients had no
pathology at autopsy (Schneider et al. 2009).
Finally, no significant pathological differences
have been observed between the amnestic and
the nonamnestic subtypes of MCI nor in their
pathological outcomeafterconversion todemen-
tia (Jicha et al. 2006; Schneider et al. 2009).
ALZHEIMER NEUROPATHOLOGY IN
“NORMAL AGING”
Longitudinal prospective clinicopathological
studies in nondemented elderly people have
revealed that up to 45%of nondemented elderly
wouldmeet the NIA-RI criteria for AD had they
been demented, usually the intermediate likeli-
hood category of these criteria, and rarely the
high likelihood category (Schmitt et al. 2000;
Knopman et al. 2003; Bennet et al. 2006; Price
et al. 2009; Schneider et al. 2009). Moreover,
the pattern of regional distribution of patho-
logical changes in nondemented controls
matches that of AD patients (Arriagada et al.
1992b). Thus, mounting evidence from clini-
copathological studies support the view that
AD is a continuous spectrum between asym-
ptomatic lesions in cognitively normal elderly
and dementia, with MCI as a transition phase
between these two ends.
The apparent dissociation between AD
pathology and cognitive status in some elderly
people is remarkable because these so-called
“high-pathology nondemented controls” or
“individuals with asymptomatic AD” seem to
be resilient to the neurotoxic effects of amyloid
plaques and NFTs and to contradict the afore-
mentioned positive correlation between NFT
burden and cognitive decline. Understanding
the biochemical and morphological substrates
of this resilience to cognitive decline in the pres-
ence of abundant AD pathology might be cru-
cial to discover new therapeutic targets for the
disease. As expected from the highly significant
clinicopathological correlations of synaptic and
neuronal loss in AD, high-pathology controls
have preserved synaptophysin levels compared
to AD patients with a similar burden of plaques
and NFTs (Lue et al. 1996), and they do not
seem to have significant neuronal loss, not
even invulnerable regions such as the entorhinal
cortex and the hippocampus (Price et al. 2001;
West et al. 2004). Moreover, they have lower lev-
els of neuroinflammatory markers than pathol-
ogy-matched ADpatients (Lue et al. 1996). This
resistance to AD pathology has also been related
to a nucleolar, nuclear, and cell body hypertro-
phy of the hippocampal and cortical neurons,
suggestive of a compensatory metabolic acti-
vation to face the neurotoxic effects of AD le-
sions (Riudavets et al. 2007; Iacono et al.
2008). In keeping with these pathological
reports, a MRI-neuropathological correlation
study revealed larger brain and hippocampal
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volumes in high-pathology controls than in
pathology-matched demented patients, further
supporting the preservation of both neurons
and synapses (Erten-Lyons et al. 2009).
OVERLAP OF AD WITH LEWY
BODY DISEASE
Alzheimer disease and Parkinson’s disease (PD)
are the leading causes of dementia and move-
ment disorders in the aging population. It is
estimated that over 10 million people live with
these devastating neurological conditions in
the United States. It is estimated that over 10
million people live with these devastating neu-
rological conditions in the United States, and
that this country alone will see a 50% annual
increase of AD and PD by the year 2025 (Her-
bert et al. 2001).
PD and AD are two distinct clinicopatho-
logical entities. While in AD, abnormal accu-
mulation of misfolded Ab protein in the
neocortex and limbic system is thought to be
responsible for the neurodegenerative pathol-
ogy (Selkoe 1990; Sisodia and Price 1995),
intracellular accumulation of a-synuclein has
been centrally implicated in the pathogenesis
of PD (Spillantini et al. 1997; Hashimoto
et al. 1998; Trojanowski and Lee 1998). In AD,
Ab protein accumulates in the intracellular
(LaFerla et al. 1995; Skovronsky et al. 1998)
and extracellular space, leading to the forma-
tion of plaques, whereas intracellular polymeriza-
tion of phosphorylated cytoskeletal molecules
such as tau results in the formation of neuro-
fibrillary tangles (Greenberg and Davies 1990;
Lee et al. 2001). In PD, intracellular accumula-
tion of a-synuclein—an abundant synaptic ter-
minal protein (Iwai et al. 1995)—results in the
formation of characteristic inclusions called
Lewy bodies (LBs) (Fig. 1F) (Spillantini et al.
1997; Wakabayashi et al. 1997; Takeda et al.
1998). The new consortium criteria for the
classification of Lewy body diseases (LBD) rec-
ognizes two clinical entities, the first denomi-
nated dementia with LBs (DLB) and the
second PD dementia (PDD) (McKeith et al.
1996; Aarsland et al. 2004; Burn 2006; McKeith
2006; Lippa et al. 2007). While in patients with
DLB, the clinical presentation is of dementia
followed by parkinsonism, in patients with
PDD the initial signs are of parkinsonism fol-
lowed by dementia (Litvan et al. 1998; Janvin
et al. 2006; McKeith 2006). Interestingly, the
brains of patients with DLB and PDD display
very similar pathology, with the exception
that recent studies have shown extensive deposi-
tion of Ab and a-synuclein in the striatum
and hippocampus in DLB compared to only
a-synuclein in PDD cases (Duda et al. 2002;
Jellinger and Attems 2006). Because of the im-
plications for the management and treatment
of parkinsonism and dementia in patients with
PD and DLB, loss of dopaminergic neurons in
the midbrain (Dickson et al. 1994; Tsuboi and
Dickson 2005) and cholinergic cells in the
nucleus basalis of Meynert have been character-
ized in detail (Perry et al. 1978; Hansen et al.
1990). Although the severity of the neuronal
loss within these subcortical regions might
explain some of the neurological deficits in
patients with PD and DLB, the neuronal popu-
lations responsible for the more complex cogni-
tive and psychiatric alterations have not been
completely characterized. Abnormal accumula-
tion of a-synuclein in the CA2-3 region of the
hippocampus (Harding andHalliday 2001; Ber-
trand et al. 2004), insula, amygdala and cingu-
late cortex has been shown to be an important
neuropathological feature (Dickson et al. 1994;
Spillantini et al. 1997; Trojanowski et al. 1998;
Aarsland et al. 2004).
Remarkably, despite being initially con-
sidered distinct clinicopathological condi-
tions, several studies have now confirmed that
the clinical features and the pathology of AD
and PD can overlap (McKeith 2000, 2006; Lippa
et al. 2007). Approximately 25% of all patients
with AD develop parkinsonism, and about
50% of all cases of PD develop AD-type demen-
tia after 65 years of age (Hansen et al. 1990).
Moreover, 70% of patients with sporadic AD
display the formation of a-synuclein-positive
LB-like inclusions in the amygdala and limbic
structures (Lippa et al. 1998; Trojanowski et al.
1998; Hamilton 2000). Similarly, in patients
with familial AD (FAD) and Down syndrome,
LB-like pathology and parkinsonism have
A. Serrano-Pozo et al.
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been reported (Lippa et al. 1999). Last, as men-
tioned above, the single most important neuro-
pathological finding that distinguishes PDD
from DLB is the presence of Ab deposits in
the striatum (Duda et al. 2002) and in the hip-
pocampus (Masliah et al. 1993a).
A number of studies provide extensive sup-
port for an interaction between pathogenic
pathways in AD and LBD and argue against a
coincidental concurrence of both disorders
(i.e., merely because of their high prevalence
in the elderly). FAD cases with presenilin muta-
tions that present with significant LB pathology
strongly support an interaction between Ab
and a-synuclein (Rosenberg 2005; Snider et al.
2005; Leverenz et al. 2006). Although plaques,
tangles and LBs are useful neuropathological
and diagnostic markers of these disorders, the
initial injury that results in the cognitive and
movement alterations is likely the damage of
the synaptic terminals in selected circuitries
(DeKosky and Scheff 1990; Masliah and Terry
1993; Masliah et al. 1994, 2001a, Klucken et al.
2003). Several lines of investigation support
the notion that oligomeric forms of Ab and a-
synuclein, rather than the polymers and fibrils
associated with plaques and LBs, accumulate
in the neuronal membranes and lead to the
characteristic synaptic pathology (Lambert
et al. 1998; Conway et al. 2000; Lashuel et al.
2002; Haass and Selkoe 2007; Kramer and
Schulz-Schaeffer 2007; Koffie et al. 2009; Scott
et al. 2010). Some studies have shown that
underlying interactions between a-synuclein
and Ab play a fundamental role in the patho-
genesis of LBD (Lippa et al. 1998; Hashimoto
et al. 2000; Masliah et al. 2001b, Pletnikova
et al. 2005). Specifically, Ab promotes the oligo-
merization and toxic conversion of a-synuclein
(Masliah et al. 2001b; Mandal et al. 2006), Ab
exacerbates the deficits associated with a-synu-
clein accumulation, Ab and a-synuclein colo-
calize in membrane and caveolar fractions,
and Ab stabilizes a-synuclein multimers that
might form channel-like structures in themem-
brane (Tsigelny et al. 2007, 2008). Both lysoso-
mal leakage (Nixon and Cataldo 2006) and
oxidative stress (Smith et al. 1996) appear to
be involved in the process of neurotoxicity and
pathological interactions between Ab and
a-synuclein (Rockenstein et al. 2005).
Therefore, it is possible that the combined
effects ofa-synuclein and Abmight lead to syn-
aptic damage and selective degeneration of
neurons in the neocortical, limbic, and subcort-
ical regions. A more precise mapping of the
neuronal populations affected in these regions
is needed to understand the cellular basis for
the characteristic cognitive dysfunction in PDD
and DLB and to develop new treatments for
these conditions.
CONCLUSIONS
Classical neuropathological lesions including
senile amyloid plaques and neurofibrillary
tangles define AD but they likely represent the
“tip of the iceberg” of the pathological altera-
tions that cause the cognitive decline associated
with AD. Indeed, the development of new bio-
markers and imaging tools has made evident
that these neuropathological stigmata of AD
begin to accumulate a decade or more prior to
a clinical diagnosis of dementia. Synaptic loss,
plasticity changes, neuronal loss, and the pres-
ence of soluble microscopic oligomeric forms
of Ab and even of tau, likely contribute to the
progressive neural system failure that occurs
over decades. An understanding of this natural
history of the disease is critical to design pri-
mary or secondary prevention strategies to
halt the disease progression before the damage
to the neural system becomes irreversible.
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Reactive Glia not only Associates with Plaques but
also Parallels Tangles in Alzheimer’s DiseaseAlberto Serrano-Pozo,*† Matthew L. Mielke,*
Teresa Gómez-Isla,*† Rebecca A. Betensky,†‡
John H. Growdon,*† Matthew P. Frosch,*†¶ and
Bradley T. Hyman*†
From the Massachusetts General Hospital Institute for
Neurodegenerative Disease,* Massachusetts General Hospital, and
the Massachusetts Alzheimer Disease Research Center,†
Charlestown; the Harvard School of Public Health,‡ Boston; and
the C.S. Kubik Laboratory for Neuropathology,¶ Massachusetts
General Hospital, Boston, Massachusetts
Senile plaques are a prominent pathological feature
of Alzheimer’s disease (AD), but little is understood
about the association of glial cells with plaques or
about the dynamics of glial responses through the
disease course. We investigated the progression of
reactive glial cells and their relationship with AD
pathological hallmarks to test whether glial cells are
linked only to amyloid deposits or also to tangle de-
position, thus integrating both lesions as a marker of
disease severity. We conducted a quantitative stereol-
ogy-based post-mortem study on the temporal neo-
cortex of 15 control subjects without dementia and 91
patients with AD, includingmeasures of amyloid load,
neurofibrillary tangles, reactive astrocytes, and acti-
vated microglia. We also addressed the progression of
glial responses in the vicinity (<50 m) of dense-core
plaques and tangles. Although the amyloid load
reached a plateau early after symptom onset, astrocy-
tosis and microgliosis increased linearly throughout
the disease course. Moreover, glial responses corre-
lated positively with tangle burden, whereas astrocy-
tosis correlated negatively with cortical thickness.
However, neither correlated with amyloid load.
Glial responses increased linearly around existing
plaques and in the vicinity of tangles. These results
indicate that the progression of astrocytosis and
microgliosis diverges from that of amyloid deposi-
tion, arguing against a straightforward relationship
between glial cells and plaques. They also suggest
that reactive glia might contribute to the ongoing
neurodegeneration. (Am J Pathol 2011, 179:1373–1384;
DOI: 10.1016/j.ajpath.2011.05.047)Activated glia is a prominent feature of Alzheimer’s dis-
ease (AD) neuropathological features, with both reactive
astrocytes and activated microglia clustering around and
within dense-core amyloid plaques (ie, thioflavin-S–pos-
itive plaques).1 A better understanding of how these reac-
tive glial cells accrue during the disease course and how
they relate to the classic AD pathological hallmarks [ie,
amyloid plaques and neurofibrillary tangles (NFTs)] is cru-
cial for the following reasons: i) a body of preclinical evi-
dence implicates these glial cells in AD pathophysiological
features; ii) new positron emission tomographic (PET) radio-
tracers for amyloid plaques, NFTs, and, particularly, acti-
vated glial cells are being developed as diagnostic and
progression biomarkers; and iii) clinical trials with anti-in-
flammatory therapies, ranging from nonsteroidal anti-inflam-
matory drugs (NSAIDs) to i.v. Ig, are under development.
In a previous quantitative neuropathological study,2 we
observed a positive linear correlation between astrocytosis
in the temporal neocortex, as measured with a glial fibrillary
acidic protein (GFAP) enzyme-linked immunosorbent as-
say, and the duration of the disease from the onset of
cognitive symptoms, despite the plaque burden remaining
stable throughout the course of the disease. We hypothe-
sized that a certain threshold of amyloid burden might be
needed to trigger glial responses within a particular region
of the cortex and that, once triggered, glial responses would
reflect a pathogenic cascade increasingly independent of
plaques. In the present study, we sought to extend that
observation and test the hypothesis that, although initially
linked to plaques, glial responses increasingly reflect the
widespread ongoing neurodegenerative process. We
quantified the number of reactive astrocytes and activated
microglial cells in the temporal neocortex of a large cohort of
controls without dementia and subjects with AD at different
stages of the disease and investigated both their apparent
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AJP September 2011, Vol. 179, No. 3progression throughout the disease course and their relation
to the local burden of amyloid plaques and NFTs. Although
glial association with amyloid plaques has long been as-
sumed, we found a dissociation between these pathological
features, with a linear increase of reactive glia despite a rela-
tively stable plaque burden. The magnitude of these glial
changes correlated with the burden of NFTs. A closer analysis
in a subset of subjectswith AD revealed that reactive glial cells
increased both in the proximity of dense-core plaques and
near NFTs, thus supporting a previously not described asso-
ciation between glial responses and neurofibrillary degenera-
tion.
Materials and Methods
Brain Specimens and Immunohistochemical
Studies
Formalin-fixed, paraffin-embedded tissue specimens from
the temporal association isocortex (Brodmann area 38) of
91 patients with AD and 15 controls without dementia were
obtained from the Massachusetts Alzheimer Disease Re-
search Center Brain Bank. They were consecutively selected
by tissue availability. All of the study subjects or their next of kin
gave written informed consent for the brain donation, and the
Massachusetts General Hospital Institutional Review Board
approved the study protocol. The demographic characteris-
tics of both groups are depicted in Table 1. All of the patients
with AD fulfilled theNational Institute of Neurological andCom-
municative Disorders and Stroke–Alzheimer’s Disease and
Related Disorders Associations criteria for probable AD3 and
the National Institute on Aging–Reagan criteria for high likeli-
hood of AD.4 Cases with cerebrovascular disease considered
severe enough to contribute to the dementia syndrome were
excluded because cerebrovascular disease is a major cause
of focal gliosis. Cases with Lewy body pathological features
werealso excluded. Sections (8-mthick)weredeparaffinized
for immunohistochemistry by standard methods. Primary and
secondary antibodies, pretreatments for antigen retrieval, and
visualization strategies are summarized in Table 2. For stereo-
logical quantitative studies, immunostained sections were de-
Table 1. Demographic Characteristics of the Cohorts without De
Quantitative Neuropathological Study
Characteristics
Control cohort
(n  15)
AD co
(n  9
Age at death (years)* 79.9  13.3 79.0 
Female sex† 10 (66.7) 58 (63.7
Disease duration (years)‡ NA 9.8 (6.8–
APOE genotype†
APOE4 carriers 4 (26.7) 59 (64.8
APOE4 alleles§ 4 (13.3) 70 (38.5
Post-mortem interval (hours)* 22.3 12.8 13.9 
Information about cause of death was available in only 44 of the 91 sub
program. Patients with protracted death (mostly aspirative pneumonia and
emboli and myocardial infarction, n  13) regarding their age at death (P
and microgliosis (P  0.9180). Statistically significant P values are boldf
*Data are given as mean  SD. P values were obtained using the tw
†Data are given as number (percentage) of each group. P values we
‡Data are given as median (interquartile range).
§To obtain percentages, the denominators for this row were doubled.
NA, not applicable; NS, not significant.velopedwith 3,3=-diaminobenzidine (Vector Laboratories, Bur-
lingame, CA), lightly counterstained with Mayer’s hematoxylin,
dehydrated with increasing concentrations of ethanol, cleared
with xylene, and cover-slippedwith Permountmountingmedia
(Fisher Scientific, Fair Lawn, NJ). Nearly adjacent temporal
sections from a subset of 40 subjects with AD and six controls
without dementia were immunostained using fluorescently la-
beled secondary antibodies, counterstained with 0.05% thio-
flavin-S (Sigma, St Louis, MO) in 50% ethanol for 8 minutes,
and cover-slipped with Vectashield mounting media with 4’,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories).
Quantitative Neuropathological Analyses
We took advantage of stereology tools to perform unbi-
ased quantitative neuropathological studies in these
brain specimens. All analyses were conducted blinded to
disease status.
Cortical Thickness
Cortical thickness was measured in sections stained with
Luxol fast blue H&E, as previously described.5 Briefly, the
image analysis software CAST (Olympus, Copenhagen,
Denmark), mounted on an upright BX51 Olympus micro-
scope (Olympus) and coupled with a motorized stage
and a charge-coupled device camera, was used to ran-
domly sample the cortex of the entire section and mea-
sure the thickness of the full cortex. The measurements of
full cortical thickness in 20 random sites were averaged.
Amyloid Load and Number of Total Amyloid Plaques
Amyloid load and stereology-based studies on 3,3=-di-
aminobenzidine sections were conducted in an upright
Leica DMRB microscope (Leica, Wetzlar, Germany)
equipped with a motorized stage and a charge-coupled
device camera (model DC330; DAGE-MTI, Inc., Michigan
City, IN) and coupled with the software BIOQUANT NOVA
PRIME, version 6.90.10 (MBSR, Nashville, TN). Amyloid
load was measured as the percentage of total surface
and with AD and Their Corresponding Subsets Included in the
P value
Control subset
(n  6)
AD subset
(n  40) P value
NS 83.7  14.0 77.6  8.6 0.0429
NS 4 (66.7) 26 (65.0) NS
NA NA 9.9 (5.4–15.5) NA
0.0090 2 (33.3) 21 (52.5) NS
0.0070 2 (16.7) 25 (31.2) NS
0.0085 21.0  11.1 14.1  6.2 NS
ith AD because nursing homes are the main source of our brain donation
, n 31) did not differ from patients with sudden death (mostly pulmonary
1), disease duration (P  0.9898), or amount of astrocytosis (P  0.1870)
Mann-Whitney U-test.
ned using the two-tailed 2 test with Fisher’s exact test.mentia
hort
1)
7.8
)
13.7)
)
)
9.1
jects w
cancer
 0.226
aced.
o-tailed
re obtai
rch Lab
radish p
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AJP September 2011, Vol. 179, No. 3stained by the N-terminal–specific anti-amyloid  (A) anti-
body 10D5 (Elan Pharmaceuticals, Inc., Dublin, Ireland) in a
full-thickness strip of cortex (approximately 1-cm long) us-
ing the optical threshold application of the software. The
total number of amyloid plaques in a 1-cm-long strip of
cortex was calculated by dividing the total number of par-
ticles higher than the threshold by the area analyzed (both
parameters provided by the software) and then correcting
the resultant density by the cortical thickness.
Stereology-Based Quantitation of NFTs,
Astrocytes, and Microglia
Paired helical filament 1–positive NFTs, GFAP-positive as-
trocytes, and CD68-positive microglial cells were counted
with the optic dissector technique,6 using either 100 cells or
1000 optical dissectors as the end point. The objective/
dissector size used in each case was 40/150 150 m for
paired helical filament 1–positive neurons, 40/50  50 m
for GFAP-positive astrocytes, and 100/20  20 m for
CD68-positive microglial cells. Intraneuronal and extracel-
lular ghost tangles were not distinguished. Because differ-
ent pathological features tend to accumulate in specific
layers of the cortex (ie, reactive astrocytes in layer I and
NFTs in layers II and V), care was taken to cover all of the six
cortical layers in the systematic random sampling to avoid
selection bias. As with the amyloid plaques, the densities of
NFTs, astrocytes, and microglial cells were calculated by
dividing the number of cells counted in single sections by
the total area of the dissectors analyzed. To avoid any
overestimation of densities because of disease-related cor-
tical atrophy, these densities were then corrected by the
cortical thickness to estimate the total number of cells within
a full-thickness 1-cm-long strip of cortex.
Stereology-Based Quantitation of Oligomeric
A-Positive and Dense-Core Plaques
We performed additional quantitative studies in a subset of
Table 2. Antibodies, Antigen Retrieval Protocols, and Visualizati
Primary antibody Host Dilution Antigen re
10D5 (Elan Pharmaceuticals,
Inc.)
Ms 1:50 Citrate buffer
and 90% fo
for 5 minute
PHF1 (gift from Dr. Peter
Davies)
Ms 1:200 Citrate buffer
GFAP (catalogue no. G9269;
Sigma)
Rb 1:1000 Citrate buffer
CD68 (catalogue no. M0814;
Dako, Glostrup, Denmark)
Ms 1:100 Citrate buffer
Iba1 (catalogue no.
019-19741; Wako)
Rb 1:250 Citrate buffer
NAB61 (gift from Dr. Virginia
Lee)
Ms 1:500 None
*Citrate buffer  MW indicates 0.01 mol/L citrate buffer (pH 6.0) with
†All secondary antibodies were obtained from Jackson ImmunoResea
ABC, avidin-biotin complex; DAB, 3,3=-diaminobenzidine; HRP, horse40 AD cases selected from the original AD cohort on thebasis of a wide range of disease duration and in a subset of
six controls without dementia (ie, those with enough dense-
core plaques). These subsets were representative of their
corresponding cohorts in demographic characteristics, and
the AD subset was also comparable to the entire AD cohort
in neuropathological quantitative measures (Table 1; see
also Supplemental Table S1 and Figure S1 at http://ajp.
amjpathol.org). To study the progression of compact and oli-
gomeric species of A, we quantified the number of dense-
core plaques and oligomeric A-positive plaques in sections
doubly stained with thioflavin-S and NAB61 antibody. The
NAB61 antibody was provided by Dr. Virginia Lee (University
of Pennsylvania, Philadelphia) and has been previously char-
acterized. It is a conformation-specific anti-A mouse mono-
clonal antibody that binds to A dimers, small oligomers, and
higher-order A assemblies and stains a subset of mature
dense-core plaques.7 Virtually no thioflavin-S–negative plaque
was immunoreactive for NAB61. In this study, 100 dense-core
plaques per case were randomly sampled, as previously de-
scribed, and their positivity for NAB61 was qualitatively as-
sessed. The densities of dense-core plaques and NAB61-
positive plaques obtained were corrected by the cortical
thickness to calculate total numbers of plaques within a 1-cm-
long full-thickness strip of cortex.
Spatial Relationships of Dense-Core Plaques,
NFTs, Astrocytes, and Microglia
Single sections from the subset of 40 AD cases were
also doubly stained with thioflavin-S and GFAP or Iba1
to investigate the spatial relationship between glial re-
sponses and dense-core plaques and NFTs along the
course of the disease. Optimal fluorescent immunola-
beling of activated microglia was achieved with anti-
body Iba1 (Wako, Osaka, Japan), another marker
widely used for activated microglia. Sections were
placed on the motorized stage of an upright BX51
Olympus microscope equipped with CAST stereology
software. One hundred GFAP-positive astrocytes or
tegies Used in the IHC Studies
Secondary antibody† Visualization strategy
cid
HRP anti-Ms (1:200) DAB (Vector Laboratories)
Biotin anti-Ms (1:200) ABC kit  DAB (Vector
Laboratories for both)
i) Biotin anti-Rb
(1:200) and
ii) Cy3 anti-Rb
(1:200)
i) ABC kit  DAB (Vector
Laboratories for both) and ii)
none
Biotin anti-Ms (1:200) ABC kit  DAB (Vector
Laboratories for both)
Cy3 anti-Rb (1:200) None
Biotin anti-Ms (1:200) ABC kit (Vector Laboratories) 
streptavidin-Cy3 (1:200)
(Invitrogen)
Tween 20 in a microwave oven at 95°C for 20 minutes.
s (West Grove, PA).
eroxidase; Ms, mouse; Rb, rabbit.on Stra
trieval*
 MW
rmic a
s
 MW
 MW
 MW
 MW
0.05%Iba1-positive microglial cells per section were ran-
le proxy
hed a p
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AJP September 2011, Vol. 179, No. 3domly selected under the 20 or the 40 objective,
respectively, and their distance with respect to the
closest dense-core plaque or NFT was measured with
the appropriate tool of the software. For consistency,
only cells with a visible nucleus in the DAPI staining
Figure 1. Progression of cortical atrophy and amyloid deposition in the tem
along with the symptomatic disease duration, indicating that this is a reliab
increased during the first years of the clinical course of the disease but reac
Table 3. Summary of the Results from the AD and Control Coho
Variable
AD cohort (n  91)
Linear
One-phase
exponential
Cortical thickness (m)
AICc 1.804
Probability (%) 71.13 28.87
Goodness (R2) 0.1797 0.1831
Slope  0? (P) 0.0001 NA
Spearman’s r 0.3977 NA
Spearman=s P 0.0001 NA
Amyloid burden (%)
AICc 4.347
Probability (%) 10.22 89.78
Goodness (R2) 0.0657 0.1093
Slope  0? (P) 0.0142 NA
Total amyloid plaques
AICc 1.761
Probability (%) 29.31 70.69
Goodness (R2) 0.0391 0.0575
Slope  0? (P) 0.0602 NA
Total astrocytes
AICc 0.7545
Probability (%) 59.32 40.68
Goodness (R2) 0.1951 0.1884
Slope  0? (P) 0.0001 NA
Spearman’s r 0.4070 NA
Spearman’s P 0.0001 NA
Total microglia
AICc 5.171
Probability (%) 92.99 7.01
Goodness (R2) 0.0960 0.0431
Slope  0? (P) 0.0028 NA
Spearman’s r 0.3545 NA
Spearman’s P 0.0006 NA
The probability of being correct and the goodness of fit (R2) of both the
in the case of cortical thickness) are shown for the main neuropatholog
dementia and with plaques, and the AD cohort plus the entire control co
whether the slope is significantly different from 0. When the linear regress
from the Spearman’s rank correlation test are also shown. For the amyloi
the best fit, despite the linear fit yielding a straight line with a slope sign
Also, the R2 of the one-phase exponential association model is negative fo
even worse than a horizontal line. Statistics in Materials and Methods provides fu
AICc, magnitude of the difference between both fit models; CTRL, control wwere considered. Astrocytes and microglial cells were
classified into three categories: i) close to plaques, if
located 50 m from the edge of a plaque (regardless
of the presence of an NFT within this boundary); ii)
close to NFTs, if located 50 m from an NFT but far
eocortex in AD (see also Table 3). A: Cortical thickness decreased linearly,
of disease severity. Amyloid burden (B) and total number of plaques (C)
lateau soon after.
 CTRL with plaques
(n  101) AD  all CTRL (n  106)
ar
One-phase
exponential Linear
One-phase
exponential
NA NA
Not converged 100 Not converged
130 NA 0.2296 NA
001 NA 0.0001 NA
523 NA 0.4649 NA
001 NA 0.0001 NA
10.83 18.23
4 99.56 0.01 99.99
317 0.3099 0.3117 0.4205
001 NA 0.0001 NA
11.96 21.72
5 99.75 0.01 	99.99
101 0.2983 0.2952 0.4258
001 NA 0.0001 NA
3.005 3.953
0 18.20 87.83 12.17
433 0.2204 0.2705 0.2428
001 NA 0.0001 NA
037 NA 0.5471 NA
001 NA 0.0001 NA
33.18 42.25
9 0.01 	99.99 0.01
728 0.1489 0.2109 0.1755
001 NA 0.0001 NA
326 NA 0.4728 NA
001 NA 0.0001 NA
regression and the one-phase exponential association models (or decay,
asures in the AD cohort alone, the AD cohort plus the controls without
e best-fit model is boldfaced. In the linear regression model, P indicates
el was the preferred-fit model, the correlation coefficient and the P value
n and the total number of amyloid plaques, the nonlinear model remains
different from 0 (because of the anchoring effect of controls close to 0).
neuropathological measures, indicating that the best-fit curve fits the dataporal nrts
AD
Line
100
0.2
0.0
0.4
0.0
0.4
0.2
0.0
0.2
0.2
0.0
81.8
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0.0
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0.0
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0.0
0.4
0.0
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plaques and NFTs, if the closest plaque and NFT to the
glial cell were located 	50 m. Densities of glial cells
in each of these categories were obtained as previ-
ously described.
APOE Genotyping
The APOE genotype was determined in all of the study
subjects by restriction fragment length polymorphism
analysis, as previously described.8
Statistics
Statistics were performed, and graphs were obtained with
GraphPad Prism software for Mac, version 5.0. The normality
of data sets was tested with the D’Agostino-Pearson omnibus
test. For correlations of cortical thickness, amyloid load, and
total number of astrocytes/microglia with disease duration, two
different fit models were examined using the least-squares
fittingmethod: linear regression versus one-phase exponential
association (or decay in thecaseof cortical thickness). The first
model assumes a linear increase of the pathological features
over time, whereas the second model consists of an initial
increase followedbyaplateau.Next, these two fitmodelswere
compared using the Akaike’s Informative Criteria method with
no constraints, and the model most likely to have generated
the data was selected based on the magnitude of the differ-
ence between both fit models, the probabilities of the models
being correct (as calculated by the statistical software), and
their goodness of fit (R2). When the straight-line model was
preferred, aP value indicatingwhether the slope of the straight
line is significantly different from 0 and both the correlation
coefficient (r) and the P value of Spearman’s rank correlation
test were also reported. Because none of the data sets wasnormally distributed, cross correlations between these patho-
logical quantitative measures were investigated with the
Spearman’s rank correlation test. The significance level was
set at a two-sided P  0.05 in all statistical analyses.
Results
Disease Duration Is a Reliable Proxy of Disease
Severity
We have previously used disease duration (defined from
the onset of cognitive symptoms) as a proxy of disease
severity to avoid the floor effects of neuropsychological
tests in patients with advanced dementia, who are typically
not testable. More important, the three major pathological
correlates of cognitive decline (ie, NFT burden, neuron loss,
and synaptic loss) also correlated with disease duration in
our previous quantitative post-mortem studies2,9,10 on the
temporal neocortex. Herein, wemeasured the cortical thick-
ness of the temporal neocortex specimens from the AD
cohort as an index of synaptic, dendritic, and neuronal
integrity. We found a significant negative correlation be-
tween cortical thickness and symptomatic disease duration,
further validating the use of disease duration as a surrogate
of disease severity (r  0.3977, P  0.0001) (Figure 1A
and Table 3).
Progression of Amyloid Deposition in the
Temporal Neocortex
Next, we traced the progression of amyloid deposition
and patterns of glial immunostaining throughout the
clinical disease course. Amyloid burden, determined
as the percentage of cortical surface immunoreactive
Figure 2. Progression of fibrillar and oligomeric
A burden in the temporal neocortex (see also
Table 4). A and C: Only the AD subset is shown
(open circles, n  40). B and D: The highly se-
lected subset of controls without dementia and
with dense-core plaques is also included, with a
disease duration of 0 years (dark gray circles, n 
6). In A and B, a small increase in the number of
dense-core plaques was only detectable during
the first years after the onset of cognitive symp-
toms. In C and D, the number of NAB61-positive
oligomeric A-enriched plaques remained un-
changed after symptom onset.
ontrol w
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after symptomatic onset and remained relatively stable
thereafter (Figure 1B and Table 3). An analysis of total
number of plaques yielded similar results (Figure 1C
and Table 3). Like 10D5-immunoreactive plaques in
the original AD cohort, the number of dense-core
plaques determined in a subset of 40 AD cases re-
mained relatively stable throughout the disease clinical
course after an initial increase (Figure 2, A and B, and
Table 4). Last, the amount of NAB61-positive oligo-
meric A-enriched plaques also remained constant
throughout the disease clinical course (Figure 2, C and
D, and Table 4).
Table 4. Summary of the Results from the AD and Control Subse
Variable
AD subset (n
Linear One-p
Total dense-core plaques
AICc 0.2525
Probability (%) 46.85
Goodness (R2) 0.0248
Slope  0? (P) 0.3313
Total NAB61  plaques
AICc NA
Probability (%) 100 No
Goodness (R2) 0.0002
Slope  0? (P) 0.9313
Spearman’s r 0.0037
Spearman’s P 0.9816
The AICc represents the magnitude of the difference between the t
indicates whether the slope is significantly different from 0. When the line
the P value from the Spearman’s rank correlation test are also shown. Th
analysis, despite the linear fit yielding a straight line with a slope significan
Statistics in Materials and Methods provides further details.
AICc, magnitude of the difference between both fit models; CTRL, cProgression of Glial Responses and
Relationship to AD Pathological Hallmarks
Despite being traditionally regarded as plaque-associ-
ated pathological features, the progression of astro-
cytic and microglial responses differed from that of
amyloid plaques both qualitatively and quantitatively.
Both reactive glial cell types increased linearly through
the entire clinical course of the disease, even when the
amyloid burden was no longer increasing [r  0.4070
(P  0.0001) and r  0.3545 (P  0.0006) for astro-
cytes and microglia, respectively]. The inclusion in
these analyses of either controls without dementia who
cerning Fibrillar and Oligomeric A Burden
AD  CTRL with dense-core
plaques (n  46)
xponential Linear One-phase exponential
1.833
28.57 71.43
10 0.1297 0.1637
0.0140 NA
NA
erged 100 Not converged
0.0361
0.2060
0.2267 NA
0.1298 NA
odels compared. The best-fit model is boldfaced. In the linear model, P
ession model was the preferred-fit model, the correlation coefficient and
ear model is the best fit for total dense-core plaques in the AD  CTRL
ent from 0 (likely because of the anchoring effect caused by the controls).
ithout dementia; NA, not applicable.
Figure 3. Progression of glial responses in the
temporal neocortex (see also Table 3). A and C:
Only the AD cohort is shown (open circles, n 
91). B and D: The controls without dementia and
with plaques are also included, with a clinical
disease duration of 0 years (dark gray circles, n 
10). Both astrocytosis (A and B) and microgliosis
(C and D) significantly increased in a linear fash-
ion, along with disease progression.ts Con
 40)
hase e
53.15
0.03
NA
t conv
NA
NA
wo fit m
ar regr
e nonlin
tly differ
Reactive Glia in Alzheimer’s Disease 1379
AJP September 2011, Vol. 179, No. 3had plaques (n  10) or all controls (n  15) further
accentuated the difference in the patterns of progres-
sion of amyloid burden and glial responses (Figure 3,
A–D, and Table 3). Indeed, neither astrocytosis nor
microgliosis correlated with the amyloid burden [r 
0.0963 (P  0.3637) and r  0.0062 (P  0.9538),
respectively] or the total number of plaques [r 
0.0774 (P  0.4660) and r  0.1124 (P  0.2888),
respectively] (Figure 4, A–D).
Unlike the measures of amyloid deposition, both as-
trocytosis and microgliosis correlated positively withthe NFT burden [r  0.3419 (P  0.0009) and r 
0.4635 (P  0.0001) respectively]. Also, astrocytosis,
but not microgliosis, correlated negatively with cortical
thickness [r  0.4647 (P  0.0001) and r  0.0199
(P  0.8517), respectively] (Figure 5, A–D), further
arguing that the relationship between reactive glia and
amyloid plaques might not be as straightforward as
previously thought. Last, astrocytosis and microgliosis
tightly covaried together (r  0.3377, P  0.0011) (data
not shown).
Figure 4. Correlations between glial responses
and measures of amyloid deposition in AD. Nei-
ther astrocytosis nor microgliosis correlated with
amyloid burden (A and B) or total number of
plaques (C and D).
Figure 5. Correlations between glial responses
and markers of neurodegeneration in AD. Astro-
cytosis (A) and microgliosis (B) correlated posi-
tively with the burden of NFTs. Patients with
higher astrocytosis tended to have more cortical
atrophy (C), but no association was observed be-
tween the extent of microgliosis and cortical thick-
ness (D). PHF, paired helical filament.
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astrocytosis or microgliosis and did not significantly in-
fluence the progression of glial responses (see Supple-
mental Figure S2 at http://ajp.amjpathol.org).
Spatial Relationships between Glial Responses
and Amyloid Plaques/NFTs
It is well established that activated glial cells are associated
with individual senile plaques. In an attempt to better un-
derstand the previous results, we examined reactive glia in
the microenvironment near plaques and tangles. We com-
pared the progression of plaque-associated reactive glial
cells with NFT-associated reactive glial cells and reactive
glial cells in the neuropil not close to either a plaque or a
tangle in the subset of 40 AD cases using the stereology-
based procedures described in Materials and Methods.
We observed a significant increase in the density of
reactive astrocytes and, to a lesser extent, activated
microglia in the proximity of dense-core plaques, along
with disease progression [r  0.6275 (P  0.0001) and
r  0.3073 (P  0.0538), respectively] (Figure 6, A, D,
G, and J). We also observed a significant, although
weaker, linear increase of astrocytosis and, particu-
larly, microgliosis in the vicinity of NFTs as the disease
progresses [r  0.3125 (P  0.0497) and r  0.3586
(P  0.0231), respectively] (Figure 6, B, E, H, and K),
suggesting that a causal link underlies the positive
correlations between accumulation of reactive glia and
NFT burden previously shown. By contrast, the density
of astrocytes and microglial cells not associated with
either dense-core plaques or NFTs (ie, free in the neu-
ropil) did not significantly correlate with the progres-
sion of the disease [r  0.1883 (P  0.2447) and r 
0.0921 (P  0.5720), respectively] (Figure 6, C, F, I,
and L).
Discussion
Much evidence from previous clinicopathological stud-
ies9–15 has established that the NFT burden and both neu-
ronal and synaptic loss, but not amyloid plaque burden,
correlate with the severity of cognitive impairment in AD.
However, despite invariably accompanying these classic
hallmarks, particularly amyloid plaques, these previous re-
ports have not addressed the progression of glial re-
sponses in AD. Although post-mortem studies are inher-
ently cross-sectional and, therefore, any longitudinal
extrapolation should be interpreted with caution, quantita-
tive unbiased stereology-based analysis in a large cohort of
subjects with a broad range of disease duration enabled us
to track the progression of amyloid deposition, NFTs, and
glial responses within the AD temporal neocortex and to
investigate their relationships. Our findings can be summa-
rized as follows: i) astrocytosis and microgliosis occur both
around dense-core plaques and in the proximity of NFTs; ii)
astrocytosis and microgliosis increase linearly with disease
duration, despite amyloid burden reaching a plateau early
in the clinical course of the disease; iii) astrocytosis and
microgliosis covary with the burden of NFTs through theentire clinical course of the disease. Taken together, the
number of reactive astrocytes and activated microglial cells
tracks better with tangles than with plaques (Figure 7).
Dynamics of Amyloid Deposition in the
Temporal Neocortex
Previous post-mortem studies2,9–13 have established that
the amyloid burden remains relatively stable after the first
stages of AD dementia and, thus, does not correlate with
the severity of dementia. The inclusion of controls without
dementia and with AD pathological changes and, particu-
larly, of patients with AD who died shortly after the clinical
onset enabled us to trace the natural history of brain -am-
yloidosis as a continuum between normal aging and AD.
Taken together, our analyses of amyloid deposition support
a saturation model in which most amyloid accumulation
occurs in the earliest phases, after which there is little or no
further accumulation of total amyloid burden in a particular
brain region (Figure 7). The pace at which this pattern of
deposition and plateau occurs may well play out at different
rates or times, depending on the brain region, as suggested
by the hierarchical distribution of amyloid deposits previ-
ously described.9,16–18 The type of amyloid plaque did not
vary substantially once plaques were deposited. The natu-
ral history of fibrillar (thioflavin-S–positive) amyloid deposi-
tion paralleled that of total (10D5-immunoreactive) amyloid
deposition, also in keeping with our previous results.2 Inter-
estingly, NAB61-positive oligomeric A was readily ob-
served in association with the dense-core plaques through-
out the disease course.
Implications for the Role of Reactive Glial Cells
in AD
Because the increase in reactive glial cells cannot be
attributed to a progressive buildup of plaque burden, we
reasoned that it might be explained by either the same
original plaques accumulating more reactive glial cells as
the disease advances or the reactive glial cells spreading
throughout the neuropil, perhaps contributing to neuronal
dysfunction and neurodegeneration as additional neuro-
nal lesions and synaptic loss accrue. Both explanations
are supported by our results. On one hand, we observed
a progressive increase in the density of reactive astro-
cytes and activated microglial cells in the proximity (50
m) of dense-core plaques, indicating that A plaques
are permanently recruiting and activating glial cells. On
the other hand, both astrocytosis and microgliosis cova-
ried with the number of NFTs and increased in their
proximity, and astrocytosis also correlated negatively
with cortical thickness, suggesting a partial emancipation
of glial cells from amyloid plaques. Whether the increas-
ing number of reactive glial cells is responding to the
ongoing neurodegenerative process (and, thus, a surro-
gate marker of neurodegeneration) or actively contrib-
utes to neurodegeneration cannot be determined by
cross-sectional human neuropathological studies. How-
ever, along this line, astrocytosis was the best correlate of
neuron loss and cognitive deficits in an A precursor
significa
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capitulates the pathological features of human AD.19 In
addition, recent experimental studies with in vitro and
mouse models of AD have linked both astrocytes and
microglia to neurodegeneration20–25 and have shown
that activated microglia can lead to  hyperphosphoryla-
tion and aggregation.26,27
The idea of reactive glia as a hostile environment for
Figure 6. Spatial relationship of glial responses and dense-core plaques and
green), and DAPI (blue) in an AD case. GFAP-positive reactive astrocytes (a
also be seen in close association to NFTs (B, arrows) and free in the neuro
the proximity of dense-core plaques (D) and close to NFTs (E); by contrast, r
(F). G–I: Photomicrographs of triple staining for Iba1 (red), ThioS (green), an
cluster in the vicinity (50 m) of dense-core plaques (G), but they can als
Microgliosis increased linearly close to both plaques (J) and NFTs (K), but no
m) from dense-core plaques and NFTs (L).neurons in the context of neurodegeneration has beenrecently proposed by elegant studies28,29 on amyo-
trophic lateral sclerosis and tauopathy mouse models. If
this idea proves to apply to AD, an increasing number of
reactive glial cells around dense-core plaques might well
contribute to their local toxicity by releasing soluble bio-
logically active toxic molecules, such as pro-inflamma-
tory cytokines and reactive oxygen species. These toxic
biomolecules, together with soluble A oligomers exist-
–C: Photomicrographs of triple staining for GFAP (red), thioflavin-S (ThioS;
ad) cluster in the vicinity (50 m) of dense-core plaques (A), but they can
Scale bar  20 m. The density of reactive astrocytes increased linearly in
astrocytes did not increase far (	50 m) from dense-core plaques and NFTs
(blue) in an AD case. Iba1-positive activated microglial cells (arrowheads)
nd near NFTs (H, arrows) and free in the neuropil (I). Scale bar  20 m.
nt increase in the number of activated microglial cells was observed far (	50NFTs. A
rrowhe
pil (C).
eactive
d DAPI
o be fouing around the plaques, might account for the plaque-
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ritic dystrophies, an increased neurite curvature ratio,
and synaptic and neuron loss, which might be slowly
progressive.
Diagnostic and Therapeutic Implications
Follow-up PET studies using the fibrillar amyloid-specific
radiotracer Pittsburgh compound B (PiB) have yielded
conflicting results regarding the progression of amyloid
deposition in vivo in patients with AD-type dementia, with
some studies30,31 reporting little or no increase in PiB
uptake over time and other studies32,33 describing a sig-
nificant increase in patients with dementia. Technical is-
sues inherent to PET, such as test-retest reliability or a
dynamic range of detection, might account for these di-
vergent findings to some extent. Our post-mortem anal-
yses argue against a marked increase in PiB uptake in a
region with established amyloid deposition (eg, the tem-
poral neocortex) once the dementia syndrome is overt.
However, PiB might be useful to track the spreading of
amyloid deposition to additional cortical areas in vivo in
elderly controls without dementia, patients with mild cog-
nitive impairment, and perhaps patients with mild demen-
tia. It is also possible that regions of interest with later
amyloid deposition, such as the occipital cortex, might
still show increasing PiB uptake in patients with estab-
lished dementia.30 Longer serial PET studies,34 com-
bined with serial cognitive assessments in larger samples
of elderly controls and patients with mild cognitive impair-
ment and AD, will determine whether PiB PET is useful as
a surrogate biomarker of progression at each stage of the
Figure 7. A model of the progression of AD-related pathological features in
the temporal neocortex based on the present results. The regression lines for
each of the pathological measures were plotted within a single graph. For
clarity purposes, the regression line for cortical thickness was linked to the y
axis with a different scale (right). Amyloid deposition reaches a plateau early
after the onset of cognitive symptoms, whereas reactive astrocytes, activated
microglial cells, and NFTs keep accumulating as the cortical mantle atrophies
through the disease course. Remarkably, the slopes indicate that, within a
reference area of 1-cm-long full-thickness temporal neocortex, activated
microglia and reactive astrocytes accumulate at a strikingly similar average
rate of 270 and 275 cells per year, respectively, which is	10-fold higher than
the rate of neurofibrillary degeneration (average, 18 tangles per year). Last,
cortical thickness decreased at an average rate of 37 m/year.disease. The current post-mortem quantitative analysissuggests that imaging some sort of glial marker might
also be a useful approach to track the progression of AD
in vivo. A positive glial PET might also add diagnostic and
prognostic specificity to a positive amyloid PET study at
the preclinical and mild cognitive impairment phases of
the disease. Our results predict that the pattern of glial
radiotracer uptake would closely match those of PiB up-
take and cortical atrophy. However, the first PET studies
using [11C]-(R)-PK11195, a radiotracer for the peripheral
benzodiazepine receptor expressed by activated micro-
glia, have reported contradictory results: although the
original study35 described an abnormal uptake in vulner-
able cortical regions of patients with mild AD but not in
controls without dementia, more recent studies36–38 have
reported a great overlap between both groups and no
correlation between [11C]-(R)-PK11195 uptake and se-
verity of cognitive decline. Novel radioligands targeting the
same receptor in microglia have recently proven to track
considerably better with -induced neurodegeneration in
mice overexpressing mutant human  than with amyloid
burden in animals modeling A plaque deposition.39
If glial responses become partially independent from
amyloid plaques and their contribution to neurodegen-
eration is relevant, then removal of amyloid plaques with
anti-A-directed therapies, such as passive or active im-
munization, might not be sufficient to block this neurotox-
icity. In this scenario, the transient microglial response
triggered by anti-A immunization might have deleterious
effects on the neuropil, even though there is an overall
decrease in gliosis on clearance of amyloid plaques.40,41
Glia-mediated inflammation has already been consid-
ered as a therapeutic target. NSAIDs became promising
agents after the first large epidemiological studies42,43
revealed that a long-term treatment substantially reduced
the risk of AD. Preclinical research44 has demonstrated
that NSAIDs can decrease A42 levels by modulating the
activity of the -secretase complex, independently from
their inhibitory effect on the pro-inflammatory cyclooxy-
genase and peroxisome proliferator-activated receptor-
pathways. However, the clinical trials44 with NSAIDs
completed thus far have failed to delay the progression of
cognitive decline in AD or the conversion from mild cog-
nitive impairment to AD, and recent epidemiological stud-
ies have suggested that NSAIDs might have no effect on
the risk of AD45 or might even increase it.46 Moreover, two
neuropathological studies45,47 found an increased bur-
den of AD pathological features, particularly amyloid
plaques, in NSAID users compared with nonusers. Other
molecular targets involved in the first steps of glial acti-
vation, rather than in the production of singular pro-in-
flammatory cytokines, remain to be explored. Recently,
the activation phenotype of both astrocytes and micro-
glial cells was reported to be largely mediated through
the calcineurin–nuclear factor of activated T cells path-
way.48,49 Fibrillar and particularly oligomeric A can ab-
errantly activate this molecular signaling pathway in glial
cells48,50 and neurons, causing the morphological triad of
dystrophic neurites, dendritic simplification, and loss of
dendritic spines, subsequently leading to cognitive im-
pairment.51–53 More important, Food and Drug Adminis-
tration–approved and available calcineurin inhibitors,
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these A-related pathological changes both in vitro and in
vivo and ameliorate both the neuropathological features
and the memory deficits of AD mouse models.26,51–53
In summary, our findings indicate a major role of gliosis
in the pathophysiological features of both amyloid
plaques and NFTs, suggesting that glial cells might be
proactive players linking A with downstream neurode-
generative events beyond their role in the initial steps of
the amyloid cascade. The implications of these results for
the development of imaging biomarkers and disease-
modifying drugs encourage further research.
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Supplementary Table 1. The subsets of AD and control cases are representative of the corresponding 
entire cohorts in their demographic and neuropathological characteristics 
 
CTRL 
subset (n=6) 
Remaining 
CTRL cases 
(n=9) 
P 
value 
AD subset 
(n=40) 
Remaining 
AD cases 
(n=51) 
P 
value 
Age at death, y * 83.7 (14.0) 77.3 (13.0) n.s. 77.6 (8.6) 80.2 (6.9) n.s. 
Gender, n female (%) † 4 (66.6) 6 (66.6) n.s. 26 (65.0) 32 (62.7) n.s. 
Disease duration, y * NA NA NA 9.9 (5.4-15.5) 9.5 (7.0-12.0) n.s. 
APOE genotype: † 
APOEε4 carriers, n (%) 
   APOEε4 alleles, n (%) 
 
2 (33.3) 
2 (16.6) 
 
2 (22.2) 
2 (11.1) 
 
n.s. 
n.s. 
 
21 (52.5) 
25 (31.2) 
 
38 (74.5) 
47 (46.1) 
 
0.0458 
0.0480 
Postmortem interval, h * 21.0 (11.1) 23.3 (14.6) n.s. 14.1 (6.2) 13.7 (10.8) n.s. 
Cortical thickness, µm ‡ ƒ 2651 (97.7) 2730 (122.1) n.s. 2351 (63.2) 2411 (49.2) n.s. 
Amyloid burden, % * 1.2 (0.3) 0.1 (0.1) 0.0069 3.8 (0.3) 3.8 (0.2) n.s. 
Total amyloid plaques * 566.6 (130.7) 67.5 (57.4) 0.0099 1651 (105.0) 1759 (87.7) n.s. 
Total NFTs * 21.8 (13.2) 4.7 (2.0) n.s. 419.2 (43.3) 453.5 (38.4) n.s. 
Total astrocytes * 1687 (977.3) 665 (182.7) n.s. 4092 (439.7) 3128 (346.0) n.s. 
Total microglia * 6996 (1349) 5568 (1004) n.s. 10669 (672.8) 10179 (448.2) n.s. 
 
Age at death and postmortem interval are presented as Mean (SD), whereas the disease duration is 
reported as Median (interquartile range) and the neuropathological data are depicted as Mean 
(SEM). * Two-tailed Mann-Whitney test. † Two-tailed Chi-square with Fisher’s exact test. ‡ Two-
 2 
tailed unpaired Student’s t test. Statistically significant differences (p<0.05) are highlighted in bold 
fonts. NA = not applicable; n.s. = not significant. The criterion for selecting the subset of control 
cases (a high number of dense-core plaques) is reflected in the statistically significant difference in 
amyloid burden and total amyloid plaques respect to the remaining control cases. Compared to the 
remaining AD cases, the APOEε4 genotype was less represented in the AD subset, although APOE 
genotype did not influence significantly the progression of glial responses (see Supplementary 
Figure S2 at http://ajp.amjpathol.org). 
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Anti-amyloid-b immunization leads to amyloid clearance in patients with Alzheimer’s disease, but the effect of vaccination on
amyloid-b-induced neuronal pathology has not been quantitatively examined. The objectives of this study were to address the
effects of anti-amyloid-b active immunization on neurite trajectories and the pathological hallmarks of Alzheimer’s disease in
the human hippocampus. Hippocampal sections from five patients with Alzheimer’s disease enrolled in the AN1792 Phase 2a
trial were compared with those from 13 non-immunized Braak-stage and age-matched patients with Alzheimer’s disease, and
eight age-matched non-demented controls. Analyses included neurite curvature ratio as a quantitative measure of neuritic
abnormalities, amyloid and tau loads, and a quantitative characterization of plaque-associated neuritic dystrophy and astro-
cytosis. Amyloid load and density of dense-core plaques were decreased in the immunized group compared to non-immunized
patients (P50.01 and P50.001, respectively). The curvature ratio in non-immunized patients with Alzheimer’s disease was
elevated compared to non-demented controls (P50.0001). In immunized patients, however, the curvature ratio was normalized
when compared to non-immunized patients (P50.0001), and not different from non-demented controls. In the non-immunized
patients, neurites close to dense-core plaques (within 50 mm) were more abnormal than those far from plaques (i.e. beyond
50 mm) (P50.0001). By contrast, in the immunized group neurites close to and far from the remaining dense-core plaques did
not differ, and both were straighter compared to the non-immunized patients (P50.0001). Compared to non-immunized
patients, dense-core plaques remaining after immunization had similar degree of astrocytosis (P = 0.6060), more embedded
dystrophic neurites (P50.0001) and were more likely to have mitochondrial accumulation (P50.001). In addition, there was
a significant decrease in the density of paired helical filament-1-positive neurons in the immunized group as compared to the
non-immunized (P50.05), but not in the density of Alz50 or thioflavin-S positive tangles, suggesting a modest effect of
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anti-amyloid-b immunization on tangle pathology. Clearance of amyloid plaques upon immunization with AN1792 effectively
improves a morphological measure of neurite abnormality in the hippocampus. This improvement is not just attributable to the
decrease in plaque load, but also occurs within the halo of the remaining dense-core plaques. However, these remaining plaques
still retain some of their toxic potential. Anti-amyloid-b immunization might also ameliorate the hippocampal tau pathology
through a decrease in tau phosphorylation. These data agree with preclinical animal studies and further demonstrate that human
anti-amyloid-b immunization does not merely clear amyloid from the Alzheimer’s disease brain, but reduces some of the
neuronal alterations that characterize Alzheimer’s disease.
Keywords: Alzheimer’s disease; amyloid; immunization; AN1792
Abbreviations: Ab = amyloid-b; DAPI = 40,6-diamidino-2-phenylindole; PHF1 = paired helical filament-1;
VDAC1 = voltage-dependent anion-selective channel protein 1
Introduction
The major pathological hallmarks of Alzheimer’s disease are neur-
onal loss, amyloid senile plaques and neurofibrillary tangles within
the cerebral cortex (Braak and Braak, 1991). Senile plaques
are extracellular deposits of amyloid-b (Ab) peptide, a byproduct
of the metabolism of the amyloid precursor protein after its se-
quential cleavage by the b- and -secretases. Neurofibrillary tan-
gles are intraneuronal somatic aggregates comprised of the
microtubule-stabilizing protein tau, which is abnormally hyperpho-
sphorylated. Other pathological findings include synaptic loss in
cortical areas, as well as astrogliosis and microgliosis surrounding
senile plaques; cerebral amyloid angiopathy (i.e. Ab deposits in the
wall of cortical and leptomeningeal vessels) is a common concomi-
tant pathological process. Clinicopathological studies have shown
that neurofibrillary tangles, synaptic loss and neuronal loss correl-
ate with dementia progression and severity better than amyloid
deposits (DeKosky and Scheff, 1990; Terry et al., 1991;
Go´mez-Isla et al., 1996, 1997). However, substantial biochemical
and genetic evidence points to Ab as an essential trigger for the
disease (Hardy and Selkoe, 2002). Ab might directly trigger a cas-
cade of pathogenic events that lead to synaptic and dendritic
abnormalities, neurofibrillary tangles and neuronal death, but the
course down these pathways to disease may remain dependent on
Ab or might become independent of Ab once initiated. The latter
proposal raises the possibility that therapies directed at reduction
in brain levels of Ab might not be capable of preventing the pro-
gression of dementia.
Immunotherapy against Ab, either through active immunization
with Ab aggregates or by passive transfer of anti-Ab antibodies,
has proven to be effective in the prevention of Ab deposition and
the clearance of already existing Ab plaques in a number of trans-
genic mouse models of Alzheimer’s disease (Schenk et al., 1999;
Bard et al., 2000; Bacskai et al., 2001, 2002; DeMattos et al.,
2001; Lemere et al., 2003; Wilcock et al., 2004). Moreover, both
active and passive immunization approaches prevented, improved
or even reversed the memory deficits described in those mouse
models (Janus et al., 2000; Morgan et al., 2000; Dodart et al.,
2002; Kotilinek et al., 2002). Also, an amelioration of tau path-
ology has been reported after anti-Ab immunization in several
mouse models with both amyloid plaques and neuronal tau
aggregates (Oddo et al., 2004, 2008; Wilcock et al., 2009).
The first immunotherapy clinical trial in patients with
Alzheimer’s disease was an active immunization trial with a
pre-aggregated preparation of synthetic human Ab42 (AN1792).
The phase 2a of this trial was halted due to the occurrence of
subacute meningoencephalitis among some patients in the treat-
ment group, so that patients only received one to three injections
out of the four doses initially planned (Orgogozo et al., 2003).
Despite the interruption of the trial, a modest but significant posi-
tive effect of immunization on some cognitive and functional out-
come measures has been documented (Hock et al., 2003; Gilman
et al., 2005). Recently, two long-term follow-up studies have
yielded conflicting results, with no difference in the rates of sur-
vival to death and progression to severe dementia in subjects from
an earlier phase 1 trial (Holmes et al., 2008) and a reduced rate of
functional decline in a subset of subjects from the phase 2a trial
(Vellas et al., 2009).
To date, the effects of AN1792 immunization on Alzheimer’s
disease neuropathology have been reported in five single case re-
ports (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005;
Bombois et al., 2007; Uro-Coste et al., 2010) and one case series
(Boche et al., 2008; Holmes et al., 2008). These neuropathological
findings can be summarized as (i) significant reduction in amyloid
load, with relative abundance of the collapsed or ‘moth-eaten’
morphology among the remaining plaques; (ii) increased extension
and severity of cerebral amyloid angiopathy and increased fre-
quency of cerebral amyloid angiopathy-related microhaemor-
rhages; (iii) decreased density of dystrophic neurite clusters;
(iv) reduced density of reactive astrocytes clusters; (v) decreased
density of activated microglia clusters, with some examples of
microglial cells engulfing amyloid-b fibrils; and (vi) advanced
neurofibrillary pathology (i.e. Braak stages V–VI). Interestingly,
the amount of remaining amyloid load seems to correlate inversely
with the anti-Ab antibody titres in serum (Holmes et al., 2008).
While there is evidence of the beneficial effects of active and
passive anti-amyloid immunization on neurite morphology and
synapses in Alzheimer’s disease mouse models (Lombardo et al.,
2003; Buttini et al., 2005; Brendza et al., 2005; Spires-Jones et al.,
2009), little is known about the effects of AN1792 on neurites and
neurons in the human Alzheimer’s disease brain. Although there
was a description of the appearance of collapsed ‘moth-eaten’
plaques, the characteristics of the amyloid plaques remaining
after immunization have not been well described.
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Additionally, the relationship between Ab clearance and neurofib-
rillary tangles, tau phosphorylation and aggregation status has not
been fully documented in AN1792-treated patients.
The present study was aimed at (i) addressing the effect of
AN1792 on Ab-related neurite abnormalities; (ii) characterizing
the properties of amyloid plaques remaining after immunization;
and (iii) characterizing the phosphorylation and aggregation status
of neuronal tau after AN1792 immunization.
Materials and methods
Brain specimens
Formalin-fixed paraffin-embedded sections from the hippocampus of
five patients who participated in the phase 2a active immunization trial
with AN1792 (Elan-Wyeth Pharmaceuticals, Inc.) were compared with
the hippocampal sections from non-demented controls (n= 8) and pa-
tients with Alzheimer’s disease (n= 13) from the Massachusetts
Alzheimer Disease Research Center Brain Bank. All the study subjects
or their next-of-kin gave written informed consent for the brain do-
nation at their respective institutions and the Massachusetts General
Hospital Institutional Review Board approved the study protocol. Four
of the immunized patients with Alzheimer’s disease have been previ-
ously described as single reports (Ferrer et al., 2004; Masliah et al.,
2005; Bombois et al., 2007; Uro-Coste et al., 2010). The three groups
were matched by age and gender. Immunized patients and
non-immunized Alzheimer’s disease subjects were also matched by
Braak stage (Table 1 and Supplementary Table 1).
Quantitative immunohistochemical
studies
Eight-micrometre-thick sections were deparaffinized for immunohisto-
chemistry by standard methods. Primary and secondary antibodies,
pretreatments for antigen retrieval and developing strategies are
listed in Supplementary Table 3. To minimize variability, all sections
were stained in single batches. Negative controls lacking primary
antibody were performed in parallel for all experiments. Immuno-
histochemical staining was performed with 3,30-diaminobenzidine
(Vector Lab, Burlingame, CA), counterstained with haematoxylin,
dehydrated with increasing concentrations of ethanol, cleared with
xylene and coverslipped with Permount mounting media (Fisher
Scientific, Fair Lawn, NJ). When fluorescently labelled secondary
antibodies were used, sections were counterstained with Thioflavin S
(Sigma, St. Louis, MO) 0.05% in 50% ethanol for 8 min and
coverslipped with Vectashield mounting media with 40,6-diamidino-
2-phenylindole (DAPI; Vector Lab., Burlingame, CA).
Amyloid load and amyloid plaque size
distribution
Amyloid load was measured as the percent of total surface stained for
Ab by 10D5 antibody (Elan Pharmaceuticals, Inc.) in sections counter-
stained with haematoxylin and periodic acid–Schiff base method (for
vascular basement membranes). Sections were imaged on an upright
Leica DMRB microscope equipped with a motorized stage and a CCD
camera (model DC330, DAGE-MTI, Inc. Michigan City, IN), and
coupled with the BIOQUANT NOVA PRIME software (version
6.90.10, MBSR, Nashville, TN). Amyloid load was measured in three
anatomical regions: the molecular layer of the dentate gyrus, CA1 and
subiculum-presubiculum. Plaque and vascular amyloid loads were
determined separately in order to detect a potential shift of the amyl-
oid from plaques to blood vessel walls. The size distribution of the
amyloid plaques was also measured.
Stereology-based studies
Stereological studies were performed using an Olympus BX51 upright
microscope (Olympus, Tokyo, Japan) equipped with a motorized stage
and an Olympus DP70 camera, and coupled with the CAST software
(version 2.3.1.5). Densities of amyloid plaques and neurofibrillary tan-
gles were quantified with the optical dissector technique as described
previously (Hyman et al., 1998) in sections stained with thioflavin-S
and immunostained either with 3D6 anti-Ab antibody (Elan
Pharmaceuticals, Inc) or with the anti-tau antibodies paired helical
filament (PHF)-1 or Alz50 (both kind gifts from Dr Peter Davies).
Coefficient errors were calculated in preliminary studies to obtain ap-
propriate sampling fractions. The regions of the hippocampus (granular
layer of the dentate gyrus, molecular layer of the dentate gyrus, CA1
and subiculum-presubiculum) were outlined under the 4 objective
and randomly sampled under the 20 objective, typically with a
10% sampling fraction. PHF1, Alz50 and thioflavin-S positive neurons
were counted in the granular layer of the dentate gyrus, CA1 and
subiculum-presubiculum with a counting frame of 5% (7130 mm2).
Amyloid plaques (3D6-immunoreactive and thioflavin-S positive)
were counted in the molecular layer of the dentate gyrus, CA1 and
subiculum-presubiculum with a counting frame of 10% (14 261 mm2).
Dense-core plaques immunoreactive for the mitochondrial marker
Table 1 Baseline characteristics of study subjects
Non-demented
controls
(n = 8)
Non-immunized
patients
(n = 13)
AN1792-treated
patients
(n = 5)
P value
Age, years (mean SD) 82.710.7 77.4 7.3 78.6 5.9 NS
Gender, n (% female) 4 (50) 8 (61.5) 2 (40) NS
Duration of disease, years (mean SD) NA 10.0 4.5 8.4 3.5 NS
Post-mortem interval, h (mean SD) 21.613.8 12.7 5.3 21.2 29.9 NS
ApoE genotype:
ApoE4 carriers, n (%)
ApoE4 alleles, n (%)
2 (25)
2 (12.5)
10 (76.9)
13 (50)
3 (60)
3 (30)
0.0318a
0.0203a
NA = not applicable; NS = non significant.
a Differences were significant only between non-demented controls and non-immunized patients (2 with Fisher’s exact test).
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voltage-dependent anion-selective channel protein 1 (VDAC1) (porin,
Abcam, ab15895) were counted in these same regions with a 20%
sampling fraction and a counting frame of 10% (14 261 mm2).
Curvature ratio analysis
Neurites were identified by immunohistochemistry directed against
neurofilament heavy chain (Abcam, ab40796) and sections were coun-
terstained with thioflavin-S and DAPI prior to imaging in the manner
described above for stereologic measurements. The hippocampal
regions were outlined with the CAST software under the 4objective
of the microscope, and randomly sampled under the 20objective,
with the following sampling fractions: 25% in the molecular layer of
the dentate gyrus, 15% in the CA1 and 15% in the subiculum-
presubiculum. Pictures were coded and stored in a blinded manner
prior to analysis with ImageJ (http://rsbweb.nih.gov/ij/download
.html). Neurite segments identified by the presence of neurofilament
heavy chain were numbered, and their lengths measured by an obser-
ver blinded to the condition of the subject or the presence of
dense-core plaques in the field under study. Curvature ratio of each
neurite segment was calculated as the ratio of measured length to the
end-to-end length of the same neurite; thus, increased neurite curva-
ture results in a higher curvature ratio (Knowles et al., 1999). Only
segments with a measured length longer than 20mm were included in
the analyses. The number of 20hippocampal fields analysed was not
significantly different across groups [214 fields in 8 non-demented
controls (mean SEM; 26.7 2.6), 388 in 13 non-immunized patients
with Alzheimer’s disease (29.7 2.1) and 122 in 4 immunized patients
with Alzheimer’s disease (30.5 3.9)]. The neurofilament heavy chain
immunohistochemistry was not feasible in one of the immunized cases.
To address the relationship between neurite curvature and their
proximity to dense-core plaques, the curvature ratio analysis was
focused on the CA1 subfield. 100% of CA1 was sampled and pictures
of fields containing dense-core plaques were coded and stored in sep-
arate folders for neurofilament heavy chain and thioflavin-S images.
Using ImageJ, dense-core plaques in the thioflavin-S pictures were
outlined and transferred to the corresponding neurofilament heavy
chain images. The curvature ratio of neurite segments within 50 mm
from the dense-core plaques edge was compared with the curvature
ratio of neurite segments located beyond this boundary (i.e. either in
previous pictures containing dense-core plaques or in pictures lacking
them). The distance of neurite segments to dense-core plaques edge
was calculated as the average of three distances: distances from the
nearest plaque edge to each end of the neurite segment as well as
the distance from the plaque edge to the midpoint of the neurite
segment.
Number of dystrophic neurites per
plaque
To identify dystrophic neurites around dense-core plaques, immuno-
histochemistry was performed with SMI312 antibody (Covance,
SMI-312R), followed by thioflavin-S and DAPI counterstaining.
Hippocampal regions were outlined with the CAST software under
the 4objective as described previously. 100% of the molecular
layer of the dentate gyrus, CA1, and subiculum-presubiculum was
sampled under the 20objective. Images of fields containing
dense-core plaques were coded and stored in a blind fashion and
analysed with ImageJ software. Dense-core plaques in the
thioflavin-S pictures were outlined and transferred to the correspond-
ing SMI312 pictures. Dystrophic neurites and varicosities/swellings
either embedded or in contact with the thioflavin-S positive area
were counted manually.
Number of reactive astrocytes per
plaque
To visualize reactive astrocytes around dense-core plaques immunohis-
tochemistry with a glial fibrillar acid protein antibody (Sigma, G9269)
was done, followed by thioflavin-S and DAPI counterstaining. The
same protocol as for SMI312-positive dystrophic neurites was fol-
lowed, except that glial fibrillar acid protein and thioflavin-S pictures
of the same fields were merged with the appropriate tool in ImageJ
software. Reactive astrocytes with a visible nucleus by DAPI staining
surrounding dense-core plaques as far as 50mm from the plaques edge
were manually counted. Reactive astrocytes located close to two or
more dense-core plaques (i.e. within 50 mm) were ‘split’ among those
plaques (i.e. 0.5 astrocytes for those close to two plaques, 0.33 for
those close to three plaques and 0.25 for those close to four plaques).
This conservative method was implemented to avoid double-counting
of astrocytes per plaque in areas with high density of dense-core
plaques, a situation that would be presumably more common in
non-immunized Alzheimer’s disease patients and might otherwise
bias the results.
Statistical analysis
All statistical analyses were conducted with the statistical package
PRISM Graph Pad for Mac (version 5.0). Normality of datasets was
assessed with Kolmogorov–Smirnov and Schapiro–Wilk tests.
Non-normal measures included the size of total amyloid plaques and
dense-core plaques, neurite curvature ratio, number of dystrophic
neurites per plaque and number of astrocytes per plaque. For these
data, results are expressed as median (interquartile range). A
non-parametric one-way ANOVA (Kruskal–Wallis) with Dunn’s mul-
tiple comparison post-test was used for all-group comparisons and a
non-parametric two-tailed t-test (Mann–Whitney, U) was run for pair-
wise comparisons. Normal data included amyloid load, densities of
total amyloid plaques and dense-core plaques, and densities of
PHF1, Alz50 and thioflavin-S positive neurons. For these, results are
expressed as mean SEM. All-group comparisons were performed
with a parametric one-way ANOVA with Bonferroni correction, and
pairwise comparisons were done with a parametric two-tailed t-test
with Welch’s correction when variances were significantly different
between groups. Pairwise comparisons between proportions were per-
formed with 2 with Fisher’s exact test. Correlations were carried out
with the Pearson’s statistic if both datasets were normally distributed
or with the Spearman’s rank test if one or both datasets were not
normal. The level of significance was set at P50.05.
Results
Baseline characteristics
Baseline characteristics of the three groups are listed in Table 1
and Supplementary Table 1. Additional characteristics of the
immunized patients with Alzheimer’s disease can be found in
Table 2 and Supplementary Table 2. Non-demented controls
and non-immunized and immunized patients with Alzheimer’s dis-
ease were matched by age and gender. These two latter groups
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were also matched for Braak stage of neurofibrillary tangles and
did not differ in terms of disease duration or ApoE genotype. Post-
mortem interval was not significantly different across groups.
The detailed results of each case for the main quantitative analyses
are shown in Supplementary Table 4.
Amyloid load and density of amyloid
plaques
Plaque and vascular amyloid loads were measured as the percent
of total surface stained by 10D5 anti-Ab antibody in the neuropil
and vessels of hippocampal sections counterstained with haema-
toxylin and periodic acid-Schiff. Plaque amyloid load in the
hippocampus was significantly different across the three groups
(ANOVA, F= 15.11, P50.0001) (Fig. 1A, Supplementary
Fig. 1). As expected, hippocampal plaque amyloid load was
significantly higher in non-immunized Alzheimer’s disease patients
than in non-demented controls (0.700 0.098% versus
0.080 0.050%, t= 5.588, df= 17, P50.0001). Plaque amyloid
load in the immunized Alzheimer’s disease patients was
significantly lower than that in the non-immunized patients
(0.146 0.069% versus 0.700 0.098%, t= 3.315, df= 16,
P= 0.0044); in fact, the load in these treated subjects was not
different from age-matched non-demented controls
(0.146 0.069% versus 0.080 0.050%, t= 0.7781, df= 11,
P= 0.4529). No vascular amyloid was detected in non-demented
controls. Hippocampal vascular amyloid load in immunized pa-
tients did not differ significantly from non-immunized patients
(0.013 0.005% versus 0.026 0.008%, t= 0.8895, df= 16,
P= 0.3869) (Fig. 1B).
Densities of total and dense-core plaques were quantified with
an unbiased stereological approach in hippocampal sections
double-stained with 3D6 anti-Ab antibody and thioflavin-S
(Fig. 1C–D). There were significant differences across groups in
the densities of 3D6 (total) and of thioflavin-S positive (dense-core)
plaques (ANOVA, F= 34.68 and 27.06, respectively, P50.0001 for
both comparisons). As expected, non-immunized Alzheimer’s
disease patients had a density of both total and dense-core amyloid
plaques significantly higher than non-demented controls (3D6:
22.07 1.956 plaques/mm2 versus 1.738 0.970 plaques/mm2,
t= 9.311, df= 16, P50.0001; thioflavin-S: 16.17 1.570
plaques/mm2 versus 1.408 0.788 plaques/mm2, t= 8.399,
df= 16, P50.0001). By contrast, AN1792-treated patients had a
density of total and dense-core amyloid plaques significantly
lower than non-immunized patients (3D6: 4.566 2.799
plaques/mm2 versus 22.07 1.956 plaques/mm2, t= 4.846,
df= 16, P= 0.0002; thioflavin-S: 4.102 2.349 plaques/mm2
versus 16.17 1.570 plaques/mm2, t= 4.122, df= 16, P= 0.0008)
and not significantly different from non-demented controls (3D6:
4.566 2.799 plaques/mm2 versus 1.738 0.970 plaques/mm2,
t= 1.137, df= 11, P= 0.2796; thioflavin-S: 4.102 2.349
plaques/mm2 versus 1.408 0.788 plaques/mm2, t= 1.087,
df= 4, P= 0.3381). A sub-regional analysis revealed significant
differences between both Alzheimer’s disease groups in all the
hippocampal regions analysed (data not shown).
We also calculated the proportion of dense-core plaques among
the total amyloid plaques in each group using the same sections
double-stained with 3D6 and thioflavin-S and the raw data ob-
tained with the quantification above (Fig. 1E). This proportion was
significantly different across groups (2 = 22.30, df= 2, P50.0001;
2 for trend = 8.499, df= 1, P= 0.0036). Pairwise comparisons
revealed that the immunized group had a significantly higher pro-
portion of dense-core plaques than the non-immunized
Alzheimer’s disease cases (89.09% versus 72.89%, Fisher’s exact
test, P50.0001). Non-demented controls had a proportion of
dense-core plaques intermediate between non-immunized and
immunized patients, but not significantly different from them
(82.26% versus 72.89%, Fisher’s exact test, P= 0.1082 and
82.26% versus 89.09%, Fisher’s exact test, P= 0.1840, respect-
ively). A comparison of the correlation between density of total
and dense-core amyloid plaques in both Alzheimer’s disease
groups also revealed the overwhelming predominance of the
dense-core type of amyloid plaques in the immunized group
(r= 0.9990, P50.0001 in the immunized group versus
r= 0.6624, P= 0.0136 in the non-immunized group; Pearson’s cor-
relation test) (Fig. 1F).
The size of total amyloid plaques was measured in
10D5-immunostained sections and that of dense-core plaques
was measured in thioflavin-S stained sections. Both total and
dense-core amyloid plaques were significantly smaller in immu-
nized patients with respect to non-immunized patients
(Fig. 1G–H, Supplementary Fig. 2A–B) [total amyloid plaques:
197.1 (98.88–404.7) mm2 versus 261.1 (126.6–638.3) mm2,
U= 1039 000, P50.0001; dense-core plaques: 930.7
(555.2–1565) mm2 versus 1181 (753.4–1974) mm2, U= 119 700,
P50.0001]. No significant differences were found in the size of
both total and dense-core amyloid plaques between the
Table 2 Additional characteristics of AN1792-treated patients in this study
Subject Number
of doses
Antibody
titres
Survival
after first
dose (months)
Reference
22 2 IgG+ 15 Ferrer et al. 2004
23 3 1:2771 12 Masliah et al. 2005
24 2 Not detectable 40 Uro-Coste et al. 2010
25 2 TAPIR 1/4 46 Unpublished
26 2 IgM41:3500 IgG410 000 34 Bombois et al. 2007
TAPIR = tissue amyloid plaque immunoreactivity assay. A score of 1 (out of 4) denotes weak staining of amyloid plaques in immunohistochemical brain sections of
APPswe PS1M146L double transgenic mice with the patient’s serum.
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Figure 1 Decreased hippocampal amyloid deposition after anti-Ab immunization. Plaque amyloid load in AN1792-treated Alzheimer’s
disease patients is reduced down to the levels of non-demented controls (NC) (A), without significant increase of vascular amyloid load
(B). Density of both total amyloid plaques (C) and dense-core plaques (D) is significantly decreased in the immunized group. Bars in
scatter-dot plots A–D denote mean SEM. Two-tailed unpaired t-tests were run for these pairwise comparisons (n.s. = non-significant;
**P50.01; ***P50.001; #P50.0001). (E, F) The proportion of dense-core plaques is significantly increased after immunization. In E, the
Continued
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non-immunized Alzheimer’s disease group and the non-demented
group [total amyloid plaques: 261.1 (126.6–638.3) mm2 versus
224.5 (107–734.3) mm2, U= 437 100, P= 0.5765; dense-core pla-
ques: 1181 (753.4–1974) mm2 versus 1089 (503.9–2117) mm2,
U= 27 460, P= 0.6599]. Lastly, total amyloid plaques were also
significantly smaller in the immunized group compared to
non-demented controls, but this difference did not reach statistical
significance for dense-core plaques [total amyloid plaques: 197.1
(98.88–404.7) mm2 versus 224.5 (107–734.3) mm2, U= 61 760,
P= 0.0062; dense-core plaques: 930.7 (555.2–1565)mm2 versus
1089 (503.9–2117) mm2, U= 6894, P= 0.1575].
Analysis of neurite curvature ratio
Neurite curvature ratio was measured in sections immunostained
with an anti-neurofilament heavy chain antibody and counter-
stained with thioflavin-S and DAPI.
When considering neuritic curvature independent of the
distance to dense-core plaques, there was a significant positive
correlation between the median curvature ratio and density of
both total amyloid plaques and dense-core plaques in the
non-immunized Alzheimer’s disease group (total amyloid plaques:
r= 0.7692, P= 0.0021; for dense-core plaques: r= 0.5714,
P= 0.0413, Spearman’s rank test) (Fig. 2A–B). There were statis-
tically significant differences in the curvature ratio across the three
groups of subjects (Kruskal–Wallis ANOVA = 84.73, P50.0001).
As expected, the curvature ratio was abnormally higher in
non-immunized Alzheimer’s disease patients compared to
non-demented controls [1.027 (1.014–1.047) versus 1.020
(1.010–1.037), U= 1129 000, P50.0001]. Importantly, the curva-
ture ratio was significantly lower in immunized compared to
non-immunized patients [1.021 (1.010–1.041) versus 1.027
(1.014–1.047), U= 567 400, P50.0001], reaching a value not
different from non-demented controls [1.021 (1.010–1.041)
versus 1.020 (1.010–1.037), U= 339 700, P= 0.0960] (Fig. 2C,
Supplementary Fig. 2C).
We then examined the influence of the proximity to dense-core
plaques on the curvature ratio, performing the analysis in a
plaque-based rather than in a random fashion, focusing on the
CA1 subfield (Fig. 2D). As expected, in the non-immunized
Alzheimer’s disease group, the curvature ratio was significantly
higher close to the plaques (550mm) than far away from them
(50 mm) [1.043 (1.023–1.075) close versus 1.028 (1.015–1.049)
far, U= 453 600, P50.0001]. Conversely, in the immunized group
both curvature ratio values close to and far from the dense-core
plaques were almost identical [1.022 (1.009–1.038) close versus
1.020 (1.010–1.036) far, U= 40 570, P= 0.5641]. Moreover, both
curvature ratio values in the immunized group were significantly
lower than the corresponding curvature ratio values in the
non-immunized group (close: U= 117 200, P50.0001; far:
U= 100 800, P50.0001). Importantly, in neither of the
Alzheimer’s disease groups was the curvature ratio of neurites
close to plaques influenced by the size of the plaques (Kruskal–
Wallis ANOVA with Dunn’s multiple comparison post-test:
P40.05), whereas the significant difference observed in the curva-
ture ratio close to plaques between both Alzheimer’s disease
groups was preserved across different plaque size intervals
(Kruskal–Wallis ANOVA with Dunn’s multiple comparison
post-test: P 0.001, except for the plaque size interval 1500–
2000 mm2, which did not reach significance, probably due to the
small number of neurites measured close to plaques of this size in
the immunized group, n= 18) (Fig. 2E).
Dystrophic neurites/varicosities per
dense-core plaque
Dystrophic neurites and axonal swellings or spheroids per
dense-core plaque were counted within the thioflavin-S positive
area in sections stained with SMI312 antibody and counterstained
with thioflavin-S. Dense-core plaques in non-immunized
Alzheimer’s disease patients had significantly more dystrophic
neurites compared to plaques in non-demented controls [2 (1–4)
dystrophies/plaque versus 1 (0–3) dystrophy/plaque, U= 20 790,
P= 0.0007]. Unexpectedly, there was a significant increase in
the number of dystrophic neurites per dense-core plaque in the
immunized patients compared to non-immunized patients [4 (2–6)
dystrophies/plaque versus 2 (1–4) dystrophies/plaque,
U= 116 800, P50.0001] (Fig. 3A, Supplementary Fig. 2D).
Proportion of VDAC1-immunoreactive
dense-core plaques
Accumulation of mitochondria in dystrophic neurites of dense-core
plaques was examined by immunohistochemistry for the outer
mitochondrial membrane marker VDAC1 with thioflavin-S coun-
terstaining. The proportion of dense-core plaques immunoreactive
for VDAC1 in non-immunized Alzheimer’s disease patients
was higher than that in non-demented controls, although this
Figure 1 Continued
bar graph shows total amyloid plaques counted on sections immunostained for 3D6 anti-Ab antibody normalized to 100%. Filled bars
represent the percent of amyloid plaques co-stained with thioflavin-S (dense-core plaques). Raw fractions are presented in parenthesis
within the filled bars, with the number of total amyloid plaques counted in the denominator and the number of dense-core plaques in the
numerator. In F, the correlation between total amyloid plaques and dense-core plaques in both Alzheimer’s disease groups is shown.
Pairwise comparisons in E were done with 2 with Fisher’s exact test (#P50.0001), whereas correlations in F were performed with
Pearson’s test. (G, H) Remaining total amyloid plaques and dense-core plaques in immunized patients are significantly smaller compared to
plaques in non-immunized patients, whereas their size does not differ between non-immunized patients and non-demented controls.
Single-symbol plots in G and H represent median values, whereas bars denote interquartile ranges. These pairwise comparisons were
performed with a Mann–Whitney test (**P50.01, #P50.0001). Automatic measurement of total amyloid plaques size included 225
plaques from non-demented controls (NC), 626 plaques from immunized patients (AD + TX) and 3973 plaques from non-immunized
patients (AD w/o TX). Manual measurement of dense-core plaques size was performed on 55 plaques from non-demented controls, 285
plaques from immunized patients and 1035 plaques from non-immunized patients.
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Figure 2 Improvement of neurite trajectories in immunized patients with Alzheimer’s disease. (A, B) Neurite curvature ratio correlates
significantly with the density of total and dense-core amyloid plaques in non-immunized patients with Alzheimer’s disease. Correlations
were performed with Spearman’s rank test. Dotted lines represent the 95% confidence intervals. (C) Neurite trajectories in the
Continued
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difference did not reach statistical significance (38.96% versus
31.43%, respectively, Fisher’s exact test, P= 0.4771).
Remarkably, more than half (56.25%) of the dense-core plaques
in the AN1792-treated patients were VDAC1-positive, a propor-
tion significantly higher compared to the other two groups
(P= 0.0009 versus non-immunized group; P= 0.0121 versus
non-demented group, Fisher’s exact test) (Fig. 3B).
Reactive astrocytes per dense-core
plaque
We counted the number of glial fibrillar acid protein-positive re-
active astrocytes per dense core-plaque (up to 50 mm from the
edge of the plaque) in sections counterstained with thioflavin-S.
Dense-core plaques had a more severe astrocytosis in
non-immunized Alzheimer’s disease patients than that in
non-demented controls [1.5 (0.4575–3) astrocytes/plaque versus
0.33 (0–1.040) astrocytes/plaque, U= 22 070, P50.0001]. The
extent of astrocytosis surrounding dense-core plaques remaining
after immunization was slightly but not significantly decreased,
when compared to plaques from non-immunized patients with
Alzheimer’s disease [1 (0–3) astrocyte/plaque versus 1.5
(0.4575–3) astrocytes/plaque, U= 73 110, P= 0.6060], but still
more severe than that around dense-core plaques from
non-demented controls (U= 3548, P= 0.0006) (Fig. 3C,
Supplementary Fig. 2E).
Alterations in neuronal tau
To analyse the amount of abnormal neuronal tau quantitatively,
we performed immunohistochemical studies with two different
anti-tau antibodies: the phosphorylation-dependent antibody
PHF1 to assess the phosphorylation status of tau and the
conformation-dependent antibody Alz50 to evaluate the misfold-
ing status of tau (Fig. 4A–B). The density of thioflavin-S positive
neurofibrillary tangles (i.e. tau fibrillar aggregates with a b-sheet
conformation) was also quantitated in a stereological fashion
(Fig. 4C).
As expected, densities of Alz50-positive and PHF1-positive
neurons and thioflavin-S positive neurofibrillary tangles were sig-
nificantly higher in non-immunized Alzheimer’s disease patients
(Braak stages IV–VI) than in non-demented controls (Braak
stages I–III) (Alz50: 16.08 2.534 neurons/mm2 versus
6.948 2.915 neurons/mm2, t= 2.305, df= 19, P= 0.0326; PHF1:
47.44 6.138 neurons/mm2 versus 5.464 2.042 neurons/mm2,
t= 6.489, df= 14, P50.0001; thioflavin-S: 34.12 6.990 neuro-
fibrillary tangles/mm2 versus 4.468 1.885 neurofibrillary tan-
gles/mm2, t= 4.096, df= 13, P= 0.0013). Of note, immunized
patients showed a significant reduction in the density of
PHF1-positive neurons compared to non-immunized patients, des-
pite being matched for the Braak stage (18.53 10.49 neu-
rons/mm2 versus 47.44 6.138 neurons/mm2, t= 2.445, df= 16,
P= 0.0264) (Figs 4A and 4E–L). No difference was found in the
densities of Alz50-positive neurons and thioflavin-S positive neuro-
fibrillary tangles between the Alzheimer’s disease groups (Alz50:
17.42 9.152 neurons/mm2 in AN1792-treated versus
16.08 2.534 neurons/mm2 in non-treated, t= 0.1407, df= 4,
P= 0.8949; thioflavin-S: 18.56 7.690 neurofibrillary tangles/mm2
in AN1792-treated versus 34.12 6.990 neurofibrillary tangles/
mm2 in non-treated, t= 1.261, df= 16, P= 0.2255). A correlation
between densities of PHF1-positive and Alz50-positive neurons for
both Alzheimer’s disease groups revealed a predominance of
PHF1-positive over Alz50-positive neurons in non-immunized pa-
tients with Alzheimer’s disease whereas both densities were similar
in the immunized group (r= 0.3899, P= 0.1878, in the
non-immunized group, versus r= 0.9755, P= 0.0046, in the immu-
nized group, Pearson’s correlation test) (Fig. 4D).
Discussion
Successful removal of hippocampal
amyloid
Both active and passive immunotherapy against Ab peptide have
been shown to clear amyloid plaques or prevent Ab deposition in
Figure 2 Continued
hippocampus of immunized patients are significantly straighter compared to non-immunized patients and similar to non-demented
controls. Curvature ratio was analysed in 1231 neurites from 8 normal controls, 580 neurites from 4 immunized patients and 2243 neurites
from 13 non-immunized patients. In one of the immunized cases an appropriate neurofilament heavy chain immunostaining was not
feasible, probably due to differences in fixation protocols. (D) Improvement of curvature ratio in immunized patients is not only attrib-
utable to a lower plaque load but also occurs within the vicinity (550 mm) of remaining dense-core plaques. Curvature ratio was
determined in 321 neurites close to and 260 neurites far from plaques in the immunized group, and in 1256 neurites close to and 972
neurites far from plaques in the non-immunized group. Pairwise comparisons in C and D were performed with Mann–Whitney test
(#P50.0001). (E) Curvature ratio of neurites close to plaques is not simply due to a ‘mass effect’ caused by the plaques because plaque
size does not affect the curvature ratio of surrounding neurites (within-group comparisons were not significant but are not illustrated for
clarity purposes). Moreover, the improvement of the curvature ratio close to plaques in the immunized subjects is not explained by the
smaller size of their plaques because between-group significant difference is preserved across different plaque size intervals. This analysis
included 143, 281, 202, 171 and 276 neurites close to plaques of increasing size intervals from the non-immunized Alzheimer’s disease
subjects, and 112, 59, 41, 18 and 50 neurites close to plaques of the same size intervals from the AN1792-treated Alzheimer’s disease
subjects. A Kruskal–Wallis ANOVA with Dunn’s multiple comparison post-test was run (***P50.001, #P50.0001, n.s. = non significant).
(F, G) Representative pictures of neurite segments within the vicinity of a dense-core plaque in the CA1 region of a non-immunized patient
with Alzheimer’s disease (F, Case 1), and an AN1792-treated patient with Alzheimer’s disease (G, Case 22). Neurites were immunostained
with a neurofilament heavy chain antibody (in red) and plaques were stained with thioflavin-S (in green). Neurite curvature ratio was
calculated as the ratio of the measured length (white line) to the end-to-end length (pink line). Compare the abnormally curve trajectory of
neurites in F with the straighter trajectory of neurites in G. Scale bars = 20 mm. NC = non-demented controls; AD + TX = plaques from
immunized patients; AD w/o TX = non-immunized patients.
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Figure 3 Dense-core plaques remaining after immunization retain some of their toxic properties. (A) Representative images of dense-core
plaques (in green) from a non-demented control (Case 19), a non-immunized patient (Case 2) and an AN1792-treated patient (Case 23),
with the neurofilament antibody SMI312 depicting associated dystrophic neurites and axonal varicosities or swellings (in red).
Quantification of the number of dystrophic neurites and varicosities per plaque yielded a significant increase in the amount of neuritic
dystrophy in the remaining plaques of immunized patients, as compared to non-immunized patients. Pairwise comparisons were done
with the Mann–Whitney test [***P50.001, #P50.0001; n= 55, 285 and 1035 plaques in normal controls (NC), immunized patients
(AD + TX) and non-immunized patients (AD w/o TX), respectively]. (B) Representative images of mitochondria accumulation in
dense-core plaques associated-dystrophic neurites from a non-demented control (Case 19), a non-immunized patient (Case 3) and an
Continued
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several mouse models of Alzheimer’s disease (Schenk et al., 1999;
Bard et al., 2000; Morgan et al., 2000; Janus et al., 2000; Bacskai
et al., 2001, 2002; DeMattos et al., 2001; Lemere et al., 2003;
Wilcock et al., 2004). Post-mortem studies of brain specimens
from participants in the Phase 2a active immunization trial also
revealed a significant decrease in amyloid pathology, as measured
with either amyloid load or density of amyloid plaques per field
(Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005;
Bombois et al., 2007; Holmes et al., 2008).
Our results are in agreement with these previous autopsy re-
ports. Compared to the hippocampus of non-immunized patients
from our brain bank, the hippocampus of this subset of immunized
Alzheimer’s disease patients had a significantly lower amount of
amyloid deposits, as measured in sections stained with the 10D5
antibody, an antibody that recognizes the N-terminus of the Ab
peptide. Indeed, active immunization reduced the hippocampal
plaque amyloid load in the treatment group down to the levels
existing in age-matched non-demented controls. The same result
was achieved after the stereological quantification of density of
amyloid plaques in sections stained with the 3D6 antibody, which
also binds to the N-terminus of the Ab peptide. Since anti-Ab
antibodies generated after AN1792 immunization are mainly dir-
ected against the N-terminus of the Ab peptide (Lee et al., 2005),
the results herein could be explained by a competition between
10D5 and 3D6 antibodies and de novo endogenous anti-Ab anti-
bodies to bind amyloid plaques. However, stereological quantifi-
cation of plaques in thioflavin-S stained sections also yielded
similarly lower density of dense-core plaques in immunized
patients, ruling out this possibility.
Interestingly, our quantitative analysis revealed a significantly
higher proportion of dense-core plaques among the remaining
amyloid plaques in the immunized cases, as compared to
non-immunized Alzheimer’s disease cases. A sub-regional analysis
showed that this difference was mainly driven by the stereological
quantification in the subiculum-presubiculum (data not shown).
Indeed, the hippocampal sections from four out of the five immu-
nized Alzheimer’s disease patients were virtually devoid of the
confluent, diffuse, ‘cloud-like’ amyloid deposits, typically seen in
the parvopyramidal layer of the presubiculum (see Supplementary
Fig. 1) (Kalus et al., 1989; Akiyama et al., 1990; Wisniewski et al.,
1998). Thus, these data indicate that AN1792 immunization was
comparatively more effective at clearing diffuse amyloid deposits
than dense-core plaques.
We compared the size distribution of amyloid plaques in hippo-
campal sections from the three groups of subjects and found that
both total amyloid plaques and dense-core plaques were signifi-
cantly smaller in immunized patients, with respect to non-
immunized patients and non-demented controls. Despite the
static nature of any post-mortem study, this result is consistent
with the in vivo observation of a reduction in dense-core plaques
size after topical administration of anti-Ab antibodies in an
Alzheimer’s disease mouse model (Bacskai et al., 2002). This
observation, together with the relative abundance of collapsed
‘moth-eaten’ plaques remaining after AN1792 immunization
already noted in previous post-mortem reports (Nicoll et al.,
2003; Ferrer et al., 2004), also points towards a sequential pattern
of amyloid removal: plaques halo, containing more soluble amyloid
species, would be removed more readily, whereas insoluble amyl-
oid fibrils compactly packed within the plaque core would be
harder to solubilize.
According to previous reports, amyloid removal seems to be
proportional to the immunological response to AN1792 as mea-
sured with antibody titres in plasma or CSF (Holmes et al., 2008).
Of note, in our study, both an antibody responder patient who
developed a subacute meningoencephalitis and a patient with un-
detectable antibody titres by enzyme-linked immunosorbent assay
had the highest amyloid loads and densities of dense-core plaques
among the immunized patients.
A recent post-mortem study of eight other AN1792-immunized
patients showed an overall increase in the extension and severity
of cerebral amyloid angiopathy, suggesting that amyloid peptide is
cleared through the vessels wall and efflux to the circulation
(Boche et al., 2008). Unlike this study, the clearance of amyloid
plaques in the hippocampus of our subset of immunized patients
was not translated into an increase of their vascular amyloid load,
which was not significantly different from non-immunized pa-
tients. However, since cerebral amyloid angiopathy is usually
more prominent in neocortical areas and our analysis was
restricted to the hippocampus, we cannot rule out an overall
increase of cerebral amyloid angiopathy in our immunized group.
Removal of amyloid plaques leads to
recovery of neurite abnormal trajectories
We previously showed that the neurites within the dense-core
amyloid plaques in the human Alzheimer’s disease brain have a
more abnormal trajectory compared to the neurites outside the
Figure 3 Continued
AN1792-treated patient (Case 22), as revealed by the mitochondrial marker VDAC1 (in red). Quantification of dense-core plaques
immunoreactive for VDAC1 in the three study groups revealed an increase of the proportion of plaques VDAC1-positive in the immunized
group, as compared to the non-immunized group. Dense-core plaques were normalized to 100% and filled bars represent the proportion
of dense-core plaques immunoreactive for VDAC1. Raw fractions are shown in parenthesis within the filled bars, with the number of
dense-core plaques counted in the denominator and the number of VDAC1-positive plaques in the numerator. Pairwise comparisons were
done with 2 with Fisher’s exact test (*P50.05, ***P50.001). (C) Representative images of reactive astrocytosis surrounding dense-core
plaques (in green) from a non-demented control (Case 18), a non-immunized patient (Case 5) and a patient treated with AN1792 (Case
23), as shown with a glial fibrillar acid protein immunostaining (in red). Quantification of the number of astrocytes per plaque resulted in a
non-significant decrease of plaque-associated astrocytosis in the immunized group compared to the non-immunized patients. However,
plaques from immunized patients still have more severe astrocytosis than plaques from non-demented controls. Pairwise comparisons
were done with the Mann–Whitney test (***P50.001, #P50.0001; n= 66, 151 and 994 dense-core plaques, in the non-demented,
immunized and non-immunized groups, respectively). Scale bars in A–C= 20 mm.
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Figure 4 Decreased tau phosphorylation in neurofibrillary tangles after anti-Ab immunization. (A) Hippocampal density of PHF1-positive
neurons is significantly decreased in the immunized Alzheimer’s disease patients compared to the patients with non-immunized
Alzheimer’s disease, despite both groups being matched for Braak stage. (B, C) No significant difference is observed in the densities of
Alz50-positive neurons and thioflavin-S positive neurofibrillary tangles (NFT) between both Alzheimer’s disease groups. Pairwise com-
parisons in A–C were done with a two-tailed t-test and bars represent mean SEM (*P50.05, **P50.01, #P50.0001). (D) Correlations
between densities of PHF1-positive neurons and Alz50-positive neurons in both Alzheimer’s disease groups reveal a predominance of the
late-stage phospho-tau species (PHF1) over the early-stage misfolded tau species (Alz50) in the non-immunized group. By contrast,
neither of both tau epitopes is predominant in the Braak-matched immunized Alzheimer’s disease group. Black circles represent each of
non-immunized patients and grey squares represent immunized patients. Correlations were done with Pearson’s test and dotted lines
indicate the 95% confidence interval. For clarity purposes, non-demented controls are not represented. (E–L) Pictures show some of the
PHF1-immunostained hippocampal sections used in the above analysis. The transition from the CA1 region to the subiculum (left-to-right
in each picture) is illustrated for two representative non-immunized Alzheimer’s disease patients (E, Case 4, Braak VI; and F, Case 12, Braak
IV), one representative non-demented control (G, Case 18, Braak II) and the five AN1792-treated Alzheimer’s disease patients (H–L, Cases
22–26). Scale bars = 200mm.
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plaques, and also compared to the neurites in the brain of
non-demented controls (Knowles et al., 1999). We also showed
in Alzheimer’s disease transgenic mouse models that the curvature
ratio in neurites within 50mm from the edge of the dense-core
plaques is abnormally higher than the curvature ratio far away
from this boundary (D’Amore et al., 2003; Lombardo et al.,
2003; Spires-Jones et al., 2009). In addition, in vivo imaging of
the brain in one of these models revealed that changes in neurite
trajectories follow the appearance of new plaques, arguing that
this morphologic change is secondary to Ab deposition
(Meyer-Luehmann et al., 2008). Lastly, passive immunotherapy
in these Alzheimer’s disease mouse models was able to normalize
the curvature ratio of the neurites upon removal of amyloid pla-
ques (Lombardo et al., 2003; Spires-Jones et al., 2009).
Based on this previous work in transgenic models of Ab depos-
ition, we analysed the curvature ratio of the neurites (dendrites
and axons) in the hippocampus of the three groups of subjects
and studied the influence of their proximity to dense-core plaques.
The presence of a curvature ratio significantly higher in
non-immunized Alzheimer’s disease patients compared to
non-demented controls confirmed the reproducibility and validity
of this measure of neurite morphological abnormality. A subse-
quent analysis in the CA1 subfield with a plaque-based approach
yielded a significantly higher curvature ratio of neurites located
close to dense-core plaques (550 mm), as compared to neurites
far from them (50 mm), in non-immunized patients with
Alzheimer’s disease. This higher curvature ratio close to plaques
was not influenced by the plaque size, supporting a local toxic
effect of dense-core plaques on the trajectories of surrounding
neurites rather than a ‘mass effect’, and further reinforcing the
usefulness of this morphological measure. Examination of
double-labelled hippocampal sections revealed that the 50 mm
boundary around the edge of the thioflavin-S positive area was
far away from the thin halo of more diffuse 3D6-positive but
thioflavin-S-negative amyloid, also arguing against this ‘mass
effect’ (results not shown).
Importantly, in the first of the two analyses, the neurite curva-
ture ratio was significantly lower in AN1792-immunized patients
than in non-immunized patients. Indeed, we observed an apparent
normalization of this parameter of neuronal degeneration, since
there was no significant difference between immunized patients
and non-demented controls. This result is not merely due the ex-
istence of fewer plaques in the immunized Alzheimer’s disease
group, because in the plaque-based analysis performed subse-
quently, curvature ratios of both neurites located close to and
far from dense-core plaques also were significantly lower in
AN1792-treated patients, compared to the non-immunized pa-
tients. In fact, unlike these results in the non-immunized group,
in the immunized patients both curvature ratios were almost iden-
tical. In addition, the significant difference observed in the curva-
ture ratio close to plaques between both Alzheimer’s disease
groups is not merely due to the plaques from the immunized
group being smaller and exerting less ‘mass effect’ on surrounding
neurites; first, as mentioned above, the plaque size did not influ-
ence the curvature ratio of surrounding neurites, and second, the
difference was preserved across different plaque size intervals.
Thus, the significantly lower curvature ratio in the proximity of
the remaining plaques in the AN1792 group unequivocally
points to the reduction of an abnormal neurite morphology other-
wise existing around the dense-core plaques.
Taken together, these results indicate that AN1792 immuniza-
tion reproduces the beneficial effects on neurite trajectories
observed with anti-Ab passive immunization in preclinical studies
(Lombardo et al., 2003; Spires-Jones et al., 2009) and further
extend previous evidence of anti-Ab immunization-induced im-
provement in markers of neuronal degeneration in the human
Alzheimer’s disease brain (Nicoll et al., 2003; Ferrer et al., 2004;
Masliah et al., 2005). While we have previously shown that
plaque-induced neuritic curvature can potentially contribute to
the cognitive deficits seen in Alzheimer’s disease by disrupting
the cortical synaptic integration (Knowles et al., 1999; Stern
et al., 2004), the restoration of neurite trajectories observed in
the hippocampus of this subset of immunized patients may not
be sufficient to slow their cognitive decline (Supplementary
Table 2) (Ferrer et al., 2004; Masliah et al., 2005; Bombois
et al., 2007; Uro-Coste et al., 2010).
Toxic potential of amyloid plaques
remaining after immunization
Passive anti-Ab immunotherapy can promote a rapid recovery of
amyloid-associated neuritic dystrophy in mouse models of
Alzheimer’s disease (Brendza et al., 2005), and also previous
autopsy reports of AN1792-treated patients have described a
decrease in the density of clusters of dystrophic neurites upon
amyloid removal (Nicoll et al., 2003; Ferrer et al., 2004; Masliah
et al., 2005). We sought to compare the amount and character-
istics of plaque-associated neuritic dystrophy in hippocampal
sections from the three groups of subjects. First, we counted the
number of SMI312-positive dystrophic neurites and axonal
swellings or spheroids within the boundaries of dense-core plaques
and observed an unexpected increase in dystrophic neurites asso-
ciated with the remaining plaques of AN1792-treated patients, as
compared to non-immunized patients. Next, we wondered
whether this resistance of dystrophic neurites to anti-Ab immuno-
therapy might be due to their end-stage properties. Electron
microscopy studies have described the accumulation of degenerat-
ing mitochondria in the dystrophic processes of dense-core amyl-
oid plaques (Kidd, 1964; Fiala et al., 2007). Indeed, a staging of
mitochondrial degeneration has been proposed, starting with the
accumulation of smaller but otherwise normal-looking mitochon-
dria, followed by the swelling of mitochondrial cristae and the
formation of lamellar bodies, and lastly clustering into multivesi-
cular, presumably autophagic, bodies (Fiala et al., 2007). We
sought to depict this pathological feature with immunostaining
for VDAC1 (porin, voltage-dependent anion channel type 1), a
channel protein present in the outer mitochondrial membrane.
As expected by these previous ultrastructural descriptions,
VDAC1 decorated dystrophic processes of some dense-core
plaques, intermingled with the fibrillar amyloid. Surprisingly, we
found a significantly increased proportion of VDAC1-
immunoreactive dense-core plaques in the immunized group.
Thus, the results of this characterization of plaque-associated
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neuritic dystrophy suggest that anti-Ab active immunization might
be ineffective in ameliorating amyloid-embedded end-stage dys-
trophic neurites unless compact amyloid is completely removed. By
contrast, we postulate that the restoration of the trajectory of
surrounding neurites would occur as soon as the process of
plaque removal begins. Alternatively, new dystrophic neurites
and axonal swellings and further mitochondrial degeneration
might occur within the remaining dense-core plaques as a result
of the ongoing solubilization of amyloid fibrils, perhaps due to an
increase in the local concentration of toxic Ab oligomers (Cruz
et al., 1997; Carulla et al., 2005; Patton et al., 2006; Martins
et al., 2008).
Previous autopsy studies of AN1792-treated patients have re-
ported a lower density of reactive astrocyte clusters upon amyloid
clearance but have not assessed the amount of astrocytosis sur-
rounding the remaining plaques (Nicoll et al., 2003; Masliah et al.,
2005). We measured the number of reactive astrocytes per dense
core-plaque up to 50 mm from the edge of the plaques in the three
study groups, and found no significant difference between plaques
remaining after immunization and those from non-immunized
patients, further suggesting that the former still retain toxic
properties.
Notably, despite being similar in size, dense-core plaques were
substantially less toxic in non-demented controls than in
non-treated Alzheimer’s disease patients, as judged by these
measures of neuritic dystrophy and astrocytosis.
Active immunization also ameliorates
the hippocampal tau pathology
In the triple transgenic mouse (3Tg), which sequentially de-
velops both amyloid plaques and neuronal tau aggregates,
anti-Ab immunization not only removed amyloid but also im-
proved early tau pathology in the same sequential fashion. Yet
success was not complete because late hyperphosphorylated tau
aggregates remained intact after treatment (Oddo et al., 2004).
However, the same authors have shown that, when initiated at an
earlier stage, before the mice develop plaques and tau aggregates,
anti-Ab immunization is able to prevent the development of both
amyloid and tau pathologies in this mouse model (Oddo et al.,
2008). Recently, anti-Ab active immunization has been shown to
decrease tau hyperphosphorylation in two other mouse models
that sequentially develop amyloid plaques and neuronal aggre-
gates of hyperphosphorylated native murine tau, thus adding fur-
ther evidence for its potential beneficial effect on tau pathology
(Wilcock et al., 2009). By contrast, previous autopsy studies of
AN1792-treated patients have reported a density of neurofibrillary
tangles and neuropil threads similar to non-treated patients with
Alzheimer’s disease and a pattern of neurofibrillary tangles distri-
bution consistent with Braak V–VI stages. However, in a subset of
11 antibody responders with baseline and follow-up CSF samples
tau levels were significantly reduced, as compared with 10 placebo
recipients (Gilman et al., 2005).
To analyse tau neuronal pathology, we used two different
well-characterized antibodies, PHF1 and Alz50. While PHF1
binds tau protein phosphorylated at serine residues 396 and 404
(Otvos Jr. et al., 1994), Alz50 is a phosphorylation-independent
but conformation-dependent anti-tau antibody, with an epitope
consisting of the N-terminus and one of the microtubule-binding
domains of the tau molecule (Carmel et al., 1996). Although both
antibodies are highly specific for tau species in the Alzheimer’s
disease brain, Alz50 has been shown to label early misfolded tau
(Carmel et al., 1996), whereas PHF1 binds to later-stage hyper-
phosphorylated tau (Augustinack et al., 2002).
Surprisingly, stereological quantification of the density of
PHF1-positive neurons yielded a significant reduction in immu-
nized patients, as compared to non-immunized patients.
However, no difference was found in the quantification of Alz50
positive cells between both Alzheimer’s disease groups.
Furthermore, there was no significant difference between the
groups in the density of late-stage thioflavin-S positive neurofib-
rillary tangles.
Taken together, these results suggest that anti-Ab active im-
munization is able to decrease tau hyperphosphorylation but is
less effective in ameliorating the misfolding and aggregation of
the tau molecules. Further, they are in line with a previous autopsy
study of one of these immunized patients describing a reduced
immunoreactivity of phospho-tau and the stress kinases stress-
activated protein kinase/c-Jun N-terminal kinase and p38 within
the dystrophic neurites surrounding collapsed plaques (Ferrer
et al., 2004). Remarkably, among the immunized patients, both
the subject who developed an autoimmune meningoencephalitis
and the subject who did not generate an enzyme-linked immuno-
sorbent assay-detectable anti-AN1792 antibody response had the
highest densities of Alz50, PHF1 and thioflavin-S positive neurons.
Therefore, it is possible that immunization at an earlier stage of
the disease (i.e. in patients with mild cognitive impairment) would
have reverted or even prevented the development of neurofibril-
lary tangles to a greater extent. These findings suggest a link be-
tween Ab and tau, and provide strong support for the amyloid
cascade hypothesis, which postulates that Ab accumulation trig-
gers the onset of Alzheimer’s disease and that tau hyperphosphor-
ylation, subsequent neurofibrillary tangles formation and neuronal
death are downstream consequences of the Ab aggregation
(Hardy and Selkoe, 2002). To our knowledge, this is the first evi-
dence of improvement of neuronal tangle pathology upon anti-Ab
immunization in patients with Alzheimer’s disease. Differences
with previous reports might be due to the different tau epitopes
depicted in the immunohistochemical studies and to the different
quantification approaches (sterology-based versus non-stereology
based).
In summary, we show that clearance of amyloid plaques by
anti-Ab active immunization within the hippocampus promotes
potentially beneficial structural changes of neurites and decreases
the hyperphosphorylation of tau. However, dense-core plaques
that remain after immunization retain at least some of their
toxic properties. The morphological improvements are relatively
subtle and may not be sufficient to alter the clinical course of
these patients. Nonetheless, they extend previous evidence that
an Ab-directed therapy can modify the neuropathology of the
human disease beyond the effects on amyloid plaques and support
the idea that Ab toxicity directly mediates at least some of the
neurodegenerative phenomena associated with neural system
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collapse in Alzheimer’s disease. Immunization of patients at an
earlier stage of the disease might enhance these positive changes
and render a more robust improvement of cognitive functions.
Larger clinicopathological studies on patients enrolled in ongoing
active and passive immunization clinical trials are needed to con-
firm these results. Also, whether plaque removal by immunization
leads to an increase of synaptic density or prevents further synap-
tic loss—the main pathological correlate of cognitive function in
Alzheimer’s disease—remains to be investigated.
Acknowledgements
The authors want to thank the patients and caregivers involved in
research in their respective institutions.
Funding
National Institutes of Health [grant numbers AG08487 and
P50AG05134 to B.T.H., M.P.F, J.H.G and C.M.W]; the
Programme Hospitalier de Reserche Clinique Re´gional
[02-029-08 to E.U.C. and M.B.D.] and the Fondo de
Investigaciones Sanitarias-Instituto de Salud Carlos III of the
Spanish Ministerio de Ciencia e Innovacio´n [CM06/00161 to
A.S.P.].
Supplementary material
Supplementary material is available at Brain online.
References
Akiyama H, Tago H, Itagaki S, McGeer PL. Occurrence of diffuse amy-
loid deposits in the presubicular parvopyramidal layer in Alzheimer’s
disease. Acta Neuropathol 1990; 79: 537–44.
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau
phosphorylation sites correlate with severity of neuronal cytopathology
in Alzheimer’s disease. Acta Neuropathol 2002; 103: 26–35.
Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al.
Imaging of amyloid-b deposits in brains of living mice permits direct
observation of clearance of plaques with immunotherapy. Nat Med
2001; 7: 369–72.
Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D,
et al. Non-Fc-mediated mechanisms are involved in clearance of amy-
loid-b in vivo by immunotheraphy. J Neurosci 2002; 22: 7873–8.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al.
Peripherally administered antibodies against amyloid b-peptide enter
the central nervous system and reduce pathology in a mouse model of
Alzheimer disease. Nat Med 2000; 6: 916–9.
Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al.
Consequence of Ab immunization on the vasculature of human
Alzheimer’s disease brain. Brain 2008; 131: 3299–310.
Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-
Cordoliani MA, Black RS, et al. Absence of b-amyloid deposits after
immunization in Alzheimer disease with Lewy body dementia. Arch
Neurol 2007; 64: 583–7.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991; 82: 239–59.
Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE,
et al. Anti-Ab antibody treatment promotes the rapid recovery of
amyloid-associated neuritic dystrophy in PDAPP transgenic mice.
J Clin Invest 2005; 115: 428–33.
Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K,
et al. b-amyloid immunotherapy prevents synaptic degeneration in a
mouse model of Alzheimer’s disease. J Neurosci 2005; 25: 9096–101.
Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of mono-
clonal antibody Alz50’s selectivity for Alzheimer’s disease pathology.
J Biol Chem 1996; 51: 32789–95.
Carulla N, Caddy GL, Hall DR, Zurdo J, Gairi M, Feliz M, et al. Molecular
recycling within amyloid fibrils. Nature 2005; 436: 554–8.
Cruz L, Urbanc B, Buldyrev SV, Christie R, Go´mez-Isla T, Havlin S, et al.
Aggregation and disaggregation of senile plaques in Alzheimer disease.
Proc Natl Acad Sci 1997; 94: 7612–6.
D’Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT.
In vivo multiphoton imaging of a transgenic mouse model of
Alzheimer disease reveals marked thioflavin-S-associated alterations
in neurite trajectories. J Neuropathol Exp Neurol 2003; 62: 137–45.
DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in
Alzheimer’s disease: Correlation with cognitive severity. Ann Neurol
1990; 27: 457–64.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM,
Holtzman DM. Peripheral anti-Ab antibody alters CNS and plasma
Ab clearance and decreases brain Ab burden in a mouse model of
Alzheimer’s disease. Proc Natl Acad Sci 2001; 98: 8850–5.
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C,
et al. Immunization reverses memory deficits without reducing
brain Ab burden in Alzheimer’s disease model. Nat Neurosci 2002;
5: 452–7.
Ferrer I, Boada-Rovira M, Sa´nchez-Guerra ML, Rey MJ, Costa-Jussa´ F.
Neuropathology and pathogenesis of encephalitis following amyloid-b
immunization in Alzheimer’s disease. Brain Pathol 2004; 14: 11–20.
Fiala JC, Feinberg M, Peters A, Barbas H. Mitochondrial degeneration in
dystrophic neurites of senile plaques may lead to extracellular deposi-
tion of fine filaments. Brain Struct Funct 2007; 212: 195–207.
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al.
Clinical effects of Ab immunization (AN1792) in patients with AD in
an interrupted trial. Neurology 2005; 64: 1553–62.
Go´mez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH,
Hyman BT. Profound loss of layer II entorhinal cortex neurons
occurs in very mild Alzheimer’s disease. J Neurosci 1996; 16:
4491–500.
Go´mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC,
et al. Neuronal loss correlates with but exceeds neurofibrillary tangles
in Alzheimer’s disease. Ann Neurol 1997; 41: 17–24.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: pro-
gress and problems on the road to therapeutics. Science 2002; 297:
353–6.
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Mu¨ller-
Tillmanns B, et al. Antibodies against b-amyloid slow cognitive decline
in Alzheimer’s disease. Neuron 2003; 38: 547–54.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A,
et al. Long-term effects of Ab42 immunisation in Alzheimer’s disease:
follow-up of a randomised, placebo-controlled phase I trial. Lancet
2008; 372: 216–23.
Hyman BT, Go´mez-Isla T, Irizarry MC. Stereology: a practical primer for
neuropathology. J Neuropathol Exp Neurol 1998; 57: 305–10.
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al.
Ab immunization reduces behavioural mathewsimpairment and
plaques in a model of Alzheimer’s disease. Nature 2000; 408: 979–82.
Kalus P, Braak H, Braak E, Bohl J. The presubicular region in Alzheimer’s
disease: topography of amyloid deposits and neurofibrillary changes.
Brain Res 1989; 494: 198–203.
Kidd M. Alzheimer’s disease. An electron microscopical study. Brain
1964; 87: 307–20.
Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME,
et al. Plaque-induced neurite abnormalities: implications for disruption
1326 | Brain 2010: 133; 1312–1327 A. Serrano-Pozo et al.
of neural networks in Alzheimer’s disease. Proc Natl Acad Sci 1999;
96: 5274–9.
Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L,
Hyman BT, et al. Reversible memory loss in a mouse transgenic
model of Alzheimer’s disease. J Neurosci 2002; 22: 6331–5.
Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Ab42
immunization in Alzheimer’s disease generates Ab N-terminal antibo-
dies. Ann Neurol 2005; 58: 430–5.
Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF,
et al. Evidence for peripheral clearance of cerebral Ab protein following
chronic, active Ab immunization in PSAPP mice. Neurobiol Dis 2003;
14: 10–8.
Lombardo JA, Stern ES, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ,
et al. Amyloid-b antibody treatment leads to rapid normalization of
plaque-induced neuritic alterations. J Neurosci 2003; 23: 10879–83.
Martins IC, Kupperstein I, Wilkinson H, Maes E, Vanbrabant M,
Jonckheere W, et al. Lipids revert inert Ab amyloid fibrils to neurotoxic
protofibrils that affect learning in mice. Embo J 2008; 27: 224–33.
Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Ab
vaccination effects on plaque pathology in the absence of encephalitis
in Alzheimer disease. Neurology 2005; 64: 129–31.
Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcı´a-Alloza M, de
Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity
of amyloid-b plaques in a mouse model of Alzheimer’s disease.
Nature 2008; 451: 720–5.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J,
et al. Ab peptide vaccination prevents memory loss in an animal model
of Alzheimer’s disease. Nature 2000; 408: 982–5.
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO.
Neuropathology of human Alzheimer disease after immunization with
amyloid-b peptide: a case report. Nat Med 2003; 9: 448–52.
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Ab immunother-
apy leads to clearance of early, but not late, hyperphosphorylated tau
aggregates via the proteasome. Neuron 2004; 43: 321–32.
Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, et al.
Blocking Ab42 accumulation delays the onset and progression of tau
pathology via the C terminus of Heat Shock Protein70-Interacting
Protein: a mechanistic link between Ab and tau pathology.
J Neurosci 2008; 28: 12163–75.
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al.
Subacute meningoencephalitis in a subset of patients with AD after
Ab42 immunization. Neurology 2003; 61: 46–54.
Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VMY.
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated
at serine residues 396 and 404. J Neurosci Res 1994; 39: 669–73.
Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD,
Luehrs DC, et al. Amyloid-b peptide remnants in AN-1792-immunized
Alzheimer’s disease patients. A biochemical analysis. Am J Pathol
2006; 169: 1048–63.
Schenk D, Barbour R, Whitney D, Gordon G, Grajeda H, Guido T, et al.
Immunization with amyloid-b attenuates Alzheimer-disease-like
pathology in the PDAPP mouse. Nature 1999; 400: 173–7.
Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M,
de Calignon A, Bacskai BJ, et al. Passive immunotheraphy rapidly
increases structural plasticity in a mouse model of Alzheimer disease.
Neurobiol Dis 2009; 33: 213–20.
Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT.
Cortical synaptic integration in vivo is disrupted by amyloid-b plaques.
J Neurosci 2004; 24: 4535–40.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al.
Physical basis of cognitive alterations in Alzheimer’s disease: synapse
loss is the major correlate of cognitive impairment. Ann Neurol 1991;
30: 572–80.
Uro-Coste E, Russano de Paiva G, Guilbeau-Frugier C, Sastre N,
Ousset PJ, Adolfo da Silva N, et al. Cerebral amyloid angiopathy
and microhaemorrhages after amyloid b vaccination: case report and
brief review. Clin Neuropathol 2010 in press.
Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-
term follow-up of patients immunized with AN1792: reduced func-
tional decline in antibody responders. Curr Alzheimer Res 2009; 6:
144–51.
Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S,
Alamed J, et al. Passive amyloid immunotherapy clears amyloid and
transiently activates microglia in a transgenic mouse model of amyloid
deposition. J Neurosci 2004; 24: 6144–51.
Wilcock DM, Gharkholonarche N, Van Nostrand WE, Davis J, Vitek MP,
Colton CA. Amyloid reduction by amyloid-b vaccination also reduces
mouse tau pathology and protects from neuron loss in two mouse
models of Alzheimer’s disease. J Neurosci 2009; 29: 7957–65.
Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M,
Wegiel J. Diffuse, lake-like amyloid-b deposits in the parvopyramidal
layer of the presubiculum in Alzheimer disease. J Neuropathol Exp
Neurol 1998; 57: 674–83.
Beneficial effect of anti-Ab immunization Brain 2010: 133; 1312–1327 | 1327


 1 
LEGENDS OF SUPPLEMENTARY FIGURES 
Supplementary Figure 1: Decreased hippocampal amyloid deposition after anti-Aβ 
immunization. 
Pictures show some of the 10D5-immunostained hippocampal sections used in the 
analysis of amyloid load. Vessels were counterstained with PAS (in magenta). The 
typical distribution of amyloid deposition within the hippocampus is illustrated in a 
subject with advanced AD (case 4): one row of conspicuous plaques in the molecular 
layer of the dentate gyrus (upper row in the picture); a parallel row of plaques in the 
pyramidal layer of the CA1 region (lower row in the picture), which becomes wider as it 
enters the subiculum, and diffuse cloud-like amyloid deposits in the parvopyramidal layer 
of the presubiculum. Note the overall reduced amyloid load in the AN1792-treated AD 
group, which at least in cases 25 and 26 is comparable to the amyloid load of the non-
demented control (case 14). Scale bars, 200 µm. 
 
Supplementary Figure 2: Frequency distribution histograms of neuropathological 
quantitative measures. 
Frequency distribution histogram of total amyloid plaques size (A) and of dense-core 
plaques size (B) reveals a shift of the immunized group to the left, compared to the non-
immunized group (i.e. smaller size). (C) Frequency distribution histogram of neurite 
curvature ratio also shows a shift of the immunized group to the left, compared to the 
non-immunized group (i.e. lower curvature ratio, straighter neurites), paralleling the non-
demented group. (D) Frequency distribution histogram of the number of SMI312-positive 
dystrophic neurites per dense-core plaque shows a shift of the immunized group to the 
 2 
right, compared to the non-immunized group (i.e. more dystrophic neurites per plaque), 
due to an apparent bimodal distribution. By contrast, non-demented group is shifted to 
the left (i.e. less dystrophic neurites per plaque). (E) Frequency distribution histogram of 
the number of GFAP-positive reactive astrocytes per dense-core plaque reveals a similar 
distribution in both AD groups. Conversely, non-demented group is shifted to the left (i.e. 
less astrocytes per plaque).  
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Supplementary Table 1. Demographic characteristics, pathological diagnosis and 
APOE genotype of study subjects. 
 
Subject Age Gender Diagnosis 
Duration of 
disease (y) 
Braak APOE alleles PMI (h) 
1 72 F AD 13 VI 3,4 14 
2 79 M AD 9 VI 3,4 14 
3 79 F AD 5 VI 3,4 11 
4 71 F AD 10 VI 4,4 5 
5 71 F AD 17 VI 4,4 14 
6 78 F AD 9.9 VI 3,4 22 
7 78 F AD 17 VI 3,4 20 
8 78 M AD 4.9 VI 3,3 14 
9 87 F AD 10 V 3,3 15 
10 89 F AD 14 V 3,3 12 
11 88 M AD 9.5 V 4,4 10 
12 66 M AD 1.5 IV 3,4 12 
13 70 M AD+DLB 10 IV 3,4 2 
14 63 M CTRL N.A. III 3,3 3 
15 88 F CTRL N.A. II 3,3 16 
16 92 F CTRL N.A. II 2,3 24 
17 85 M CTRL N.A. II 3,3 24 
18 85 F CTRL N.A. II 3,4 27 
19 97 M CTRL N.A. II 3,3 7 
20 76 F CTRL N.A. I 3,3 24 
21 76 M CTRL N.A. I 3,4 48 
22 76 M AD 4.2 VI 3,4 4 
23 72 M AD 11 VI 3,4 6 
24 88 F AD 13 V-VI 3,4 ? 
25 79 M AD 7 V-VI 3,3 66 
26 78 F AD+DLB 7 IV 3,3 7 
 4 
M = male; F = female; AD = Alzheimer’s disease; DLB = Dementia with Lewy Bodies; CTRL = non-
demented control (white rows). N.A. = not applicable. PMI = postmortem interval. ? = missing data. Dark-
grey rows depict non-immunized cases, whereas light-grey rows show AN1792-treated patients. 
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Supplementary Table 2. Additional clinical and pathological characteristics of 
AN1792-treated patients in this study. 
Subject 
Baseline 
MMSE 
MMSE 
at death 
Survival after 
first dose (mo) 
Other clinical and/or 
pathological features 
Reference 
22 18 0 15 
Severe CAA with microbleeds, 
T-cell mediated autoimmune 
meningoencephalitis 
Ferrer et al., 2004 
23 ? 12 12 
Severe CAA, low amyloid load in 
the frontal cortex 
Masliah et al., 2005 
24 21 4 40 
Severe CAA with microbleeds, 
low amyloid load in the frontal 
cortex 
Uro-Coste et al., 2010 
25 26 12 46 
Clinical course typical of AD, 
with behavioral disturbances and 
parkinsonism at the late phase 
Unpublished 
26 15 19 34 
AD-DLB patient with cognitive 
fluctuations and delirium 
episodes but globally stable 
cognition and function 
Bombois et al., 2007 
 
MMSE = MiniMental State Examination; CAA = Cerebral amyloid angiopathy; AD = Alzheimer’s disease; 
DLB = Dementia with Lewy bodies; ? missing data (note that an inclusion criteria in this clinical trial was a 
baseline MMSE score of 15 to 26) 
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Supplementary Table 3. Antibodies, antigen retrieval protocols and developing strategies used in the immunohistochemical studies. 
PRIMARY Ab HOST 
BLOCKING 
SOLUTION 
SECONDARY Ab ANTIGEN RETRIEVAL  
DEVELOPING 
STRATEGY 
10D5  
(1:50, Elan 
Pharmaceuticals, Inc.) 
Ms 
5% fat-free 
milk in TBS 
HRP anti-ms IgG 
(1:200) 
-Citrate buffer 0.01M pH 6 with 
Tween20 in MW 95ºC 20 min. 
-Formic acid 90% 5 min 
DAB (Vector Lab.) 
3D6 
(1:1000, Elan 
Pharmaceuticals, Inc.) 
Ms 
10% NGS in 
TBS 
Cy3 anti-ms IgG 
(1:200) 
-Citrate buffer 0.01M pH 6 with 
Tween20 in MW 95ºC 20 min. 
None 
PHF1  
(1:200, Dr. Peter Davies’ 
kind gift) 
Ms 
5% fat-free 
milk in TBS 
Biotin anti-ms IgG 
(1:200) 
-Citrate buffer 0.01M pH 6 with 
Tween20 in MW 95ºC 20 min. 
-ABC kit (Vector Lab.) 
-Streptavidin-
AlexaFluor546 (1:200) 
Alz50  
(1:50, Dr. Peter Davies’ 
kind gift) 
Ms 
5% fat-free 
milk in TBS 
Biotin anti-ms IgM 
(1:200) 
-Citrate buffer 0.01M pH 6 with 
Tween20 in MW 95ºC 20 min 
-ABC kit (Vector Lab.) 
-Streptavidin-
AlexaFluor546 (1:200) 
NF-H  
(1:100, Abcam, ab40796) 
Rb 
10% NGS in 
TBS 
Biotin anti-rb IgG 
(1:200) 
-Citrate buffer 0.01M pH 6 with 
Tween20 in MW 95ºC 20 min. 
-ABC kit (Vector Lab.) 
-TSA-AlexaFluor594 
 7 
-Formic acid 70% 10 min. (1:100, Invitrogen) 
SMI-312 (1:1000,  
Covance, SMI-312R) 
Ms 
10% NGS in 
TBS 
Cy3 anti-ms IgG 
(1:200) 
None None 
VDAC1  
(1:500, Abcam, ab15895) 
Rb 
10% NGS in 
TBS 
Cy3 anti-rb IgG 
(1:200) 
-Citrate buffer 0.1M pH 6 with 
Tween20 in MW 95ºC 20 min 
None 
GFAP  
(1:1000, Sigma, G9269) 
Rb 
5% fat-free 
milk in TBS 
Cy3 anti-rb IgG 
(1:200) 
-Citrate buffer 0.1M pH 6 with 
Tween20 in MW 95ºC 20 min 
None 
 
Abbreviations: NF-H = Neurofilament-Heavy Chain; VDAC1 = Voltage-Dependent Anion Channel type 1; GFAP = Glial Fibrillar Acid Protein; TBS = Tris-Buffered Saline; 
NGS = Normal Goat Serum; HRP = Horseradish Peroxidase; ms = mouse; rb = rabbit; MW = Microwave oven; DAB = 3,3’-diaminobenzidine; ABC = Avidin-Biotin 
Complex; TSA = Tyramide Signal Amplification. All secondary antibodies were from Jackson ImmunoResearch Labs. 
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Supplementary Table 4. Pathological quantitative measures obtained in the study subjects. 
Subject 
Plaque amyloid 
load (%) 
Vascular amyloid 
load (%) 
Total amyloid 
plaques (n/mm2) 
Dense-core 
plaques (n/mm2) 
Median 
neurite CR 
Alz50+ 
neurons 
(n/mm2) 
PHF1+ 
neurons 
(n/mm2) 
Thioflavin-S+ 
NFTs (n/mm2) 
1 1.138 0.016 21.74 15.64 1.024 3.07 68.11 44.39 
2 0.308 0.093 14.23 9.91 1.022 28.46 51.00 39.02 
3 0.948 0.000 13.76 12.82 1.020 31.20 43.89 26.14 
4 1.438 0.000 31.99 28.18 1.043 18.01 65.10 43.93 
5 0.640 0.012 26.45 23.21 1.027 22.17 90.02 86.22 
6 0.648 0.000 15.06 12.47 1.027 12.97 39.55 34.97 
7 1.068 0.000 23.53 19.64 1.024 17.64 64.00 77.88 
8 0.772 0.032 24.40 22.76 1.029 5.48 32.13 11.23 
9 0.477 0.066 19.75 13.67 1.023 21.98 45.62 29.05 
10 0.545 0.036 23.18 14.86 1.027 11.19 35.98 14.03 
11 0.503 0.073 34.95 13.93 1.034 23.01 56.38 25.47 
12 0.258 0.020 11.86 8.77 1.024 4.55 18.26 10.69 
13 0.366 0.000 25.95 14.34 1.026 9.34 6.67 0.56 
 9 
14 0.003 0.000 0.00 0.00 1.020 2.65 2.87 0.45 
15 0.079 0.000 2.36 2.36 1.024 0.26 0.77 0.00 
16 0.001 0.000 0.00 0.00 1.019 8.82 5.81 8.33 
17 0.006 0.000 0.00 0.00 1.014 17.74 15.73 10.80 
18 0.412 0.000 7.90 6.46 1.011 4.35 5.21 3.24 
19 0.143 0.000 2.88 1.68 1.022 21.05 12.42 12.72 
20 0.001 0.000 0.00 0.00 1.029 0.33 0.00 0.00 
21 0.000 0.000 0.76 0.76 1.026 0.38 0.90 0.20 
22 0.191 0.031 4.15 4.15 1.023 46.89 55.72 37.15 
23 0.093 0.010 1.43 1.43 - 7.53 2.22 20.47 
24 0.396 0.010 15.47 13.15 1.015 30.53 27.59 33.21 
25 0.051 0.017 1.50 1.50 1.033 0.00 0.39 0.24 
26 0.001 0.000 0.28 0.28 1.016 2.14 6.71 1.73 
 
CR = curvature ratio. NFTs = neurofibrillary tangles. Dark-grey rows depict non-immunized patients; white rows, non-demented controls, and light-grey rows, AN1792-
treated patients. Median CR is not available for one immunized patient because of the poor quality, likely fixation-dependent, of NF-H immunohistochemical study in that 
case.
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5.4. Summary of results.  
 
Original article#1 
 
1. Amyloid burden plateaus early after onset of symptoms in AD; 
 
2. Despite this stabilization of amyloid deposition, cerebral cortex suffers a progressive 
atrophy over the clinical course of the disease (due to loss of synapses, neuritis and 
neurons);  
 
3. Despite the stabilization of amyloid burden, glial responses —reactive astrocytes and 
activated microglia traditionally associated with plaques– increase linearly through 
the clinical course of the disease;  
 
4. Glial responses correlate positively with the number of NFTs but not with the 
amyloid burden; the astrocytic response also correlates with the severity of cortical 
atrophy; 
 
5. The linear increase of both astroglial and microglial responses observed over the 
clinical course of the disease occurs in the proximity of dense-core amyloid plaques 
but also in the vicinity of NFTs. 
 
Original article#2 
 
1. Anti-Aβ active immunotherapy is effective at clearing and reducing the burden of 
amyloid plaques at the hippocampus of AD patients; 
 
2.  Anti-Aβ active immunotherapy is more effective at clearing diffuse amyloid deposits 
(i.e. “lake-like” deposits at the presubiculum), whereas dense-core amyloid plaques 
are more resistance to clearance; 
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3. Both diffuse and dense-core plaques remaining after immunization are smaller than 
those plaques from non-immunized AD patients; 
 
4. Anti-Aβ active immunotherapy improves the abnormal trajectory of neurites 
observed in the vicinity of dense-core plaques in AD; this correction of neurite 
abnormal trajectories is not only due to the overall reduction of the number of 
amyloid plaques, but also occur in the vicinity of dense-core plaques remaining after 
immunization; 
 
5. However, dense-core plaques remaining after immunization retain some of their toxic 
features, as indicated by the number of embedded neuritic dystrophies, the 
mitochondrial accumulation in those dystrophic neurites, and the magnitude of their 
surrounding astrocytic response; 
 
6. Anti-Aβ active immunotherapy is associated with a reduction of tau 
hyperphosphorylation in the hippocampal NFTs, as revealed by 
immunohistochemistry with the PHF1 antibody (pTauSer396/401), but does not affect the 
aberrant misfolding and aggregation, as indicated by immunohistochemistry with the 
Alz50 antibody and by staining with Thioflavin-S.  
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CONCLUDING 
REMARKS  
 
 
 
 
 
 
 
 
The results of the present work support the two-stage hypothesis of the pathophysiology 
and progression of Alzheimer disease: 
 
1. The progression of the pathological hallmarks of AD was quantitatively assessed in the 
temporal association cortex using unbiased stereology-based techniques and clinical disease 
duration as a proxy of dementia severity. The results of these quantitative analyses provide 
evidence that amyloid deposition in the temporal cortex occurs primarily before symptom onset 
and reaches a plateau either before or early on during the symptomatic stage of the disease. By 
contrast, neurofibrillary degeneration, glial responses and cortical atrophy continue to increase 
during this symptomatic phase, becoming progressively more independent from amyloid 
plaques. The results from this cross-sectional postmortem study are largely in agreement with the 
evidence obtained from longitudinal imaging studies using volumetric MRI and amyloid PET in 
cognitively intact elderly individuals, and patients with MCI and AD dementia, which have 
enabled the study of the pathophysiology of AD in vivo. Although some controversy remains 
about whether amyloid continues to accumulate during clinically full-blown dementia, these 
6 
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studies have helped to establish a sequential order of pathological events in AD, with amyloid 
deposition largely predating cortical atrophy (reviewed in Jack et al., 2010).  
 
2. The results of our quantitative neuropathological study on the hippocampus of AD 
patients that were treated with anti-Aβ active immunotherapy in the mild-to-moderate phase of 
the disease also support this model. The anti-Aβ active immunization was effective at clearing 
amyloid plaques and also caused some potentially beneficial effects on neurite morphology and 
tau hyperphosphorylation. The latter observation is not attributable to a different stage of 
neurofibrillary degeneration since both AD groups were matched by disease duration and Braak 
stage of NFTs. This finding is in agreement with the original postulate of the amyloid cascade 
hypothesis that NFTs are a downstream consequence of Aβ accumulation. However, despite 
these promising results, it should be recognized that the observed effects were overall subtle and 
likely had little impact on the progression of cognitive decline and survival in these patients 
(Holmes et al., 2008). Thus, they support the idea that the pathological processes downstream of 
Aβ become independent of Aβ and progress on their own, so that anti-Aβ directed therapies may 
only be effective if administered at the initial stage of the disease. In fact, ongoing and future 
clinical trials are aiming at enrolling patients at earlier stages of the disease, including patients 
with MCI and positive biomarkers of AD (i.e. CSF and/or amyloid PET) or even FAD mutation 
carriers at pre-symptomatic stages (Dominantly Inherited Alzheimer Network, DIAN initiative). 
 
Of note, the efforts of two international consensus panels have recently made possible 
important advances in the clinical and pathological diagnostic framework of AD, which will 
have direct consequences on the design of clinical trials with disease-modifying drugs and in the 
clinical management of AD patients. The clinical diagnostic criteria of mild-cognitive 
impairment due to AD and of AD dementia have been updated to implement for the first time the 
use of CSF and imaging biomarkers of amyloid deposition and neuronal injury in order to 
classify the natural history of the patient’s disease in one of these two distinct pathophysiological 
stages (Albert et al, 2011; McKahn et al., 2011). Moreover, based on these biomarkers, a new 
diagnostic category termed “preclinical AD” has been devised to anticipate the diagnosis of AD 
at the pre-symptomatic stage, that is, when there is no evidence of cognitive decline or only 
subjective complaints that are not corroborated by neuropsychological testing (Sperling et al.,  
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2011). On the other hand, the criteria for the neuropathological diagnosis of AD have also been 
updated after 15 years to recognize that AD is a pathological continuum between normal aging 
and dementia, so that for the first time the presence of dementia is not required to make a definite 
diagnosis of AD. Instead, neuropathologists will report the severity of “AD pathological 
changes” using descriptors of the amount and distribution of amyloid plaques (CERAD grades 
and Thal stages) and NFTs (Braak stages) (Montine et al., 2011; Hyman et al., 2011). 
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